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AIM: To study the epidemiological profile i.e the clinical, biochemical and radiological 
parameters relating to bone mineral disease in CKD Stage 4-5 
PATIENTS AND METHODS: A hospital based cross sectional survey was carried out in Stage 4-5 
CKD patients, involving standard biochemical tests such as serum calcium, phosphate, PTH, 25 
hydroxyvitamin D and alkaline phosphatase; imaging in the form of lateral abdominal X rays and 
Echocardiography to look for vascular and valvular calcification and a DEXA scan to diagnose co-
existent osteoporosis.  
RESULTS:  Of the 710 patients enrolled, 45% had no CKD-MBD related symptom. 73.8% were 
hypocalcemic (< 8.5 mg%), 58.4% had serum phosphate > 4.5 mg%, 76.5% had PTH > 150 pg/mL and 
87.8% had Vitamin D deficiency (< 30 ng/ml). Risk factors for Vitamin D < 15 ng/mL were diabetes, 
reduced sunlight exposure, BMI > 23, high socioeconomic status and female sex. Vitamin D deficiency 
was significantly associated with dyslipidemia (elevated total cholesterol, LDL and triglycerides). 
Vascular calcification was seen in 6.8% and associated with diabetes or hypertension for > 5 years, age > 
50 yrs, postmenopausal status, smoking and low BMD. 78% had low BMD (T score < -1), the risk 
factors for osteoporosis being age > 50 yrs, amenorrhea > 1 year, Vitamin D < 15 ng/ml, low sunlight 
exposure and S. bicarbonate < 22 mmol/L. 51% had significant valvular calcification (Echocardiographic 
calcification score ≥ 5), which was associated with PTH levels < 300 pg/mL and S. calcium > 9.5 mg%. 
CONCLUSIONS: In predialysis Indian CKD patients, widespread hypocalcemia and vitamin D 
deficiency aggravate hyperparathyroidism and are associated with low BMD and a high prevalence of 
valvular calcification at a young age. CKD-MBD related complications therefore require a multi-pronged 
treatment strategy and careful monitoring of biochemical parameters once treatment is initiated. 
 INTRODUCTION 
Chronic kidney disease has now become an international public health problem affecting 5-10% 
of the world population. As renal function declines, there is a progressive impairment in the 
kidney’s ability to regulate mineral homeostasis, leading to altered serum concentrations of 
calcium, phosphate, parathyroid hormone (PTH), 25 hydroxy vitamin D and fibroblast growth 
factor 23 (FGF-23), among others. 
These changes are seen as early as CKD stage 3 (GFR< 60 ml/min/1.73m2), when the ability of 
the kidney to appropriately excrete a phosphate load is diminished, leading to 
hyperphosphatemia. The body compensates by raising levels of PTH and FGF-23 (both of which 
are phosphaturic) and decreasing 1,25(OH)2D (which has a net phosphate retentive role). The 
conversion of 25(OH) vitamin D to 1,25(OH) 2D which takes place in the kidney, is impaired, 
reducing intestinal calcium absorption, and resulting in an  increase in PTH (in a bid to raise 
serum calcium levels). At the same time there is end organ resistance to the action of PTH and 
FGF-23 and downregulation of vitamin D receptors, amplifying the above changes.  
The end result of these biochemical abnormalities is disordered bone growth and remodeling as 
well as extraskeletal calcification; these entitities now collectively known as chronic kidney 
disease related mineral bone disorders (CKD-MBD) 
According to the KDIGO guidelines(1), CKD-MBD is defined as: 
 
“A systemic disorder of mineral and bone metabolism due to CKD manifested by either one or a 
combination of the following: 
1. Abnormalities of calcium, phosphorus, PTH, or vitamin D metabolism. 
 2. Abnormalities in bone turnover, mineralization, volume, linear growth, or strength. 
3. Vascular or other soft-tissue calcification.”  
CKD-MBD is now receiving widespread attention due to the association between several aspects 
of CKD-MBD, namely hyperphosphatemia, hypovitaminosis D, hyperparathyroidism and 
vascular calcification, and the risk of cardiovascular mortality(2). The early detection and 
treatment of CKD-MBD therefore plays an important role in the management of patients with 
CKD. With the paucity of information regarding the characteristics of CKD-MBD in the Indian 
population, the first step, and one that this study tries to address, is to determine the 
characteristics of CKD-MBD in a subset of Indian predialysis patients. This information may 
then serve as the basis for future studies that can look into appropriate intervention strategies and 










 REVIEW OF LITERATURE 
Chronic kidney disease (CKD) is defined by KDOQI as the presence of kidney damage 
(abnormalities in histopathology, urine, blood or imaging) or reduced GFR (< 60 ml/min/1.73m2) 
for ≥ 3 months. The kidney plays an important role in calcium and phosphorus regulation and 
hence renal dysfunction is necessarily associated with abnormalities in mineral homeostasis 
which have wide ranging effects not only on the bone but also at extraskeletal sites, resulting in 
vascular or soft tissue calcification.  
Normal bone remodeling 
Bone remodeling is an orderly process of bone resorption and its replacement by new bone. The 
first step is the stimulation of osteoblast precursors derived from pluripotent mesenchymal stem 
cells. Parathyroid hormone (PTH) or locally produced cytokines such as IL -1 and TNF-α 
stimulate the release of soluble factors (macrophage colony stimulating factor, granulocyte 
colony stimulating factor, IL-6, IL-11) from osteoblasts which in turn stimulate proliferation and 
differentiation of osteoclast precursors(3)(4). Bone resorption is aided by PTH, IL-1, and TNF-α 
which stimulate the secretion of collagenase(5) and tissue plasminogen activator (t-PA) and 
inhibit collagen synthesis(6).  Once extracellular matrix interactions are disrupted, chemotactic 
factors (osteocalcin, osteopontin etc) are released locally, and osteoclast integrins bind to specific 
sequences on these molecules(7)(8)(9). The bound osteoclast then forms interactions with the 
underlying matrix to form an ‘osteoclast clear zone’ which is not permeable to ions. Insertion of 
vacuolar ATPases and cathepsins into the plasma membrane overlying the clear zone results in 
matrix degradation and mineral dissolution(10). 
 Bone resorption increases local concentrations of calcium or cytokines in the bone matrix 
(e.g., TGF-β, fibroblast growth factor) leading to feedback inhibition of osteoclast activity 
and apoptosis(11). These same cytokines that inactivate osteoclasts, attract osteoblasts into 
the resorption lacunae and activate them. Bone formation is initiated, leading to osteoblast 
proliferation and differentiation, osteoid synthesis, mineralization of the osteoid, and gradual 
replacement of the newly formed ‘woven’ bone by ‘lamellar’ bone.   
1. Role of PTH and Calcitriol in bone remodeling 
PTH stimulates bone formation by increasing the pool of osteoblast precursors, thus 
increasing the laying down of bone matrix(12).  Osteitis fibrosa, which is associated with 
high PTH levels, is therefore characterized by an increase in osteoblast numbers and new 
bone formation, which in turn stimulates increased bone resorption, which is why it is termed 
high turnover bone disease.  
Calcitriol is critical for the maturation and differentiation of both osteoblasts and osteoclasts. 
It also upregulates the transcription of osteocalcin and osteopontin genes, which are secreted 
by osteoblasts at the time of mineralization(13). Impaired secretion of these matrix proteins 
by osteoblasts then affects matrix organization and mineralization. Calcitriol deficiency is 
therefore characterized by abnormal and unmineralized osteoid and a reduced bone turnover. 
2. The kidney and bone mineral homeostasis 
The most common type of metabolic bone disease seen in patients with CKD is high turnover 
bone disease which is associated with hyperparathyroidism. Hyperparathyroidism in turn is 
the end result of hyperphosphatemia, reduced calcitriol synthesis, changes within the 
 parathyroid gland and end organ resistance to PTH, all of which are established early in the 
course of CKD and increase with progressive renal dysfunction. 
2.1 The role of phosphate retention 
As the kidney fails, its ability to excrete a phosphate load diminishes, resulting in progressive 
increase in ambient phosphate levels. The ‘trade off’ hypothesis(14) states that 
hyperphosphatemia transiently reduces serum ionized calcium levels, which in turn triggers 
PTH release, resulting in a normalization of calcium and phosphorus levels (by increasing 
calcium reabsorption and phosphate excretion in the kidney) and a new higher set point for 
PTH. In this model, therefore, hyperparathyroidism is a ‘trade off’ for maintaining normal 
calcium and phosphate levels. While early studies which demonstrated an increase in PTH 
levels with dietary phosphate loading(15) and a reduction in PTH levels with phosphate 
restriction(16) seemed to support this theory, it was later noted that hypocalcemia was not 
always demonstrable with phosphate loading, that hypocalcemia was fairly uncommon 
except in advanced CKD and that calcium loading failed to suppress PTH(17). The 
mechanism whereby hyperphosphatemia resulted in PTH elevation is therefore unlikely to be 
entirely mediated through hypocalcemia. 
Hyperphosphatemia inhibits calcitriol synthesis by a feedback mechanism and low calcitriol 
levels stimulate PTH release(18). Calcitriol supplementation has been shown to reduce 
hyperparathyroidism and may be one mechanism by which hyperphosphatemia and 
hyperparathyroidism are linked(17). 
This is not all, however, since phosphate has been shown to stimulate PTH release 
independent of calcium and calcitriol. One mechanism is by increasing the transcription of 
 PTH mRNA(19) and the second is by stimulating parathyroid gland hyperplasia through 
TGF-α expression, which interacts with the epidermal growth factor (EGF) receptor to 
activate the MAP kinase pathway, leading to cyclin-1 induction and cell 
proliferation(20)(21). 
2.2 Reduced calcitriol synthesis 
The kidney is the site of calcitriol synthesis and calcitriol levels decline as renal function 
worsens. The inability of PTH to upregulate 1-α hydroxylase in the kidney in response to low 
circulating calcitriol levels, points to the presence of factors other than reduced nephron mass 
acting to inhibit calcitriol synthesis. These include phosphate retention and FGF-23, a 
putative phosphaturic hormone whose levels rise as GFR declines, both of which have been 
shown to inhibit 1-α hydroxylase(22). Additionally, as GFR declines, less 25 (OH) vitamin D 
is filtered by the glomerulus bound to vitamin D binding globulin, thus limiting its delivery 
to the proximal tubule to be taken up by megalin and delivered to tubular 1-α 
hydroxylase(23). This limitation in substrate delivery further reduces the kidney’s ability to 
synthesize calcitriol. In renal failure associated with significant proteinuria, vitamin D 
binding globulin along with bound 25 (OH) vitamin D are lost in the urine, and is another 
mechanism for reduced substrate delivery(24). Apart from inhibition of 1-α hydroxylase 
activity by phosphate and FGF-23 and reduced delivery of 25 (OH) vitamin D which limit 
calcitriol synthesis, there is also end organ resistance to the action of calcitriol. Vitamin D 
receptor (VDR) expression in target organs such as the parathyroid gland is reduced(25)(26) 
and the ability of the VDR to interact with its response element on DNA is compromised by 
uraemic toxins which non specifically bind to the VDR(27). 
 2.3 Abnormalities within the parathyroid gland 
Calcitriol inhibits PTH release by increasing intestinal absorption of calcium (thus 
normalizing serum calcium), by increasing VDR expression in the parathyroid gland(28), by 
inhibiting transcription of PTH mRNA(29) and by its effect on parathyroid cell growth(30). 
This last effect is mediated via induction of the cyclin dependent kinase inhibitor p21. The 
ability of hypocalcemia to cause PTH release from the parathyroid gland is mediated through 
the calcium sensing receptor (CaSR), the expression of which is also increased by calcitriol 
via the VDR(31). Hyperparathyroidism is characterized initially by parathyroid cell 
hyperplasia, which if left untreated results in monoclonal expansion of groups of parathyroid 
cells leading to the formation of autonomously functioning parathyroid nodules(32). Both 
VDR and CaSR expression within the parathyroid gland have been found to be reduced in 
renal failure(33)(34), which makes the gland resistant to regulation by calcitriol. 
2.4 End organ resistance to PTH 
The primary function of PTH is to maintain a normal serum calcium level. In renal failure, 
however, the ability of PTH to generate a calcemic response is blunted. The factors 
responsible for this resistance to PTH include hyperphosphatemia(35), low calcitriol 
levels(36), reduced expression of PTH receptors(37) and non specific binding of inactive 
PTH fragments to PTH receptors(38). 
3. MINERAL BONE DISEASE IN CKD 
3.1 Clinical signs and symptoms 
CKD-MBD is generally asymptomatic or characterized by the presence of non-specific 
symptoms that are often ignored. These include bone pains, proximal muscle weakness, red 
 eyes, pruritus, spontaneous tendon rupture and pathological fractures. Symptoms do not help 
to distinguish between low and high turnover bone disease. Extraskeletal calcification 
manifests as necrotizing calcific arteriolopathy and calcification of heart valves and major 
arteries.  
     3.2   Classification of CKD-MBD 
     L – Presence of laboratory abnormalities alone 
     LB – Presence of laboratory abnormalities and bone disease 
     LC – Presence of laboratory abnormalities and calcification 
     LBC – Presence of aboratory abnormalities, bone disease and calcification 
3.3  Biochemical abnormalities 
Although examination of undecalcified bone biopsy specimens remains the gold standard for 
assessing bone mineral disease in CKD, its invasive nature precludes its widespread use as a 
diagnostic modality. Biochemical investigations therefore are the mainstay of diagnosis and 
serve as markers to formulate and assess treatment strategies. 
3.3.1  Prevalence 
Data on the prevalence of biochemical abnormalities in predialysis CKD patients is sparse 
because of the absence of national registries in most countries and the lack of large cohort 
studies. There is also heterogeneity between referred and non-referred CKD patients, further 
skewing data. The Study to Evaluate Early Kidney Disease(39), a large outpatient cross-
sectional study involving 1800 predialysis (Stage 3-5) patients spread across 153 centres in 
North America, showed that calcium and phosphorus levels remained relatively normal till a 
 GFR of < 40 ml/min while both 25 (OH) vitamin D and PTH levels showed progressive and 
significant changes early in CKD. 12% of patients with GFR > 80 ml/min and 60% of those 
with GFR < 60 ml/min, had a PTH > 65 pg/ml. Likewise, 13% of patients with GFR > 80 
ml/min/1.73m2 and > 60% of those with GFR < 30 ml/min had low vitamin D levels (< 22 
ng/ml).  The Kidney Education and Evaluation Program(40) was a community based 
screening programme sponsored by the NKF which targeted a population at high risk for 
developing CKD, namely adults with GFR < 60ml/min/1.73m2, who were either diabetic or 
hypertensive or had a family history of diabetes, hypertension or CKD. In the 2646 
individuals screened over a 1 year period, as eGFR decreased from 60 ml/min to 30ml/min, 
calcium level decreased (9.55 ± 0.47 to 9.34 ± 0.62 mg/dL), phosphorus increased (3.70 ± 
0.59 to 4.15 ± 0.80 mg/dL) and PTH increased (66.3 ± 36.3 to 164 ± 109 pg/mL). 
3.3.2  Assessment 
Calcium: Only 1% of the total body calcium is present extracellularly and measurable in the 
serum. Of this, 40-50% is ionized. Although monitoring ionized calcium is preferred to total 
serum calcium as it is physiologically active, it is expensive, not readily available and 
therefore not recommended for routine evaluation. Using a colorimetric assay, serum calcium 
levels can be measured with a fair degree of precision, the normal range being between 8.5 – 
10.5 mg/dL, though these values vary from laboratory to laboratory. Since the non-ionized 
portion of serum calcium is bound to albumin and anions such as citrate, bicarbonate and 
phosphate, hypoalbuminemia  will tend to underestimate total calcium and a correction factor 
of 0.8 mg% for every 1 g decrease in albumin below 4 g% needs to be used to arrive at the 
‘corrected calcium’ value. 
 Phosphorus: Unlike calcium which is extracellular, phosphate is an intracellular anion and 
measured as the sum of dihydrogen phosphate and hydrogen phosphate in the serum. In this 
regard, the terms phosphorus and phosphate are used interchangeably. The normal range on a 
colorimetric assay is 2.5 – 4.5 mg%, but values are subject to diurnal and postprandial variation 
and hence best measured as fasting morning samples.   
PTH: PTH is synthesized in the parathyroid gland as a preprohormone which undergoes 
progressive cleavage to form the 84 amino acid peptide which is called ‘intact PTH’ (iPTH).  
PTH undergoes further cleavage into N-terminal, C- terminal and mid-region fragments both 
within the parathyroid gland and in circulation, and these fragments are finally metabolized in 
the liver and kidney. The first generation assays to measure PTH were inaccurate as they 
measured both iPTH and inactive N and C terminal fragments, whose levels in the blood increase 
due to reduced clearance by the failing kidney. The second generation ‘two-site 
immunoradiometric’ assay (which uses two antibodies – one binding to the amino terminal and 
the second binding to the carboxy terminal) was initially believed to measure only the 1-84 
peptide, but was later shown to also bind the C terminal 7-84 fragment (which has antagonistic 
effects on the bone(41)) to variable degrees depending on the assay used(42). The third 
generation ‘biointact PTH’ assay is believed to measure only the 1-84 fragment, however its cost 
and failure to demonstrate a convincingly better predictive value in the diagnosis of bone mineral 
disease(43) or correlation with other markers of bone turnover(44), has precluded its widespread 
use.  Second generation assays are therefore most widely used, but care needs to be taken while 
interpreting results, which can vary depending on the type of assay, antibody specificity, type of 
specimen (serum, citrated sample or plasma) and method of collection (room temperature or on 
 ice)(45)(46). Each center must therefore standardize its procedure related to sample collection 
and storage and base therapeutic decisions on PTH trends rather than isolated values. 
25 (OH) vitamin D: This is the sum of 25 (OH) D2 (ercalcidiol) and 25 (OH) D3 (calcidiol), both 
of which are synthesized in the liver by the action of 25-α hydroxylase on the parent compounds 
Vitamin D2 (ergocalciferol) and Vitamin D3 (cholecalciferol). While the parent compounds are 
lipophilic with short half lives of < 24 hours, making them difficult to measure, 25 (OH) vitamin 
D has a half life of 3 weeks and is thus considered the best indicator of body stores of vitamin D  
derived from dietary intake and skin synthesis. There are four main methods to measure 25 (OH) 
vitamin D. The gold standard is high performance liquid chromatography (HPLC) but is used 
only in research settings because it is not readily available, is costly, and requires special 
expertise. The radioimmunoassay (RIA) and chemiluminescence assay measure total 25 (OH) 
vitamin D, while the liquid chromatography – tandem mass spectrometry (LC-MS/MS) assay, 
like HPLC, measures the calcidiol and ercalcidiol fractions separately. Again, cost is a limiting 
factor. There is an 80% agreement between these assays for the measurement of vitamin D status 
(47), and the systematic bias towards overestimation in the non-HPLC assays can be minimized 
by using a single calibrator across all laboratories. At present there is no clear definition of 
‘vitamin D deficiency’ (various studies have defined values < 10-15 ng/ml as deficiency and 
those > 10-15 ng/ml but < 20-30 ng/ml as insufficiency(48)(49)) and it has not been conclusively 
proven that supplementation of vitamin D in the CKD population offers any benefit over and 
above that offered by calcitriol supplementation in terms of reducing mortality(50). It is therefore 
important for clinicians to not only have an idea of the assay method used at their centre, but also 
to balance the cost of such assessment with the likely benefits that may accrue to the patient, 
since Vitamin D deficiency is a preventable cause for hyperparathyroidism. 
 Alkaline phosphatase:  This enzyme, which catalyzes the removal of phosphate groups from 
target proteins, has several tissue specific isoenzymes, which can be separately measured by 
fractionation and heat inactivation. The liver and bone isoenzymes are most abundant and hence 
any elevation in t-ALP requires liver disease to be ruled out before it can be ascribed to bone 
disease. Both t-ALP and b-ALP are markers of bone turnover and are elevated in primary and 
secondary hyperparathyroidism, osteomalacia, Paget’s disease and skeletal metastasis. While 
total alkaline phosphatase (t-ALP) is measured colorimetrically, the bone isoenzyme (b-ALP) is 
measured with an immunoradiometric assay. Total ALP is an acceptable adjunctive tool to 
diagnose CKD-MBD and monitor response to treatment as it is inexpensive. B-ALP, although 
more expensive and not readily available, can offer additional information in cases where PTH is 
equivocal. 
Calcium-phosphorus product (CaP): The product of serum calcium and phosphorus was 
previously held to be an important determinant of the overall risk for extraskeletal calcification, 
and KDOQI guidelines recommended maintaining this value below 55 mg2/dL2. KDIGO, 
however, in its guidelines for CKD-MBD, have warned against an over-reliance on this value 
due to the fact that fluctuations in serum phosphorus are the main determinant of the CaP and 
both normal and high values of CaP have been linked to poor outcome(51)(52). 
 
3.3.3      KDIGO Guidelines on assessment of biochemical abnormalities in CKD 
  
1. Monitoring of calcium, phosphorus, PTH and alkaline phosphatase should begin at Stage 
3 CKD in adults, and Stage 2 CKD in children.  
2. 25 (OH) vitamin D measurement is optional, but if found to be deficient may be treated 
based on strategies appropriate to the population concerned.  
 3. The frequency of monitoring should be based on the stage of CKD, the extent of 
abnormalities present and the rate of progression of CKD. (See table below)  
4. Treatment strategies should be based on individual calcium and phosphorus values rather 
than on the calcium-phosphorus product and should take into account the general trend 
rather than a single laboratory value. 
Table 1: KDIGO guidelines on frequency of measuring biochemical parameters 
 Stage 3 Stage 4 Stage 5 
Calcium, phosphorus, ALP 6-12 months 3-16 months 1-3 months 
PTH Baseline 6-12 months 3-6 months 
25 (OH) vitamin D Baseline Baseline Baseline 
 
       3.3.4  Indian data 
Data on biochemical abnormalities in CKD patients in India is sparse and in the predialysis 
population, virtually non-existent. A study in North India(53) comparing Vitamin D levels 
among 100 CKD patients (34 Stage 4 and 66 stage 5) with 72 controls showed 
hypovitaminosis D to be rampant in both the normal and CKD population (only 4% control 
and 1% of CKD subjects had values >30 ng/mL).  68% of control and 77% of the CKD 
population had vitamin D levels <15 ng/ml whereas the remaining had levels between 15-30 
ng/mL. Vitamin D levels were inversely related to PTH levels. Vitamin D levels in CKD 
patients were not only lower than in their family members, CKD patients were also more 
likely to have Vitamin D levels in the severely deficient range (< 5 ng/mL).  
 
 3.4   Metabolic bone disease in CKD 
The second component of CKD-MBD is the evaluation of bone disease, i.e abnormalities in 
bone turnover, mineralization, volume, linear growth, and strength. Turnover, mineralization, 
volume and growth are assessed by double tetracycline labeled bone histomorphometry. 
Bone strength is a composite of bone quality and bone mineral density. Bone quality is also 
evaluated by histomorphometry, while bone mineral density is evaluated by dual energy X-
ray absorptiometry (DEXA).  
3.4.1 Classification 
Based on differences in bone turnover and mineralization, renal osteodystrophy has been 
traditionally classified as: 
1. Osteitis fibrosa: High turnover with normal mineralization 
2. Osteomalacia: Low turnover with abnormal (decreased) mineralization 
3. Adynamic bone disease: Low turnover with normal mineralization and acellularity 
4. Mixed osteodystrophy:  Increased turnover with abnormal mineralization 
3.4.2  Pathophysiology 
Apart from the factors responsible for hyperparathyroidism mentioned previously, the 
following factors also play a role in the pathogenesis of bone mineral disease in CKD. 
• Reduced dietary intake of calcium(54) 
• Acidosis, which inhibits 1 α hydroxylase (thus reducing calcitriol synthesis) and 
promotes bone demineralization by buffering protons(55)(56) . 
 • Dialysis modality: Use of heparin during dialysis which results in osteopenia, the greater 
phosphate removal and dialysate calcium level, both of which predispose to adynamic 
bone disease in CAPD, and accumulation of β2 microglobulin with decline in renal 
function, which directly stimulates osteoclasts and promotes bone resorption(57) 
• Vitamin D deficiency due to reduced dietary intake and reduced skin synthesis secondary 
to  infrequent sunlight exposure and melanosis of the skin(58) 
• Premature hypogonadism which is associated with lower levels of growth factors such as 
TGFβ and IGF-1 required for bone formation(59). 
3.4.3  Assessment  
Role of bone histomorphometry: Although a bone biopsy is invasive and difficult to 
perform, it remains the gold standard for diagnosing and classifying bone mineral disease 
because biochemical parameters cannot accurately predict the type of bone mineral disease 
and because certain pathologies such as aluminium related bone disease cannot be diagnosed 
without it. 
 Fluorochrome double tetracycline labeling: 
Method: Tetracycline 250 mg thrice daily is given to the patient for 3 days (first label) and 
the dose is repeated after 14 days (second label). The patient is biopsied 5 days after the 
second label. Dairy products and aluminium containing antacids which can bind to 
tetracycline should be avoided for 2 hours before and after the label. 
Principle: Tetracycline binds to newly formed bone at the unmineralized bone/osteoid  
interface, where it can be seen as a linear fluorescence. A second dose given 11-14 days after 
 the first dose allows the measurement of the amount of bone formed in the interval as the 
distance between the two fluorescent labels 
Specimen processing:  
• Bone piece should be intact and unfractured, with an internal diameter of at least 7.5 mm 
• Ethanol (70%) is suitable for fixation, shipping, and storage. The bone should not be 
decalcified.   
Interpretation: Parameters assessed on bone histomorphometry include: 
z Static features of cortical bone 
- Cortical width (Ct.Wi): The combined thickness of both cortices 
- Cortical porosity (Ct.Po): The area occupied by intercortical holes expressed as a 
percentage of the total cortical area 
z Static features of cancellous bone 
- Cancellous bone volume (BV/TV): The area occupied by cancellous bone 
expressed as a percentage of total marrow area 
- Trabecular features: thickness (Tb.Th),  separation (Tb.Sp), number (Tb. N) 
- Osteoid features: Osteoid surface (OS/BS) – the percentage of cancellous surface 
with unmineralized osteoid;  Osteoid thickness (Os.Th) – the mean thickness in 
µm, of the osteoid 
z Dynamic features of cancellous bone 
- Activation frequency (Ac.f): This is a measure of overall remodeling activity 
- Mineralization lag time (Mlt): The time interval between osteoid formation and 
mineralization. 
 - Bone formation rate (BFR): A measure of the amount of cancellous bone volume 
or surface which is being replaced annually 
3.4.4     Prevalence data 
A systematic review of bone biopsy findings in CKD Stage 3-5 patients, carried out by 
KDIGO(1), revealed the following prevalence data: Osteitis fibrosa was the most common 
form of renal osteodystrophy (32%), followed by mixed osteodystrophy (20%) and normal 
histology (16%). Osteomalacia, adynamic bone disease and mild forms of osteodystrophy 
accounted for 8%, 18% and 6% respectively. With the initiation of dialysis, the pattern of 
osteodystrophy changed, with the majority (60%) of PD patients developing adynamic bone 
disease, and HD patients having mixed and osteitis fibrosa histologies in roughly equal 
amounts (32% and 34% respectively). Data on bone histomorphometry in predialysis patients 
in India is not available. 
      3.4.5   Relation between bone biopsy findings and clinical outcome 
Both adynamic bone disease(60)(61) and osteomalacia(62) have been shown to be associated 
with an increased risk of fracture which in turn is linked to increased mortality. In addition, 
low turnover bone disease and adynamic disease in particular, have been linked with an 
increased risk of aortic(63)(64) and coronary artery calcification(65), which is exacerbated 
by a high calcium load. 
3.4.6    Guidelines regarding indications for bone histomorphometry (KDIGO) 
1. Unexplained fractures 
 2. Unexplained hypercalcemia or hypophosphatemia, severe bone pain, or unexplained 
increase in  bone alkaline phosphatase activity 
3. Suspected aluminum bone disease 
4. Prior to parathyroidectomy 
5. Prior to initiation of bisphosphonate therapy in CKD Stage 3-5 
3.5    Standard X rays 
Standard X rays have only 60% sensitivity and 75% specificity for the diagnosis of osteitis 
fibrosa(66). The recommended battery of X rays for the diagnosis of CKD-MBD include X 
rays of the hand (AP), shoulder, skull, lumbar spine (lateral) and pelvis (AP). 
Changes in Osteitis Fibrosa: Rugger jersey spine, loss of lamina dura of the jaw, terminal 
acrolysis, subperiosteal resorption and periosteal new bone formation, ‘pepper pot’ skull. 
Changes in osteomalacia: Looser’s zones (areas of translucency at areas of mechanical stress 
where lamellar bone has been replaced by unmineralized woven bone) 
3.6   Bone mineral density 
A measure of bone strength is its mineral content per unit area, also known as the bone mineral 
density (BMD). A low BMD can be the result of a decrease in mineral content (as seen in 
osteomalacia) or a loss of bone volume (as seen in osteoporosis). BMD is measured by dual X-
ray absorptiometry (DEXA) and quantitative CT among other modalities. It is expressed in 
terms of the T score, which is the BMD of the patient compared to a healthy 30 year old of the 
same gender and race. 
 3.6.1 Prevalence data: NHANES III found 28% of female patients with CKD stage 3-4 to 
have osteoporosis(67). BMD declines as GFR declines and predialysis patients have a higher 
prevalence of osteoporosis compared to age, sex and weight matched controls(68). Similar data 
is not available for CKD patients in India. 
3.6.2 Importance of BMD:  A low BMD has been conclusively shown to be associated with 
increased fracture risk and mortality in the normal population(69). DEXA scans have therefore 
become an accepted modality for screening patients who are believed to be at a high risk for 
developing osteoporosis, namely men and women > 65 years old, postmenopausal women, 
patients on long term steroids/cyclosporine/anticonvulsant therapy, patients with prior history 
of fragility fractures and hypogonadism.  
3.6.3 DEXA scan: It uses two X-ray beams of differing energies that pass through the area of 
interest. Bone attenuates each X-ray to a varying degree and a collimator placed beneath the 
patient calculates the bone mineral content based on the degree of attenuation.  
3.6.4 DEXA in CKD: Although bone mineral density has been shown to decrease with 
progression of CKD, unlike the general population, a decreased BMD in CKD patients does 
not have the same predictive value vis a vis fracture risk(70). The measurement of BMD in 
CKD is complicated by the presence of aortic calcification, scoliosis and degenerative changes 
such as vertebral osteophytes which can confound the interpretation of lumbar spine DEXA 
scans. DEXA cannot distinguish between changes in cortical and cancellous bone which is an 
important drawback in CKD, since hyperparathyroidism results primarily in cortical bone loss, 
while trabecular bone volume increases. Different bones in the body have varying proportions 
of cortical and cancellous bone and thus yield different estimations of BMD in the same 
 patient. For example, while the forearm bones are almost wholly cortical, the spine is 42% 
trabecular and the femur 25% trabecular(71). As DEXA measures BMD in only two 
dimensions, volumetric assessment is not possible and it systematically overestimates BMD in 
tall people and underestimates BMD in short people. Finally, the most important cause for 
increased fracture risk in CKD is abnormal underlying bone architecture, which again cannot 
be assessed by BMD measurement(72). 
3.6.5 Quantitative CT (QCT): QCT uses CT technology to measure bone mineral content. 
Because of its superior resolution it is able to reliably distinguish between cortical and 
trabecular bone. Volumetric assessment of trabecular and cortical bone BMD is possible and it 
can be used at both central and peripheral sites(73). BMD measured by QCT has been found to 
correlate well with trabecular bone volume measured by histomorphometry of iliac crest 
biopsies, however it is costly and not universally available. 
3.6.6 Ultra high resolution peripheral QCT: Separate three dimensional assessment of 
trabecular and cancellous bone, endosteal and periosteal circumferences, cortical area and 
thickness is possible(74). Its higher resolution allows visualization of ultrastructural 
characteristics as fine as trabecular thickness, number and separation.  
3.6.7 Micro MRI: Offers a three dimensional visualization of ultrastructural details which can 
be analyzed like a bone biopsy(75). 
3.6.8 KDIGO guidelines on BMD in CKD: The routine use of DEXA for evaluation of CKD-
MBD in CKD Stage 4-5 is not recommended, because it cannot predict fracture risk as it does 
in the general population, and factors other than osteoporosis are responsible for poor bone 
strength in CKD.  
  
3.7        Bone markers 
3.7.1    Classification 
Collagen based markers associated with bone formation 
• N and C terminal propeptides of procollagen type 1: Generated by posttranslational 
cleavage of procollagen  
Collagen based markers associated with bone resorption 
• Carboxy and aminoterminal crosslinking telopeptide (generated by cleavage of 
pyridinoline bonds linking adjacent collagen molecules) 
• Pyridinoline and deoxypyridinoline  
Non collagen based bone markers associated with bone formation 
• Bone specific alkaline phosphatase (secreted by osteoblasts) 
• Osteocalcin 
• Osteoprotegerin 
• Receptor Activator for nuclear factor κB ligand (RANK-L) 
 Non collagen based bone markers associated with bone resorption 
1. Tartrate resistant phosphatase (secreted by osteoclasts) 
3.7.2 Bone markers and histology: KDIGO conducted a metanalysis of studies that looked at 
the correlation between bone formation rate as assessed by bone biopsy and bone markers (PTH, 
 b-ALP, osteocalcin and collagen cross-linking molecules). Osteocalcin and collagen cross-
linking peptides had correlation coefficients ranging from 0.2 – 0.7 and 0.7- 0.9 respectively(1). 
However, bone markers have not been found to be good predictors of bone volume(76). 
3.7.3 Bone markers and BMD: Bone markers are not useful in predicting BMD since, as 
mentioned previously they have not been found to correlate well with changes in bone volume 
and BMD itself is a poor guide to bone histology. In high turnover bone disease, which is often 
characterized by increased formation of new bone which is radiologically less dense, bone 
markers may be elevated though BMD may be reduced (new bone has a lower mineral content). 
On the contrary, low turnover bone disease may have a higher BMD due to a higher mineral 
content even though the overall bone volume has not increased.  
3.7.4  Current role: In the normal population, bone markers have been used to assess response 
to therapy and in some studies have been shown to predict subsequent fracture risk better than 
serial BMD measurement(77). However, in the CKD population, their role is limited at best 
since, being renal excreted, their levels are likely to be non-specifically elevated. There is also no 
evidence that they predict fracture risk any better than b-ALP or PTH(78) and hence their routine 
use in the assessment of CKD-MBD is not recommended. 
4.   EXTRASKELETAL  CALCIFICATION 
4.1  Pathophysiology 
Vascular smooth muscle cells (VSMCs) in the setting of diabetes, aging, inflammation or 
uraemic milieu, undergo phenotypic switch to osteoblast like cells due to upregulation of 
transcription factors such as RUNX-2 and MSX2(79). These osteoblast like cells lay down 
collagenous and non-collagenous proteins in the intima and media of blood vessels followed by 
 mineralization(80). Factors which accelerate this process include hyperphosphatemia, 
hypercalcemia, adynamic bone disease(81) (which prevents calcium buffering by the bone), 
osteitis fibrosa (which results in calcium resorption from the bone and higher ambient calcium 
levels) and a deficiency of inhibitors of calcification, namely fetuin-A, matrix Gla protein, 
pyrophosphate and osteopontin(82). 
4.2  Prevalence 
Valvular and vascular calcification have been shown to be strong predictors of cardiovascular 
risk in the normal population(83). CKD patients have been shown to have both a higher 
prevalence and faster progression of extraskeletal calcification. Pooled data from various studies 
suggest that 47–83% of predialysis patients had cardiovascular calcification on EBCT, while 
valvular (aortic or mitral) calcifications were present in 20–25% of 653 patients with CKD stages 
3–5 in the Multi-Ethnic Study of Atherosclerosis(84).   
4.3   Importance 
Follow up studies in CKD patients have shown that once vascular calcification is established, it 
follows a progressive course, while patients who do not have calcification at baseline are 
unlikely to develop calcification in the future(1). In CKD patients, calcification or progression of 
calcification are independent risk factors for cardiovascular and all cause mortality(85)(86). 
4.4   Assessment 
1. Electron beam CT (EBCT) and Multi-slice CT (MSCT): Current gold standard for the 
detection and quantification of vascular calcification. Calcification is quantified in terms 
of coronary artery calcification (CAC) score measured in Agatston units. In an EBCT, X- 
 rays are produced by electrons impacting a tungsten ring and 3 mm slices are obtained at 
high speed from the top to the base of the heart. MSCT uses a paired X-ray source 
detector revolving around the patient and 2–64 simultaneous sections are obtained. The 
thickness of the slices varies from 1.5–0.6 mm and hence the MSCT has a higher spatial 
resolution when compared to EBCT. 
2. Lateral abdominal X ray: Allows a semiquantitative estimation of aortic calcification 
using the aortic calcification index as described by Kaupilla et al(87), where the anterior 
and posterior aortic walls opposite lumbar vertebrae 1-4 are observed on a lateral 
abdominal X ray and scores assigned depending on the severity of calcification. 
3. Echocardiography: Assesses aortic and mitral valvular calcification 
4. Pulse pressure and Pulse wave velocity: As a bolus of blood is ejected through a vessel, 
its wall undergoes distension followed by recoil, from which the velocity of the blood 
flow can be calculated.  As a result of vascular calcification the vessel wall becomes stiff 
and traveling velocity increases. PWV is therefore an indirect marker for vascular 
calcification. 
4.5      Correlation between imaging modalities 
As mentioned above, EBCT and MSCT are the gold standard. Lateral abdominal X ray (67,91%) 
and echocardiography (53,70%) have a reasonable sensitivity and specificity compared to  CT, 
though pulse pressure correlated poorly(88).  
4.6      Guidelines 
KDIGO does not routinely recommend the screening of patients with CKD Stage 4-5 for 
vascular/valvular calcification because there is limited evidence to show that a reduction in 
 vascular calcification affords any mortality benefit. Patients with persistent hyperphosphatemia 
or those on the transplant waiting list, may be considered for screening. While EBCT is the gold 
standard for evaluation of vascular calcification, KDIGO, based on comparative studies, suggests 
that lateral abdominal X ray for aortic calcification, and echocardiography for valvular 
calcification, may be acceptable alternatives where CT is not available. KDIGO also suggests 
that patients found to have vascular calcification should be deemed to be at high cardiovascular 
risk. 
5.   MANAGEMENT OF CKD-MBD 
5.1  Management of hyperphosphatemia 
5.1.1 Evidence: Hyperphosphatemia has been associated with increased mortality and poor 
outcome in both pre-dialysis and dialysis patients, the last association being consistent across 
various countries and holding good for both haemodialysis and PD patients(89)(90). This is 
probably because of its epidemiological association with cardiovascular disease(91). 
Hyperphosphatemia has also been shown to promote and exacerbate other aspects of CKD-MBD 
such as hyperparathyroidism(92), low calcitriol levels(93) and vascular calcification(94). There 
is however, a lack of conclusive data from RCTs that lowering phosphorus levels improves 
clinical outcomes. Calcium-based and non-calcium containing phosphate binders did not differ in 
their ability to lower phosphate levels or impact patient outcomes(95), although there was a  
lower prevalence of hypercalcemia and higher mean PTH levels with the use of non-calcium 
containing binders. Sevelamer was found to retard the progression of vascular calcification in 
some studies, however this finding was not uniform(96).  
 
 5.1.2    Treatment options:  
1. Dietary phosphate restriction: KDOQI recommends a dietary phosphate intake of < 
800 mg/day as the first step in management of hyperphosphatemia, however phosphate 
restriction alone is ineffective in retarding progression of extraskeletal calcification 
unless combined with phosphate binders(97). 
2. Phosphate binders 
Aluminium hydroxide was the first phosphate binder used, and to date has the highest 
phosphate binding capacity. However, long term use of aluminium hydroxide is 
associated with neurological, haematological and bone related toxicities and hence its use 
is generally avoided, except in  patients with severe hyperphosphatemia in whom it can 
be used for < 2 weeks to bring down the calcium-phosphate product and avoid soft tissue 
calcification. 
Calcium based phosphate binders such as calcium acetate, calcium citrate and calcium 
carbonate have 25%, 22% and 40% elemental calcium respectively. While effective in 
binding phosphate, they have the potential side effects of PTH suppression and 
extraskeletal calcification due to calcium loading. They also cause GI side effects such as 
bloating and nausea. Calcium citrate is not recommended in CKD due to its ability to 
enhance dietary aluminium absorption. 
Sevelamer hydrochloride/carbonate: Being non-calcium containing and non 
absorbable, it has the potential to reduce extraskeletal calcification when compared to 
calcium containing phosphate binders. Sevelamer has also been shown to reduce LDL 
levels. The hydrochloride salt has been associated with a tendency to worsen acidosis, 
which is not seen with the carbonate salt. It is currently the costliest phosphate binder. 
 Lanthanum carbonate: Non-calcium containing binder which has a higher phosphate 
binding capacity than sevelamer. The long term clinical consequences of its use are not 
known as there is a potential for its accumulation due to GI absorption and subsequent 
deposition in the bone, although unlike aluminium, lanthanum induced bone toxicity has 
not been demonstrated(98). 
3. Dialysis: Alternative dialysis modalities that offer more frequent, long duration sessions 
have been shown to result in significant reduction in serum phosphate level, with 50% of 
such patients not requiring phosphate binders(99). This may be an option for patients who 
are refractory to diet restrictions and phosphate binders or non-compliant. 
5.1.3    Guidelines on management of hyperphosphatemia (KDIGO):  
1. Serum phosphorus levels should be maintained within the normal range for the given 
laboratory 
2.  Dietary phosphate intake should be restricted 
3. While aluminium based phosphate binders should be avoided, the use of both calcium 
and non calcium containing phosphate binders is appropriate and the choice of phosphate 
binder should be individualized based on other aspects of CKD-MBD such as the 
presence or absence of hypercalcemia, dyslipidemia etc. 
4. For patients with persistent hyperphosphatemia despite the above, increasing the 




 5.2       Maintaining calcium homeostasis 
5.2.1   Evidence: There is no data to support that hypercalcemia is associated with an increase in 
mortality or fracture risk in CKD Stage 3-5. In dialysis patients, the upper limit of serum calcium 
above which the relative risk of mortality increases has not been defined, with studies reporting 
values anywhere between 9.5 – 11.4 mg%(89)(100). Serum calcium levels < 8.5 mg% have also 
been linked to an increase in mortality(101).  
5.2.2   Treatment options 
1. Dietary intake: Calcium supplementation (upto 2g/day) has been shown to reduce PTH 
levels, however this benefit must be weighed against the risk of extraskeletal 
calcification. 
2. Dialysate calcium concentration: Although the exchangeable calcium compartment is 
very small, the net calcium flux during dialysis is an important determinant of calcium 
load in the long term. Studies in HD patients have shown that a 2.5 meq/L dialysate 
calcium concentration would result in a neutral calcium flux for the majority(102). 
Calcium flux in turn is not uniform between patients and is determined by the individual 
patient’s ionized calcium, the frequency and duration of dialysis and the rate of 
ultrafiltration(103). The dialysate calcium concentration can therefore be modified based 
on the individual patient’s needs, with a higher (3.5 meq/L) calcium bath for patients with 
hypocalcemia, 2.5 – 3 meq/L bath for patients with normocalcemia and a 2 meq/L 
calcium bath for patients with persistent hypercalcemia, adynamic bone disease or 
extraskeletal calcification. The risk of intradialytic hypotension and arrhythmias with low 
calcium dialysate needs to be kept in mind in this context(104). In PD patients, who are 
 exposed to dialysate for a longer period of time, the risk of hypercalcemia and adynamic 
bone disease is higher and it is recommended that dialysate calcium be maintained in the 
2.5-3 meq/L range. 
5.2.3    KDIGO Guidelines:  
1. Serum calcium levels should be maintained within the normal range for the given 
laboratory (and preferably in the 8.5-9.5 mg% range as per KDOQI) 
2. Dialysate calcium concentration should be individualized based on the patient’s serum 
calcium level, though in a majority a dialysate calcium concentration between 2.5 – 3 
meq/L would be optimal. 
3. In patients with persistent hypercalcemia, calcium based phosphate binders, calcitriol and 
vitamin D supplements should be avoided 
5.3    Management of hyperparathyroidism 
5.3.1  Evidence: PTH values below 2 times normal and above 9 times normal have been linked 
with increased mortality in predialysis and post dialysis patients(105)(101), however normalizing 
PTH levels has not been shown to conclusively improve mortality. This paradox can be 
explained in part by the heterogeneity in PTH assays, end organ resistance to PTH and the poor 
predictive value of elevated PTH for underlying bone histology(106).  The general consensus 
however, is to treat hyperparathyroidism due to its deleterious effects on bone histology. 
5.3.2   Treatment options:  
1. Management of hyperphosphatemia and hypocalcemia, both of which can result in 
hyperparathyroidism. Correction of serum calcium levels by the use of vitamin D 
 analogues or calcium containing phosphate binders suppresses PTH through the CaSR, 
while lowering phosphate levels reduces PTH by a posttranscriptional effect. 
2. Vitamin D analogues: These include naturally occurring forms (ergocalciferol, 
cholecalciferol and calcitriol), synthetic vitamin D2 analogues (paricalcitol, 
doxercalciferol) and synthetic vitamin D3 analogues (alfacalcidol, falecalcitriol, 
maxacalcitol). Of these doxercalciferol and alfacalcidol are 1-α derivatives that require 
25 hydroxylation in the liver. Vitamin D analogues have been shown to reduce PTH and 
other biochemical parameters of bone mineral disease with improvement in bone 
histomorphometry parameters(107)(108) and form the first line therapy for the 
management of hyperparathyroidism. 
3. Calcimimetics: Calcimimetics like cinacalcet function as allosteric modulators of the 
CaSR in the parathyroid gland, which augment intracellular signaling secondary to 
binding of ionized calcium, resulting in an increase in intracellular calcium and inhibition 
of PTH release. It has no effect on intestinal or renal handling of calcium. The ability of 
cinacalcet to lower PTH levels without causing hypercalcemia or 
hyperphosphatemia(109)(110) makes it a useful tool in the management of 
hyperparathyroidism especially in patients who have failed a trial of vitamin D analogues 
due to the above side effects. Cinacalcet related side effects include hypocalcemia, 
nausea and vomiting. 
4. Parathyroidectomy can be performed by ablation (local injection of alcohol or 
calcitriol) or surgical removal (subtotal parathyroidectomy or total parathyroidectomy 
with autologous reimplantation in the forearm). Ablation is usually carried out in small 
parathyroid glands with ≤ 2 nodular lesions that are easily accessible and is an option in 
 patients who are not fit for major surgery. It is not useful for ectopic glands or large 
nodular glands with markedly raised PTH levels, and requires expertise, as it may result 
in recurrent laryngeal nerve palsy. Surgical parathyroidectomy generally results in a 
sustained improvement in biochemical profile which is maintained for upto 5 years post 
surgery(111), though there is also the risk of recurrence(112) or persistent 
hypoparathyroidism. There are no RCTs comparing medical and surgical therapy and no 
evidence to suggest total parathyroidectomy and subtotal parathyroidectomy differ in 
their efficacy. 
Indications for parathyroidectomy 
1. Elevated PTH levels > 800 pg/ml associated with hypercalcemia and/or 
hyperphosphatemia that are refractory to medical therapy 
2. Clinical signs and symptoms associated with refractory hyperparathyroidism 
(hypercalcemia, uncontrolled hyperphosphatemia, evidence of osteitis fibrosa cystica on 
bone biopsy, radiology or bone metabolic markers, enlarged and/or nodular parathyroid 
glands (> 500 mg), calciphylaxis, intractable pruritus, EPO resistant anaemia, severe 
bone pain, severe skeletal deformity, progressive calcification of blood vessels) 
5.3.3     Guidelines on management of hyperparathyroidism (KDIGO) 
1. The optimal PTH level for CKD Stage 3-5 is not known, but levels above the upper limit 
of normal should prompt evaluation for hyperphosphatemia, hypocalcemia and Vitamin 
D deficiency. If PTH remains elevated despite correction of the above factors, treatment 
with Vitamin D analogues is advised 
 2. In patients on dialysis, PTH levels should be maintained at 2-9 times the upper limit of 
normal and levels above this range should be treated with vitamin D analogues or 
calcimimetics or a combination. Vitamin D analogues and calcimimetics should be 
stopped if PTH falls below 2 times the upper limit of normal. 
3. Vitamin D analogues should be stopped if patient develops hypercalcemia or 
hyperphosphatemia 
4. Cinacalcet should be stopped if the patient develops hypocalcemia 
5. In patients with hyperparathyroidism refractory to medical or pharmacological therapy, 
parathyroidectomy may be considered 
5.4     Management of extraskeletal calcification 
1. Use of non-calcium containing phosphate binders such as sevelamer has been shown to 
retard the progression of calcification when compared with calcium acetate(113)(109)(97). 
This, has however, not been shown to translate into an improvement in patient 
outcome(114)(115). 
2. Synthetic vitamin D analogues in general, have been shown to be associated with a lower 
risk for progressive calcification with equivalent PTH reduction compared to calcitriol(116). 
3. As calcification is part of the natural history of atherosclerosis, despite there being no 
evidence that statin therapy is associated with a reduction in cardiovascular events in CKD 




 AIMS AND OBJECTIVES 
 
1. To study the clinical, biochemical and radiological (vascular calcification, valvular 
calcification, bone mineral density) parameters relating to bone mineral disease in CKD 
Stage 4 and 5 patients. 
 
2. To determine risk factors for the development of vascular/ valvular calcification and bone 
mineral disease in this population. 
  
 PATIENTS AND METHODS 
DESIGN AND LOCATION: This hospital based cross sectional survey was conducted at the 
Department of Nephrology, Christian Medical College, Vellore. 
PATIENTS:  Stage 4 and 5 CKD patients who satisfied the following inclusion and exclusion 
criteria were included: 
INCLUSION CRITERIA: 
1. Patients with newly diagnosed Stage 4-5 CKD (based on history, eGFR of < 30 
ml/min/1.73 m2 by the abbreviated Modification of Diet in Renal Disease formula,  with 
ultrasonographic and/or  histological evidence of CKD) who:  
• Were not yet on dialysis  
or  
• Were being initiated on haemodialysis for the first time at CMC or on 
haemodialysis for < 1 month at the time of enrolment in the study      
or 
• Were being initiated on CAPD for the first time at CMC or on CAPD for < 1 
month at the time of enrolment in the study 
2. On calcium supplements/vitamin D supplements/phosphate binders for less than 3 
months and with no prior history of calcimimetic use. 
 
EXCLUSION CRITERIA: 
1. Patients on dialysis (haemodialysis or CAPD) for > 1 month 
 2. Patients on calcium supplements, vitamin D supplements or phosphate binders for more 
than 3 months or any prior history of calcimimetic use. 
3. History of steroid/cyclosporine or anticonvulsant use for > 3 months 
 
DURATION:  Patients attending the Nephrology OPD between November 2009 and August 
2010 were included in the study. 
 
METHODOLOGY: Patients attending Nephrology OPD and fulfilling the inclusion criteria 
detailed above, were selected for inclusion in the study. A detailed proforma was filled up for 
each patient recording their demographic data, socioeconomic status, history of symptoms 
suggestive of CKD-MBD, drug history with specific emphasis on phosphate binder, calcium 
supplement, calcimimetic and vitamin D use, dietary history, daily sunlight exposure and history 
and duration of dialysis. Informed consent was taken in the appropriate format. Biochemical 
parameters such as fasting and postprandial blood sugar, lipid profile, haemoglobin, B. urea, S. 
creatinine, S. bicarbonate, S. Calcium, serum albumin,  phosphate, PTH, Alkaline phosphatase 
and 25 hydroxy vitamin D were measured. Lateral abdominal X rays for aortic calcification, 
echocardiography for valvular calcification, and DEXA scan of the femoral neck for bone 
mineral density were taken.  
 
MEASUREMENTS: 
1.   ANTHROPOMETRY 
 Height and Weight were measured using height and weighing scales, standardized according to 
the specifications of  the Department of Legal Metrology of the Government of India. BMI was 
calculated by dividing weight (in kg) by height (in meters). 
 
2.   CLINICAL BIOCHEMISTRY 
Serum calcium, phosphate, bicarbonate, alkaline phosphatase, haemoglobin , blood urea, S. 
creatinine, Serum albumin, glucose fasting and post prandial and lipid profile were measured 
using automated analyzers. 
 
iPTH was measured using the Immulite™ Indirect Chemiluminometric assay (Diagnostics 
Products Corporation, CA, USA). All samples were transported on ice to the laboratory and 
processed immediately. 
Principle: This two site sandwich immunoassay uses a monoclonal mouse anti-PTH (44-84) 
antibody and a polyclonal goat anti-PTH (1-34) antibody conjugated to alkaline phosphatase.  
The unbound conjugate is removed by centrifugal wash, and a chemiluminiscent substrate, which 
is a phosphate ester of adamantly dioxetane is added and incubated. The substrate is hydrolyzed 
to an unstable intermediate which produces a sustained emission of light. The photon output 
measured by the luminometer is proportional to the concentration of PTH in the sample. 
 
25 (OH) vitamin D was measured using the Elecsys Modular Analytics E170 Immunoassay 
System (Roche Diagnostics, GmbH, Manheim, Germany) 
Principle: This is an electrochemiluminescence immunoassay (ECLIA) in which 25 (OH) 
vitamin D in the serum is incubated with a ruthenium labeled vitamin D antibody complex. Next, 
 biotin labeled 25(OH) vitamin D is added and occupies the free sites on the antibody. When 
electrically stimulated, ruthenium produces reactive species which emit light. The counts per 
second detected by the system is inversely proportional to the concentration of vitamin D in the 
serum.  
 
Estimated GFR (eGFR) calculation: Patients were classified as Stage 4 or 5 CKD based on 
estimation of their GFR using the abbreviated MDRD (aMDRD) equation, given by: 
aMDRD GFR = 186 X (S.Cr) -1.154 X  (Age) -0.203 X  (0.742 if female)  X  (1.210 if African 
American) 
 
3.  RADIOLOGICAL INVESTIGATIONS 
X  ray abdomen (lateral view) 
Lateral abdominal X-ray to detected abdominal aortic calcification was obtained with a voltage 
of 70 kV according to standard protocol with the patient in standing position and the film at 100 
cm distance. 
Calcific lesions were looked for in the area parallel and anterior to the lumbar spine (L1- L4) and 
assessed separately for the anterior and posterior walls of the aorta using the midpoint of the 
intervertebral space above and below as the boundaries according to the method described by 
Kaupilla et al.(87). The anterior and posterior walls of were graded separately for calcification as 
follows: 
0 – no calcification 
 1 – small, scattered calcific deposit filling less than 1/3rd of the longitudinal wall of the aorta 
2 – calcific deposit filling more than 1/3rd but less than 2/3rd of the longitudinal wall of the aorta 
3 – 2/3rd or more of the longitudinal wall of the aorta calcified 
The following scores were then calculated: 
Affected segments score: Number of individual segments of the aorta (either anterior or 
posterior) showing calcification. Minimum score = 0, Maximum score = 4       
Anterior and posterior affected score: The number of individual aortic segments, either anterior 
or posterior,showing calcification. Minimum score = 0, Maximum score = 8.  
Anteroposterior severity score: The scores of individual segments from the anterior and posterior 
wall are added up. Minimum score = 0, Maximum score = 24.  
DEXA scan (Femoral neck) 
Procedure: Dual Emission X ray Absorptiometry (DEXA) scan of the left femoral neck was 
obtained using the Hologic QDR 4500C system with the patient supine and the leg internally 
rotated to correct femoral anteversion. The BMD, T score and Z score were recorded. 
Principle: The DEXA scan uses two X-ray beams of differing energies focused on the area of 
interest. Differential attenuation of each beam by the bone results in prolongation of transmission 
of the beams through a filter onto a counter to a degree proportional to the bone mineral content. 
Definitions:  
BMD:  Bone mineral content divided by cross-sectional area of the bone and expressed as g/cm2. 
 T score is obtained by comparing the patient's BMD to that of a healthy 30 year old of the same 
sex and ethnicity and is expressed as standard deviations above or below the accepted normal. 
The WHO has defined the following criteria for interpreting T scores: 
Normal: T score of -1 or above 
Osteopenia: T score of -1.0 to -2.5 
Osteoporosis: T score of less than -2.5 
Z score: Comparison of the patient’s BMD with that of a normal subject of the same age, sex, 
and ethnicity and expressed as standard deviations above or below the accepted normal. 
Echocardiography for valvular calcification 
Echocardiography was carried out using a 2.5 MHz transducer, with patient in left lateral 
decubitus position, using the parasternal long and short axis views, by a single cardiologist who 
was blinded to all clinical details. Calcification was defined as the presence of echo brightness 
exceeding that of normal valve tissue. Semiquantitative assessment of valvular calcification was 
carried out using 2 separate scoring systems as described by Pressman et al(119): 
a. Simplified Echocardiographic score  
1. Aortic valve calcification (0 = absent, 1 = present) 
2. Mitral valve or annular calcification (0 = absent, 1 = present) 
3. Subvalvular apparatus calcification (0 = absent, 1 = present) 
4. Restriction of either valve (0 = absent, 1 = present) 
b. Main Echocardiographic score 
1. Posterior annulus, by thirds (Score 0-3) 
 2. PML restriction (0 = absent, 1 = present) 
3. Anterior annulus calcification (0 = absent, 1= present) 
4. AML restriction (0 = absent, 1= present) 
5. MV calcification (0 = absent, 1 = mild, 2 = > mild) 
6. Subvalvular apparatus calcification (0 = absent,1 = present) 
7. AV calcification (0 = absent, 1 = nodule in < 3 leaflets, 2 = nodules in 3 leaflets, non 
restrictive; 3 = restrictive) 
8. Aortic root calcification (0 = absent,1 = present) 
The cumulative main echocardiographic and simplified echocardiographic scores were obtained 
for each patient. 
SAMPLE SIZE: 
As there are no Indian studies on CKD-MBD in predialysis patients a sample size could not be 
arrived at. It was decided to include a minimum of 500 patients in the study. 
STATISTICAL ANALYSIS: 
Statistical analysis was done using SPSS v.15 and the various analytical techniques used were as 
follows: 
Mean ± standard deviations were used for normally distributed data and median & range (min – 
max) was used for skewed data to avoid the outlier effect.  
Significance was determined by Chi square test for categorical data and ANOVA for continuous 




PATIENT PROFILE: During the study period extending from November 2009 to August 2010, 
a total of 19828 patients attended Nephrology OPD of which 1122 patients belonged to CKD 
Stage 4 or 5 based on their aMDRD GFR. Of these, 710 patients fulfilled the criteria for 
































 CLINICAL DETAILS: The study population comprised mainly adults from a middle class 
background with only 8 patients being less than 18 years of age. Males outnumbered females by 
a ratio of almost 3:1 and 36.8% of patients were diabetics. Though 68.3% belonged to CKD 
Stage 5, a large majority (92%) of patients had never been initiated on dialysis and of the 57 who 
had been dialyzed, 52 had been on dialysis for less than 2 weeks.  
 
Table  2: Demographic profile 
Study population n = 710 
Sex (Males : Females) 517: 193 (2.7:1) 
Age (yrs)    mean ± SD 
Age distribution 
 
            < 30 (%) 
           30-50   
            >50  






Socioeconomic status (%) by modified 
Kuppuswamy scale 
 
          Lower class 
          Middle class 







Presence of diabetes (%) 261 (36.8) 
History of dialysis (%) 
          HD 
          PD 
          No history of dialysis 





CKD Stage based on aMDRD GFR (%) 
           Stage 4 





 NATIVE KIDNEY DISEASE (NKD):  As the majority of patients could not be biopsied due to 
the presence of contracted kidneys and/or poor corticomedullary differentiation, they were 
labeled as unknown NKD. Diabetic nephropathy was defined as the presence of renal 
dysfunction associated with proteinuria and fundus changes of diabetic retinopathy. Diabetics 
with renal dysfunction in the absence of significant proteinuria or fundus changes were labeled 
as unknown NKD. 
 
Table 3: Native kidney disease 
Native kidney disease n  (%) 
Unknown 413 (58.2) 
Diabetic nephropathy 221 (31.1) 
CIN 12 (1.7) 
CGN 24 (3.4) 
Obstructive nephropathy 11 (1.5) 
ADPKD 16 (2..3) 
Renal calculus disease 7 (1) 
Arterionephrosclerosis 6 (0.8) 
 
CKD-MBD RELATED SYMPTOMS: Patients were questioned regarding the presence of 
symptoms that would suggest an underlying bone mineral disease, namely: bone pains, proximal 
muscle weakness, paraesthesiae, pruritus, red eyes and history of pathological fractures. 
Although bone pain was the most common CKD-MBD related symptom found in 33.5% of 
study patients, 45% did not report ANY CKD-MBD related symptom at the time of screening. 
 There was no significant difference in the prevalence of CKD-MBD related symptoms between 
Stage 4 and 5 CKD patients. 
 








Prevalence by CKD Stage 
 
Stage 4 
(n = 225) 
n (%) 
Stage 5 





Bone pains 238 (33.5) 71 (31.5) 167 (34.4) 0.49 
Pathological fracture 3 (0.4) 1(0.4) 3(0.6) 1 
Pruritus 181 (25.5) 53 (23.5) 128 (26.3) 0.45 
Red eyes 0 (0) 0 (0) 0 (0) NA 
Proximal muscle weakness 186 (26.2) 48(21.3) 138 (28.4) 0.051 
Paraesthesiae 6 (0.8) 1(0.4) 5(1) 0.57 
 
DIETARY AND PERSONAL HISTORY: 
Table  5: Lifestyle indices 
Indices n (%) 
Smoking 112 (15.8) 
Significant alcohol intake 45 (6.3) 
Sun exposure in hours/day  (mean ± SD) 1.9 ± 2.5 
                       < 1 hour ( %) 
                      1-6 hours  





       Premenopausal 
       Menopausal 
          < 5 yrs 
         5-10 yrs 








        Vegetarian 




Milk intake (ml/day) 
      < 250 ml 
250-500 ml 






PHOSPHATE BINDER, CALCIUM  AND  VITAMIN D USAGE 
Patients who had used phosphate binders, calcium or vitamin D supplements for more than 3 
months were excluded from the study. The cumulative calcium and calcitriol dose received and 
the mean duration of their use were recorded along with details of phosphate binder usage. 
68.3% had never received calcitriol or calcium supplements while 79.4% had not received 
phosphate binders at baseline, indicating a largely treatment naïve population. 
 Table 6: Calcium, phosphate binder and vitamin D  usage 
 Mean ± SD Range 
Calcitriol cumulative dose (mg)               2.8 ± 5.6 0-30 
Duration of calcitriol use (months)  0.29 ± 0.5 0-2.5 
Duration of calcium use (months) 0.28 ±0.51 0-2.5 
Cumulative calcium dose (g) 2.8 ± 5.6 0-37.5 
Phosphate binder duration (months) 0.17 ± 0.42 0-2.5 
Phosphate binder usage (%) 
       Calcium acetate/carbonate 
       Lanthanum 
       Sevelamer 









Height and weight measurements were used to calculate the BMI. Patients were classified 
according to WHO recommended BMI strata for Asians(120) as follows: 
Severely underweight (< 16), moderately underweight (16-16.9), mildly underweight (17-18.49), 
normal (18.5-23), pre-obese (23-27.5), obesity grade I (27.5-30), obesity Grade II (30-32.5) and 
obesity Grade III (> 32.5).  
The mean BMI was 22.4 ± 3.9 kg/m2. Majority (83.9%) of the study population had a BMI in the 
normal to high range.
  
Figure 2: BMI of the study population 
 
CLINICAL BIOCHEMISTRY 
 Mean ±SD Range 
Haemoglobin (g/dL) 8.8 ± 1.9 2.6-15.9 
S. cholesterol (mg/dL) 156  ± 52.7 22-553 
Triglycerides (mg/dL) 134.7 ± 80.9 21-796 
HDL (mg/dL) 38.1 ±12.9 14-140 
LDL (mg/dL) 89.5 ±40.6 16-427 
S. bicarbonate (mmol/L) 18.2 ±4.7 6-32 
S. Albumin (g/dL) 3.8 ± 0.58 1.2-5.2 





































There was a significant fall in serum corrected calcium and a correspondingly significant rise in 
serum phosphate, calcium-phosphate product and PTH levels progressing from CKD Stage 4 to 
5. Alkaline phosphatase and Vitamin D levels were not found to change significantly from Stage 
4 to 5. 
Table  8: Bone mineral metabolism 
 Overall 
Mean ±SD  
(Range) 
(n = 710) 
According to CKD Stage 
Mean ±SD 
CKD Stage 4              CKD Stage 5 





Corrected  calcium 
(mg/dL) ; n = 700 
8.0 ± 1.03  
(4 - 12.4) 
8.4 ± 0.6 7.8 ± 1.1 .000 
S. phosphate (mg/dL) 
n = 700 
5.3 ± 1.9 
 (2 – 14.6) 
3.8 ± 0.77 5.9 ± 2 .000 
Ca x P  (mg2/dL2) 
n = 700 
41.7 ± 14.5  
(9 – 112) 
32.6 ± 6.9 45.9 ± 15.1 .000 
PTH (pg/ml) 
n = 627 
391.1±340.19  
(1.8 – 2500) 
225.8 ± 204 473 ± 363.7 .000 
25 (OH) Vit  D (ng/ml) 
n = 605 
20.9 ± 8.7  
(3.1 ± 58.2) 
21.09 ± 9.8 20.9 ± 8.2 0.845 
ALP  (U/L) 
n = 600 
110.4 ± 69.22  
(20.8 -  950) 
107.9 ± 54.3 111.6 ± 75.4 0.543 
 
  
Figure 3: Calcium and phosphate levels (% of study population with normal, high and low values as 
per KDIGO guidelines) 
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Figure 5: PTH (% of subjects with levels above KDOQI recommendations for CKD Stage) 
 
 



















































 Overall, 73.8% were hypocalcemic (S. corrected calcium < 8.5 mg%), 58.4% were 
hyperphosphatemic (cut off being 4.5 mg%) and 87.8% had vitamin D levels < 30 ng/ml. 53.8% 
and 61.3% of Stage 4 and 5 CKD patients respectively had PTH levels that were above the 
KDOQI recommendations (>150 pg/ml for Stage 4, >300 pg/ml for Stage 5) 
The significant clinical associations with PTH > 300 pg/ml were: 
1. Age < 50 years (p = .003) 
2. Diabetes < 5 years duration (p = .01) 
3. Female sex (p = .009) 
4. History of bone pains (p = .04) 
5. Amenorrhea < 5 years (p = .01) 
6. Vitamin D levels < 30 ng/ml ( p = .04) 
As expected, patients with PTH levels > 300 pg/ml were more likely to be anaemic,(p = .000), 
have S. corrected calcium <8.5 mg% (p = .000),  phosphate > 4.8 mg% (p = .000), S. bicarbonate 
< 20 mmol/L (p = .000), elevated alkaline phosphatase (p = .000) and Calcium phosphate 
product > 55 mg2/dL2 (p = .000). 
The significant clinical associations with vitamin D levels < 15 ng/ml were: 
1. Duration of diabetes > 5 years  (p = .000) 
2. Sunlight exposure < 1 hour/day (p = .004) 
3. BMI > 23 (p = .003) 
4. Higher socioeconomic status (p = .003) 
5. Female sex (p = .000) 
 The significant biochemical associations with vitamin D levels < 15 ng/ml were: 
1. Hypercholesterolemia, hypertriglyceridemia, elevated LDL and non HDL cholesterol (p 
= .000 for each) 
2. PTH > 300 pg/ml (p = .000) 
3. Elevated alkaline phosphatase ( p = .005) 
4.  S. albumin < 3.5 g% (p = .010) 
5. S. corrected calcium < 8.5 mg% (p = .01) 
BONE MINERAL DENSITY 
Bone mineral density was measured by DEXA scan of the left femoral neck. Due to logistical 
reasons, DEXA scans could not be done for the majority of patients, and out of the study 
population of 710, reports were available only for 241 (32%).  Although there was a trend 
towards increasing BMD with progression from Stage 4 to 5, this did not attain statistical 
significance.  55.1% had osteopenia and 22.9% had osteoporosis. This proportion too, did not 
change significantly from Stage 4 through 5.  Only 2 patients had pathological fractures, both of 
whom had osteoporosis on DEXA scan. 
Table 9: Bone mineral density 
 
 
Mean ± SD 
(Range) 
n = 241 
Stage 4 
Mean ± SD 
n = 78 
Stage 5 
Mean ± SD 




BMD (g/cm2) 0.703 ± 0.14 
(0.416 – 1.717) 
0.696 ± 0.177 0.706 ± 0.133 0.63 
 T score -1.664 ± 0.98 
(1 to -3.9) 
-1.720 ± 1.00 -1.636 ± 0.969 0.53 
Z score -1.00 ± 0.95 
(-1.8 to -3.2) 
-1.015 ± 0.945 -0.993 ± 0.964 0.86 
  
 
Figure 7: T score trends by CKD Stage 
 
Factors associated with osteoporosis (T score < -2.5) were: 
1. Age > 50 yrs (p = .008) 
2. Postmenopausal status > 1 year (p = .000) 
3. Vitamin D < 15 ng/ml (p = .006) 
4. Sun exposure < 1 hour per day (p = .02) 




























Echocardiography reports were available for 471 patients.  To assess the severity of valvular 
calcification, two complementary scoring systems were used, as described by Pressman et al. 
Significant valvular calcification was defined as a Main Echocardiographic score of ≥ 5 or a 
Simplified Echocardiographic Score of  ≥3.  
On the whole, while both scoring systems showed a significant increase in the burden of valvular 
calcification from CKD Stage 4 to 5 (in terms of mean score), the prevalence of significant 
valvular calcification was not found to be different between the two groups using the Main 
Echocardiographic score, while the simplified echocardiographic score showed Stage 5 CKD 
patients to have a higher prevalence of significant valvular calcification. Thus, there was a 
difference in the prevalence of significant valvular calcification as assessed separately by the two 
scoring systems (p = .000), with Cohen’s kappa showed only a 57% agreement between the two. 
However, as this study did not incorporate a gold standard (such as EBCT) to which each scoring 
system could be compared, further comparison between the two in terms of their specificity and 
sensitivity for assessing valvular calcification is not possible. The mitral valve and posterior 




 Table 10: Valvular calcification across CKD Stage 4 and 5 using two scoring systems 
 





n = 161 
 
Stage 5 






         Average score 
         Range 
        Significant calcification 
              Score  ≥ 5 
 
 
4.5 ± 2.5 





4.1 ± 2.1 





4.7 ± 2.6 











         Average score 
         Range 
         Significant calcification 
             Score  ≥3 
 
 
2.0 ± 1.0 





1.9 ± 0.9 





2.1 ± 1.0 










Kappa test for agreement between scoring systems (with regard to significant calcification): 0.57  
 
  
Figure 8: Prevalence of significant valvular calcification across CKD Stage 4 and 5 
 




















































 The predictors for valvular calcification were: 
1. PTH < 300 pg/ml (p = .011) 
2. S. corrected calcium > 9.5 mg% (p = .038) 
 
There was no association between valvular calcification and age, gender, presence of diabetes, 
presence of hypertension, BMI, lipid profile, phosphate level, vitamin D status, history of 
smoking, diet preference, post menopausal status or presence/severity of aortic calcification. 
 
VASCULAR CALCIFICATION 
Lateral abdominal X-rays were taken to detect the presence of vascular calcification involving 
the abdominal aorta. Out of the study population of 710, lateral abdominal X-rays were available 
for 558 patients. Calcification of the abdominal aorta was seen in only 38 patients (6.8%). 
Interestingly, the prevalence of calcification was proportionately lower in Stage 5 compared to 
Stage 4 (5.1% vs 10%, p= .02). Also, while the mean affected segment score, anteroposterior 
affected segment score and anteroposterior severity score was not significantly different between 
Stage 4 and 5 patients with calcification, the presence of significant calcification 
(anterioposterior severity score ≥ 7) was significantly greater in Stage 4 CKD. Using the aortic 
calcification index as described by Kaupilla et al, calcification was most commonly noted in the 





Mean ± SD 
(Range) 
n = 38 
Stage 4 CKD 
Mean ± SD 
(Range) 
n = 19 
Stage 5 CKD 
Mean ± SD 
(Range) 
n = 19 
p value 
Affected segment score 
(0 – 4) 
2.1 ± 1 
(1-4) 
2.2 ± 1.1 
(1-4) 
2.1 ± 1 
(1-4) 
0.88 
Anteroposterior affected score 
(0 – 8) 
2.9 ± 1.7 
(1-7) 
3.1 ± 2 
(1-7) 
2.7 ± 1.4 
(1-6) 
0.527 
Anteroposterior severity score 
(0 – 24) 
4.1 ± 2.8 
(1-11) 
4.6 ± 3.3 
(1-11) 













Table 11: Vascular calcification scores by CKD Stage 
 
 

























Figure 11: Distribution of abdominal aortic calcification on X ray 
Predictors identified for aortic calcification were: 
1. Duration of diabetes > 5 yrs  (p = .000) 
2. Age > 50 yrs  (p = .000) 
3. Duration of HT > 5 yrs  (p = .000) 
4. Post menopausal status > 1 yr  (p = .028) 
5. Smoking  (p = .03) 
6. Osteoporosis or osteopenia on DEXA  (p = .005) 
7. Serum calcium 8.5-9 mg% (p = .036), serum phosphate < 4.8 mg% (p = .02) and S. 
bicarbonate > 18 mmol/L (p = .022) 
 
There was no association between aortic calcification and gender, socioeconomic status, BMI, 






























The increasing incidence and prevalence of CKD is a cause for concern worldwide. Among the 
aspects of CKD management, the early diagnosis and treatment of CKD related mineral bone 
disease is now gaining importance because of clear epidemiological links with increased all 
cause and cardiovascular mortality. The fact that current interventions in this area have not been 
consistently shown to improve patient outcomes, highlights how little we know about the 
pathophysiology of CKD-MBD.  In India, matters are made worse by the paucity of data 
regarding the prevalence, nature and severity of CKD-MBD especially in the pre-dialysis 
population. This study sought to shed some light in this area, by collecting CKD-MBD related 
demographical, biochemical and imaging data in a largely pre-dialysis Indian population. 
The study population comprised new outpatients categorized to Stage 4 or 5 CKD using the 
aMDRD formula, who presented to the Nephrology OPD at Christian Medical College, Vellore, 
a tertiary care center in Tamil Nadu, over a 10 month period. Patients who had received dialysis 
for more than a month or had been on calcium/vitamin D supplements or phosphate binders for 
more than 3 months, were excluded.  
In this cohort of predominantly middle class patients with a mean age of 46 years, males 
outnumbered females 3:1, this discrepancy having more to do with an inherent social bias 
wherein men seek and receive medical attention more than women. 36.8% were diabetic, but the 
native kidney disease in at least 58% was unknown due to late referral to a nephrologist, making 
renal biopsy of small, shrunken or echogenic kidneys impractical. Although bone pain was the 
most commonly reported CKD-MBD symptom and correlated with a PTH level > 300 pg/ml, 
45% of patients were totally asymptomatic, again reinforcing the fact that CKD-MBD is a silent 
 killer. The study design excluded patients on long term CKD-MBD related medications, 
nevertheless, it was disheartening that 79.4% had never been prescribed a phosphate binder and 
68% had not received calcium or vitamin D supplements at any time prior to their presentation. 
This points to a poor knowledge among primary care physicians in India regarding the optimal 
management of CKD-MBD, and the need for education in this regard. 
Biochemical parameters in the study were typical of a treatment naïve CKD population.  The 
changes in mean values through Stage 4 and 5 were as follows: Serum calcium decreased from 
8.4 ± 0.6 mg% to 7.8 ±1.1 mg%, serum phosphate increased from 3.8 ± 0.77 mg% to 5.9 ± 2 
mg%, calcium-phosphate product increased from 32.6 ± 6.9 to 45.9 ± 15.1 mg2/dl2 and PTH 
increased from 225.8 ± 204 to 473 ± 363 pg/mL (p = .000 for all). Mean levels of 25 hydroxy 
Vitamin D and alkaline phosphatase, however did not show a significant change from Stage 4 
through 5.  These findings are consistent with those reported by the CKD Registry of India, 
which compiles data submitted from 154 centers all over India(121), and showed ALP levels to 
be stable from Stage 2 right through Stage 5. It is likely that alkaline phosphatase may not be a 
good marker of bone mineral disease and that bone alkaline phosphatase may have yielded 
different results, given its better correlation with bone histology and higher predictive value for 
differentiating between low and high turnover bone disease(1). The fact that 25 (OH) vitamin D 
levels did not change from Stage 4 through 5 indicates that in India, vitamin D deficiency is 
already established by Stage 4. 
In this predialysis population, hypocalcemia was widespread (73.8%), resulting in only 15% 
having an elevated calcium-phosphate product.  Vitamin D deficiency was also rampant, with 
87.8% having levels < 30 ng/mL, 23.5% of whom had levels < 15 ng/mL. Such a high 
prevalence of hypocalcemia and vitamin D deficiency is unique to subcontinental CKD patients 
 because they reflect an amplification of established population trends. The average calcium 
intake in the rural and urban Indian population is 264 and 356 mg/day respectively (as against 
the US RDA of 800-1000 mg/day)(122). Vitamin D deficiency is also common in India, with a 
prevalence of 66.3% using a cutoff of 15 ng/ml, which increases to 78.3% if a cutoff of 20 
ng/mL is used(123). Vitamin D deficiency in turn inhibits calcium absorption from the gut, and 
the high phytate content of the Indian diet reduces effective calcium absorption(122), further 
lowering calcium levels. Sadly, the ICMR is yet to suggest a RDA for vitamin D in Indians, the 
ICMR RDA for calcium is only 400 mg/day and we do not as yet have a national Vitamin D 
food fortification programme in place, all of which makes it unlikely that this problem will go 
away any time soon. 
In this study, vitamin D levels < 15 ng/mL were associated with diabetes, sunlight exposure < 1 
hour per day, BMI > 23, higher socioeconomic status and female sex. Patients with low vitamin 
D levels were also more likely to have PTH levels > 300 pg/mL, calcium levels < 8.5 mg% and 
elevated alkaline phosphatase, again highlighting the role of vitamin D as a reversible cause of 
secondary hyperparathyroidism and hypocalcemia.  
The link between vitamin D, diabetes, obesity and the metabolic syndrome is an area of active 
research(124). Vitamin D receptors and 1-α hydroxylase have been localized to pancreatic β 
cells, and vitamin D deficiency has been shown to cause impaired insulin secretion in response to 
a glucose load. Vitamin D likely modulates insulin secretion via regulating calcium flux through 
the β cell, as insulin secretion is a calcium dependent process. The insulin gene promoter region 
has a vitamin D response element which upregulates transcription of insulin. VDRs are 
expressed in skeletal muscle, where they increase expression of insulin receptors and enhance 
glucose uptake, thus reducing insulin resistance. Vitamin D has also been shown to downregulate  
 transcription of NF-κB, a regulator of inflammatory cytokines implicated in insulin resistance. 
The relation between vitamin D and diabetogenic risk is intriguing, especially as both vitamin D 
deficiency and diabetes are assuming epidemic proportions in India.  Early evidence suggests 
that combined dietary supplementation with vitamin D and calcium can improve glycemic 
control in those with impaired fasting glucose(125), though large scale, population based studies 
are required to validate this finding.  
That patients from a higher socioeconomic status are more likely to have Vitamin D deficiency 
may seem paradoxical, but this is easily explained by the fact that they are more likely to be 
engaged in sedentary occupations with little exposure to sunlight, compared to labourers and 
farmers who comprise the lower socioeconomic strata. Low vitamin D levels in female Indian 
CKD patients is also not unexpected, as ICMR data reveals that, despite living in a subtropical 
country, 75% of females in India have less than 1 hour of sunlight exposure per day. Most are 
housewives confined to their homes, and have a diet inadequate in calcium or vitamin D. The 
importance of sunlight exposure to achieving adequate vitamin D levels is highlighted by the fact 
that due to darker skin, Indians require longer UV exposure to achieve the same Vitamin D 
levels (UV radiation required to achieve minimal erythemal dose is 49-133 mJ/cm2 in Indians 
compared to 31-48 mJ/cm2 in Caucasians).(126) Also skin fibroblasts in Indians have been 
shown to have a higher content of 25(OH)-24 hydroxylase, which is the rate limiting enzyme for 
25 (OH) vitamin D degradation(127).  The association of vitamin D deficiency with high BMI 
points to a sedentary lifestyle with little physical exercise and sunlight exposure predisposing to 
both obesity and low vitamin D levels. Moreover, Vitamin D being lipid soluble, its 
bioavailability is altered and circulating levels lower in the obese(128). 
 Another interesting finding in this study was the association between Vitamin D deficiency and 
dyslipidemia. Karhapaa et al(129) had similar findings in a Finnish population based study, 
where low Vitamin D levels were linked to elevated total and LDL cholesterol and 
hypertriglyceridemia. The association between Vitamin D deficiency and hypertriglyceridemia 
was also confirmed in large cross-sectional study carried out in the US by the NHANES(130). 
Vitamin D directly activates the peroxisome proliferator activator receptor- , which is involved 
in the regulation of fatty acid metabolism in skeletal muscle and adipose tissue(131). Vitamin D 
mediated changes in calcium flux modulate adipocyte metabolism, with deficiency promoting 
triglyceride accumulation via increased de novo lipogenesis from fatty acids generated by loss of 
the antilipolytic effect of insulin.  At the other end of the spectrum, vitamin D was also 
associated with hypoalbuminemia, even though the majority of the study population had a 
normal or high BMI. CKD is a state of chronic microinflammation, and Vitamin D has been 
shown to reduce the levels of inflammatory cytokines such as IL-1, IL-6 and TNF-α, which 
reduce albumin synthesis by the liver. Supplementation with vitamin D was found to improve 
protein intake and albumin levels, chiefly by inhibiting TNF-α(132).  
The proportion of patients with PTH levels above 2 times normal (the cut-off suggested by 
KDIGO) increased from 53.8% in Stage 4, to 87.8% in Stage 5 CKD. KDIGO accepts that the 
optimal PTH level in Stage 4 and 5 CKD is not known because PTH does not correlate well with 
bone histology in the range of 150-600 pg/ml(1). In this study, PTH levels > 300 pg/ml were 
associated with young age, female sex, non-diabetics, and low Vitamin D levels.   
PTH levels have generally been found to be lower in diabetics, this being explained by the 
binding of advanced glycation end products(AGEs) to their receptor (R-AGE) in the parathyroid 
gland which reduces PTH release in response to hypocalcemia(133).   AGEs also inhibit collagen 
 and osteocalcin synthesis from osteoblasts in response to calcitriol, all of which explains why 
diabetics are more prone to develop adynamic bone disease(134).  Vitamin D deficiency causes 
hypocalcemia, which stimulates PTH secretion via the CaSR. While in the general population, 
PTH levels have been found to increase with age due to age related decline in GFR(135), this 
study, like others involving a purely CKD population, found old age to be associated with lower 
PTH levels and a higher risk of adynamic bone disease(136).  It was previously proposed that 
females have higher PTH levels because estrogen acting via its receptors in the parathyroid gland 
increases PTH mRNA transcription(137). Recent studies have found the opposite to be true – i.e, 
estrogen inhibits PTH release, though this is not mediated via its receptors (whose very existence 
in the PTH gland is now in doubt) but mediated indirectly, probably via FGF-23, which acts via 
the MAP kinase pathway to inhibit PTH synthesis(138). Although estrogen levels have been 
found to be normal in the majority of women on dialysis(139), anovulatory cycles and secondary 
amenorrhea are common, and progressive estrogen deficiency would be expected to result in an 
elevation of PTH levels. Vitamin D deficiency is also more common in women, thus increasing 
their risk for hyperparathyroidism. With increasing age, the opposing effect of estrogen 
deficiency (which increases PTH levels) and age related decline in PTH synthesis, would balance 
out, and PTH levels would tend to fall with increasing duration of amenorrhea.  
Significant valvular calcification on echocardiography was seen in 51% and 34% of the study 
population, using the main echocardiographic and simple echocardiographic scores respectively, 
which is higher than prevalence reported in Western literature. Ix(140) and Adeney(141) et al, 
who independently carried out subgroup analyses of Stage 3-5 CKD patients within the Multi-
Ethnic Study on Atherosclerosis, found a prevalence of 20% mitral annular calcification and 
25% aortic valvular calcification on EBCT/MSCT. This subgroup of patients had a mean age of 
 70 years, BMI of 28.5 and mean eGFR of 50 ml/min/1.73m2 pointing to relatively mild renal 
dysfunction. Since the classification of patients into Stage 3-5 was based on eGFR, most patients 
would have fallen in this category because of their age. Our study population, however, consisted 
of established Stage 4 and 5 CKD patients, in whom the prevalence of valvular calcification is 
expected to be higher. Sharma(85) found 40% prevalence of mitral annular calcification in 140 
Stage 4-5D CKD patients by echocardiography which is more in line with our findings. The 
KDIGO guidelines accept echocardiography as a suitable imaging modality for the screening of 
valvular calcification, based on a study by Bellasi(142) in which calcification of either valve 
detected on  echocardiography had a sensitivity and specificity of 53 and 70% and a likelihood 
ratio of 1.79 (95% confidence interval 1.09, 2.96) for a  CAC score of  ≥ 100. This study used 
two global calcification scoring systems described by Pressman et al(119) to assess the 
distribution and severity of valvular calcification. Although these scoring systems have yet to be 
validated in a CKD population, the original study compared them with the CAC score as 
measured by CT. A main echocardiographic score of ≥ 5 and a simple echocardiographic score 
of ≥ 3 had positive predictive values of 60 and 62% respectively for a CAC of ≥400. Although 
the two scoring systems differed in their estimation of the prevalence of significant valvular 
calcification, with a kappa of 0.57, in the absence of a gold standard such as EBCT to which 
each could be compared, their relative sensitivity and specificity could not be assessed. The 
prevalence of significant valvular calcification was found to be higher in Stage 5 CKD using the 
simplified echocardiographic score, though this was not confirmed with the main 
echocardiographic score. Longitudinal data in the CKD population seems to confirm the fact that 
the prevalence and severity of calcification increases with progression of CKD(143).  
 The mitral valve and posterior mitral annulus were the most common sites of calcification in our 
study. While aortic valve calcification increases with age and is considered a degenerative 
process, mitral annular calcification is more strongly associated with abnormalities in mineral 
metabolism(144). In our study, significant valvular calcification was associated with PTH < 300 
ng/ml and corrected calcium > 9.5 mg%. Studies in dialysis patients have confirmed the 
association between myocardial calcification and elevated calcium-phophorus 
product(144)(145), though the relation between PTH and valvular calcification has not been 
directly proven(145). Hypercalcemia would be expected to lower PTH levels, which could 
explain this association. It is for this reason that the KDIGO suggests caution in the widespread 
use of calcium supplements and calcium based phosphate binders which increase calcium load, 
and predispose to extraskeletal calcification, besides predisposing to low turnover bone disease 
by suppressing PTH levels. The presence of valvular calcification is associated with poor patient 
outcome, with 1 year all cause mortality being 57%, 40% and 15% for patients with both aortic 
and mitral valve calcification, either valve and neither valve calcified respectively(146). The 
high prevalence of significant valvular calcification in a young predialysis population without 
long term exposure to calcium supplements is thus, a cause for concern. This study highlights the 
need to closely monitor calcium and PTH in patients who have been initiated on vitamin D, 
calcium and phosphate binders, to keep calcium and PTH levels within the normal range, lest our 
treatment cause more harm than the disease itself. 
Aortic calcification as assessed by lateral abdominal X- ray, was found in 6.8%. In comparison, 
Adeney(141) et al assessed calcification in the descending thoracic aorta using EBCT/MSCT in 
439 Stage 3-5 CKD patients and  found a prevalence of 49%. Toussaint(147) found a 90% 
prevalence rate of abdominal aortic calcification on MSCT in Stage 3-5 CKD. One explanation 
 for the higher prevalence in these studies is an older cohort of patients, as the mean age of 
participants was 71 and 64.5 yrs respectively. Unfortunately, all other studies in the predialysis 
population have assessed vascular calcification in medium sized muscular arteries using EBCT 
(with prevalence ranging from 42 - 83% in the coronary artery in Stage 3-5(148)(149) and 49% 
in the superficial femoral artery in Stage 4(150)), which may not be comparable with the aorta, 
which is a large muscular artery. Available literature has shown a higher prevalence of 
calcification in the coronary bed compared to the aorta(141). The differences in prevalence 
between our study population and those in the West may be due to 1. Poor sensitivity of the 
imaging modality for detecting calcification, or 2. An actual difference in the prevalence of 
aortic calcification between the subcontinental and Western population. 
Bellasi(142) examined the correlation between the lateral abdominal  X ray and EBCT measured 
CAC scores.  Lateral abdominal X- ray calcification score of  ≥ 7 had a sensitivity and specificity 
of 67 and 91% for CAC score of  ≥100 Agatston units. Thus, though the lateral abdominal X-ray 
has a lower sensitivity, the presence of significant aortic calcification on an X-ray is strongly 
associated with a significant coronary calcification score. EBCT and MSCT are neither readily 
available nor economically viable modalities for screening in a developing country like India, a 
fact that the KDIGO took into consideration when it stated in its guidelines, that in situations 
where EBCT and MSCT are not available, the lateral abdominal X- ray is an acceptable modality 
for screening for vascular calcification.  
Can the lower prevalence of aortic calcification be explained by differences in prevalent risk 
factors for calcification between the predialysis Indian and Western populations? The known risk 
factors for calcification in CKD include diabetes, hyperphosphatemia, hypercalcemia, aging, 
inflammation and deficiency of circulating inhibitors of calcification like fetuin-A, matrix GLA 
 protein, pyrophosphate and osteopontin(79). The study population had a mean age of 46.6 years 
(56% being less than 50 years of age) and a mean BMI of 22.4, 36.8% being diabetics. Patients 
who had received calcium supplements, calcium based phosphate binders and vitamin D 
supplements for > 3 months were excluded, which may account for the low mean calcium levels 
of 8 mg%. In comparison, Adeney(141), Sigrist(150), Garland(149) and Toussaint(147), all of 
whom assessed vascular calcification in predialysis patients, had study populations with BMI of 
25-31, mean age ranging from 58 – 71 years, mean serum calcium levels of 9.5 – 10.5 mg%, 20-
50% diabetics and smoking prevalence of 13-55%.  Thus the lower prevalence of aortic 
calcification in our study may be explained by the lower sensitivity of X-ray for detecting 
vascular calcification, and a study population which was younger, had lower BMI, lower mean 
calcium levels was not on long term calcium or vitamin D supplements.   
The risk factors associated with presence of aortic calcification in this study were age > 50 years, 
duration of diabetes and/or hypertension > 5 years, smoking, postmenopausal status and low 
BMD on DEXA. While the first four are established risk factors for vascular calcification, the 
association between BMD and vascular calcification is slowly gaining recognition, with vascular 
calcification being independently associated with low BMD and/or risk of vertebral fractures in 
dialysis (151) and predialysis patients(147). DEXA is a poor modality to assess bone 
histomorphometry, with high turnover(152), adynamic bone disease(153) and osteomalacia(153) 
all being linked to low BMD. High turnover and adynamic bone disease have, however, been 
linked to an increased risk of calcification, though by different mechanisms(79). High turnover 
bone disease is associated with a high calcium-phosphate product, with hyperphosphatemia 
having an active role in initiating vascular smooth muscle phenotypic transformation into 
osteoblast like cells. Adynamic bone is unable to buffer calcium, which is then able to deposit at 
 areas of atherosclerosis or degenerating tissue. Postmenopausal women with osteoporosis have 
been shown to have a higher pulse wave velocity, which is a surrogate marker for vascular 
calcification(154). This risk of calcification in postmenopausal women could be a function of age 
and atherosclerosis due to loss of the protective effect of estrogen - pulse wave velocity has also 
been linked with presence of coronary atherosclerosis on CT(155) and calcification is  part of the 
natural history of atherosclerotic plaque.  
The study showed a surprising increase in risk of vascular calcification at calcium levels of 8.5 – 
9 mg%, phosphate levels < 4.8 mg% and bicarbonate levels > 18.  This flies against the 
conventional belief that vascular calcification is linked to hyperphosphatemia and 
hypercalcemia(141)(80).  Vascular calcification can be understood as either a process of active 
calcification, whereby phosphate or other factors stimulate a phenotypic change in vascular 
smooth muscle cells leading to vascular medial calcification, or a process of active inhibition of 
calcification, whereby circulating factors such as fetuin A, pyrophosphate and Matrix Gla protein 
inhibit vascular calcification under physiological conditions. The finding that vascular 
calcification in this study occurred at what would be considered ‘normal’ levels of calcium,, 
phosphate and bicarbonate for a CKD patient, points to the importance of the second theory. 
Fetuin-A was not measured in this study, nor is there data available on Fetuin-A levels in the 
Indian general or CKD population, but it is obvious from this data, that it may well prove crucial 
to understanding vascular calcification in the Indian context and must form the basis of future 
research endeavors in CKD-MBD. 
The higher prevalence and greater severity of calcification in Stage 4 CKD patients in the study 
cannot be explained, since longitudinal studies have repeatedly shown that both the prevalence 
and severity of calcification increases as renal function declines(143)(150). Stage 4 and 5 
 patients did not differ in their mean age, duration of hypertension or diabetic status, all of which 
were independent risk factors for calcification. How then can we explain this difference? Aortic 
calcification is more likely to be intimal rather than medial, since it is most commonly associated 
with the presence of atherosclerotic plaque. In this study, the association of diabetes, old age, 
hypertension, post menopausal status and smoking with aortic calcification, all of which are 
known risk factors for atherosclerosis, support this link. Aortic calcification has also been linked 
to all cause and cardiovascular mortality in the general(156) and dialysis population(86). One 
would hypothesize therefore, that, the presence of aortic calcification by Stage 4 CKD identifies 
a subgroup of patients at high risk for cardiovascular events who may not survive to reach Stage 
5 CKD, thus explaining the lower prevalence of aortic calcification in Stage 5 CKD patients, 
Longitudinal studies in the Indian CKD population are however, required to support this theory.   
Bone histomorphometry is not available at our center, and hence DEXA was used as a measure 
of bone quality in this study, with full knowledge of its poor predictive value for underlying bone 
histology. Bone mineral density as assessed by DEXA was found to be low in 78%. (55.1% 
were osteopenic and 22.9% osteoporotic), this proportion being consistent across Stage 4 and 5 
CKD. The finding that BMD did not significantly change from Stage 4 to 5 in our study was also 
supported by similar studies in predialysis populations in the West(157)(158). Low BMD, 
therefore, is already established by Stage 4 CKD. There was actually a non-significant trend 
towards an increase in BMD from Stage 4 to 5 in our study, which may be due to PTH induced 
subperiosteal new bone formation. DEXA cannot tell cortical from cancellous bone and hence 
the differential actions of PTH on cortical and cancellous bone cannot be dilineated. The risk 
factors associated with low BMD in this study were age > 50 years, postmenopausal status > 1 
yr, Vitamin D levels < 15 ng/ml, low exposure to sunlight, and acidosis. Age and 
 postmenopausal status are known risk factors for low BMD even in the general population. 
Acidosis inhibits 1-α hydroxylase, thus lowering calcitriol levels. Acidosis also leaches 
hydroxyapatite from the bone in the process of buffering protons, thus lowering bone mineral 
content(55)(56). Vitamin D is required for osteoblastic and osteoclastic differentiation, osteoid 
formation and mineralization, and its deficiency is therefore associated with osteomalacia and 
low bone mineral content. Since vitamin D is synthesized by the action of sunlight on the skin, 
reduced sun exposure and melanosis, both of which are common in CKD, result in low vitamin 
D levels, and hence low bone mineral density.   
Low BMD is strongly associated with increased fracture risk in the general population. Although 
in CKD, the predictive value of DEXA for fracture risk is considered debatable, both patients 
who had pathological fractures in this study, had a T score < -2.5 on DEXA (p = .000). CKD 
patients are undoubtedly at a high risk for fractures due to poor underlying bone quality, which 
adds to cumulative mortality and morbidity(78). Since these bone changes begin early in CKD, 
the importance of timely diagnosis and appropriate management of CKD-MBD cannot be 
overemphasized.  
The findings in this study have important implications for the management of CKD-MBD in 
Indian CKD patients.  In Stage 4 CKD, patients have low normal calcium and normal phosphate 
levels due to vitamin D deficiency.  PTH is generally appropriate for the degree of renal failure 
despite vitamin D deficiency, because of normal phosphate levels. Thus, although phosphate 
binders are not required in the majority of Stage 4 CKD patients, the treatment of vitamin D 
deficiency or marginally elevated PTH levels with Vitamin D supplements is likely to change 
this picture by increasing phosphate levels, which in turn will further elevate PTH levels.  In 
Stage 5 CKD, calcium levels drop further, phosphate levels and PTH increase and vitamin D 
 levels remain the same. The rise in phosphate despite no change in Vitamin D levels is because 
of declining GFR and loss of functional nephron mass. Hyperphosphatemia in turn, causes 
hyperparathyroidism. The target for therapy in Stage 5 CKD, therefore, should be the judicious 
use of calcium based phosphate binders which would correct both hypocalcemia and 
hyperphosphatemia, not Vitamin D supplements, which would further increase phosphate levels. 
There is a caveat here, though. Once treatment is initiated, PTH, calcium and phosphate levels 
need to be monitored regularly, since the study also showed that the risk of valvular calcification 
increased at calcium levels above 9.5 mg% and PTH levels < 300 pg/mL. It would therefore be 
appropriate to aim for PTH levels around 150 – 300 pg/mL in Stage 4 and a little above 300 
pg/mL in Stage 5, while ensuring calcium levels remained in the 8.5 – 9.5 mg% range.   
BMD assessment by DEXA does not seem to add much to clinical decision making, and should 
therefore not be part of routine workup, given its inherent flaws. The high prevalence of valvular 
calcification in a predialysis population without prior exposure to calcium supplements and 
vitamin D, warns against blind treatment of all CKD patients with calcium and vitamin D. The 
presence of extraskeletal calcification in patients with otherwise normal CKD-MBD parameters 
is worrying, especially as indirect evidence from this study would suggest a clear mortality risk 
associated with its presence, and this makes a strong case for studying levels of calcification 
inhibitors in the Indian CKD population, 
In conclusion, this study reveals a huge burden of CKD-MBD related complications well 
established by the pre-dialysis stage.  Nephrologists in India need to be aware of the difference in 
CKD-MBD trends between India and the West, and adopt simple and cost effective strategies to 
diagnose and treat this problem. 
 LIMITATIONS OF THIS STUDY 
1. Bone histomorphometry was not done and hence the type of osteodystrophy in these 
patients cannot be commented on. 
2. Femoral DEXA is not the ideal modality to assess BMD in CKD patients, as forearm 
bones have higher cortical bone content and may reflect changes due to 
hyperparathyroidism better.  
3. Only 32% of patients had a DEXA scan at baseline 
4. We did not have a gold standard (EBCT/MSCT) to correctly assess the prevalence of 
valvular and vascular calcification, to which X-ray and echocardiography based 
prevalences could be compared. The sensitivity and specificity of the lateral abdominal 
X-ray and Echo to diagnose extraskeletal calcification in the Indian population therefore, 
remains to be determined. 
5. Inflammatory markers and levels of calcification inhibitors such as fetuin-A which could 
have explained differences in prevalences of valvular and vascular calcification between 








1. CKD-MBD is largely asymptomatic in 45% of patients. In those who are symptomatic, 
bone pain is the most common symptom and is associated with serum PTH > 300 pg/ml 
2. 73.8% had S. calcium levels < 8.5 mg%, 58.4% had S. phosphate > 4.5 mg%, 76.5% had 
PTH > 150 pg/mL and 87.8% had Vitamin D < 30 ng/ml. S. calcium declined and S. 
phosphate and PTH significantly increased from Stage 4 to 5.  
3. ALP and Vitamin D did not significantly change from Stage 4 to 5 despite rise in PTH, 
suggesting that ALP may be not be a good marker of bone mineral disease in CKD. 
4. Risk factors for Vitamin D < 15 ng/mL were diabetes, reduced sunlight exposure, BMI > 
23, high socioeconomic status and female sex. Vitamin D deficiency was significantly 
associated with elevated total cholesterol, LDL, non HDL cholesterol and triglycerides.  
5. Vascular calcification was seen in 6.8% and associated with diabetes or hypertension for 
> 5 years, age > 50 yrs, postmenopausal status, smoking, low BMD, S. calcium 8.5-9 
mg%, phosphate < 4.8 mg% and S. bicarbonate > 18 mmol/L, suggesting the role of 
inhibitors of vascular calcification in determining the risk of vascular calcification. The 
prevalence of vascular calcification was significantly lower in Stage 5 compared to Stage 
4 (10.1 vs 5%), and provides indirect evidence of an increased mortality risk associated 
with vascular calcification.  
6. 78% had low BMD (T score < -1), the risk factors being age > 50 yrs, postmenopausal 
status of  >  1 year, Vitamin D < 15 ng/mL, low sunlight exposure and S. bicarbonate < 
22 mmol/L.  
7. 51% had significant valvular calcification (Echocardiographic calcification score ≥ 5), 
which was associated with PTH levels < 300 pg/mL and S. calcium > 9.5 mg%.  
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Modality of dialysis (HD/PD)                                                            
Residual kidney function (urine output)                                                            
GFR/1.73 m2 (aMDRD)  
History of bone pains  
                 Pathological fractures  
                 Joint effusions  
                 Red eyes  
                 Pruritus                                                                                





H/o exposure to aluminium  
  
 Personal history 
Smoking (if yes, quantity and duration)  
Alcohol (if yes, quantity and duration)  
Sun  exposure (hours per day)  
Menstrual history (in females) 
 
Obstetric history (in females) 
 
Milk consumption (ml/day) 
 Diet (vegetarian, non vegetarian) 
 
DRUG HISTORY 
Whether on calcitriol, if so for how long  
Route of administration and dose  
Whether on Phosphate binders, if so for how long 
Name and dose 
Calcium supplements (dose, duration) 









Lipid profile  
Hb  
B. urea/S. creatinine  
Ca/P  
S. Bicarbonate  
PTH (iced sample)  
ALP  
25 hydroxy vitamin D  
S. Albumin  
DEXA scan femoral neck 
• BMD 
• T score  
 
 
X ray abdomen  lateral view  
Calcification present? 






Affected segment score 
Anteroposterior affected score 




Simplified Echocardiographic score  
 
Aortic valve calcification (0 = absent, 1 = present) 
Mitral valve or annular calcification (0 = absent, 1 = present) 
Subvalvular apparatus calcification (0 = absent, 1 = present) 
 
 Restriction of either valve (0 = absent, 1 = present) 
Total score 
 
Main Echocardiographic score 
Posterior annulus, by thirds (0-3) 
PML restriction (0 = absent, 1 = present) 
Anterior annulus calcification (0 = absent, 1= present) 
AML restriction (0 = absent, 1= present) 
MV calcification (0 = absent, 1 = mild, 2 = > mild) 
Subvalvular apparatus calcification (0 = absent,1 = present) 
AV calcification (0 = absent, 1 = nodule in < 3 leaflets, 2 = nodules in 
3 leaflets, non restrictive; 3 = restrictive) 






S.no H.No Age Res Sex Edu Occ Symp nkd dial gfr pain frac prur prox para smok alc sun amen milk diet vdur vdos bind bdur
1 571414d  38 2 2 6 1 7 3 3 30 0 0 0 0 0 0 0 0.5 0 0 2 0 0 4 0
2 571791d  60 5 1 2 6 1 2 3 15 1 0 0 0 0 0 0 0.5 . 0 1 0.5 3.25 2 0.5
3 573048d  40 3 2 3 1 18 2 3 15 1 0 1 0 0 0 0 0.5 12 100 2 0 0 4 0
4 575232d  21 3 2 4 1 1 4 1 4 1 0 0 1 0 0 0 0.5 0 100 2 0 0 4 0
5 573831d  34 2 2 2 1 2 3 3 14 1 0 0 1 0 0 0 0.5 0 0 1 0.5 3.25 1 0.5
6 573889d  52 3 1 3 4 1 3 3 6 0 0 0 0 0 0 0 1.5 . 500 2 0.5 3.25 1 0.5
7 574479d  56 2 2 1 1 1 2 3 13 0 0 0 0 0 0 0 1 0 500 1 0.3 2.5 4 0
8 573845d  55 2 1 5 4 3 2 3 29 0 0 0 0 0 0 0 6 . 0 2 0 0 4 0
9 576256d  42 2 1 5 7 3 1 3 5 0 0 1 0 0 1 0 2 . 0 2 0.3 2.5 4 0
10 567480d  61 1 1 2 1 24 2 3 18 0 0 0 0 0 1 0 0.5 . 500 1 0 0 4 0
11 574085d  45 2 1 2 2 2 1 3 3 0 0 0 0 0 0 0 3 . 0 2 0 0 4 0
12 569111d  48 2 2 3 1 3 3 3 15 1 0 0 1 0 0 0 0.5 8 250 1 0 0 4 0
13 574003d  62 2 2 2 1 3 4 3 7 1 0 1 1 0 0 0 0.5 60 0 1 1 7.5 4 0
14 576925d  72 3 1 5 1 1 3 3 13 0 0 0 0 0 0 0 3 . 250 2 0 0 4 0
15 573914d  25 6 1 2 7 3 1 1 6 0 0 1 0 0 0 0 0.5 . 0 1 2.5 18.7 4 0
16 573847d  60 7 1 6 4 24 2 3 15 0 0 0 0 0 0 0 0.5 . 200 2 2 15 4 0
17 576300d  56 2 2 5 1 4 1 3 7 1 0 0 1 1 0 0 0.5 60 0 2 0 0 4 0
18 576209d  53 3 1 6 4 0 2 3 11 0 0 0 0 0 0 0 6 . 250 2 0 0 4 0
19 936663c  61 1 1 5 1 1 2 3 7 0 0 0 0 0 0 0 0 . 100 2 0 0 4 0
20 579790d  35 3 1 6 5 6 1 3 5 0 0 0 0 0 0 0 5 . 0 2 0.3 2.5 3 0.3
21 579724d  33 2 2 2 1 12 2 3 13 1 0 0 1 1 0 0 0.5 0 250 2 0 0 4 0
22 576217d  21 4 2 3 1 3 5 3 13 1 0 0 0 0 0 0 0.5 0 0 2 2 15 4 0
23 579878d  50 2 1 3 7 9 2 3 11 0 0 1 1 1 0 0 0 . 0 2 1.5 22.5 4 0
24 507233d  52 9 1 4 4 0 3 3 28 1 0 0 0 0 0 0 0.5 . 0 2 0 0 4 0
25 576687d  65 3 1 4 1 0 3 3 18 0 0 0 0 0 0 0 0.5 . 200 1 0 0 1 0.5
26 576862d  62 2 1 4 6 1 2 3 10 0 0 0 0 0 1 0 4 . 100 2 0 0 4 0
27 580058d  44 10 1 4 4 4 4 1 10 0 0 0 0 0 0 0 1.5 . 0 2 0.5 7.5 4 0
28 579828d  48 10 2 3 1 0 1 3 23 1 0 0 1 1 0 0 0.5 0 0 1 1 7.5 4 0
29 574010d  33 5 1 2 2 6 1 3 14 0 0 0 0 0 1 0 6 . 200 1 0 0 4 0
30 573748d  60 5 1 3 1 6 3 3 30 1 0 0 0 0 0 0 0.5 . 0 2 0 0 4 0
31 580342d  55 2 1 5 4 3 6 3 22 1 0 0 0 0 0 0 3 . 250 2 0 0 4 0
32 583207d  64 3 1 3 1 3 2 1 7 0 0 1 1 0 0 0 0.5 . 100 2 0 0 4 0
33 578484d  53 12 1 5 1 24 2 3 18 1 0 1 0 0 1 0 2 . 0 1 2.5 18.7 4 0
34 578920d  45 3 1 3 6 2 2 3 10 1 0 1 1 0 1 1 2.5 . 0 2 0 0 1 1
35 580745d  50 6 1 3 4 1 1 3 12 1 0 1 0 1 0 0 6 . 0 1 0.66 5 1 0.5
36 581281d  43 2 1 3 6 3 4 3 4 0 0 0 0 0 0 0 2 . 0 2 0 0 4 0
37 580677d  60 2 1 5 4 6 2 3 11 0 0 0 0 0 0 0 0.5 . 100 2 0.1 3.5 4 0
38 581120d  45 9 1 5 4 3 1 3 10 0 0 0 0 0 1 0 0.5 . 0 1 2.5 12.5 4 0
39 576413d  20 8 1 5 1 3 5 3 9 1 0 0 0 0 0 0 0.5 . 0 2 0 0 4 0
40 583649d  49 2 1 2 2 3 1 3 6 1 0 0 1 0 0 0 3 . 0 1 0 0 4 0
41 583673d  35 2 1 5 4 5 4 3 15 1 0 0 0 0 0 0 1.5 . 0 2 0 0 4 0
42 579791d  25 2 1 5 1 6 1 1 5 0 0 0 0 0 0 0 4 . 0 2 0 0 4 0
43 583766d  42 13 1 3 4 2 4 3 22 0 0 0 1 0 0 0 6 . 200 2 0 0 4 0
44 206733d  38 1 2 3 1 0 4 3 27 0 0 0 0 0 0 0 0.5 . 0 2 0 0 4 0
45 565799d  55 2 1 5 4 3 2 3 12 0 0 0 0 0 0 0 2.5 . 100 2 0 0 4 0
46 577155d  50 1 1 3 2 0 2 3 29 0 0 0 0 0 0 0 1 . 200 2 0 0 4 0
47 584881d  50 1 2 1 1 6 2 3 18 0 0 0 0 0 0 0 0.5 36 0 1 0 0 4 0
48 584613d  43 8 1 5         3 1 3 25 0 0 0 0 0 0 0 0.5 . . 2 0 0 4 0
49 583477d  34 2 2 2 1 12 1 3 5 1 0 0 0 0 0 0 0.5 . 0 2 1 7.5 4 0
50 584734d  52 2 2 6 1 24 2 3 17 1 0 1 1 0 0 0 0.5 240 0 2 0 0 4 0
51 392244c  53 2 1 5 4 3 1 3 8 1 0 0 0 0 0 0 0.5 . 0 2 0 0 4 0
52 584344d  39 2 1 2 2 1 1 3 4 0 0 0 0 0 1 0 7 . 0 2 0.6 7.5 4 0























































cdos cdur ht dm bmi hb cr chol tg hdl ldl ca phosbic pth alp vitd alb bmd tscor echo1echo2 Xray ass apas apss
0 0 0 0 29 9 2 157 201 31 75 8 4 18 1141 122 19 5 0.646 ‐1.8 . . 0 . . .
0 0 1 10 22 8 4 163 83 44 83 8 5 22 214 123 23 4 0.673 ‐1.8 . . 1 1 2 3
0 0 1 6 19 6 4 149 96 46 81 9 5 12 622 106 24 3 0.518 ‐3 . . 0 . . .
0 0 0 0 22 9 14 172 131 62 68 7 9 13 744 87 13 3 0.72 ‐1.2 . . 0 . . .
0 0 2 0 26 8 4 104 109 32 43 7 4 16 2500 950 19 4 0.816 ‐0.3 . . 0 . . .
0 0 5 0 23 7 10 109 130 30 45 7 7 11 859 88 31 5 0.651 ‐2.1 . . 0 . . .
0 0 0 0 23 9 4 193 200 24 110 9 5 23 103 168 31 4 0.892 0.4 . . 0 . . .
0 0 2 10 24 11 3 171 106 47 93 9 5 21 185 89 17 4 0.729 ‐1.5 . . 1 2 3 7
500 0.3 8 0 24 8 13 158 202 47 63 7 8 13 938 93 22 4 0.85 ‐0.6 . . 0 . . .
0 0 2 20 24 8 4 297 157 34 193 8 4 21 535 133 13 3 0.657 ‐2 . . 0 . . .
0 0 1 0 24 8 17 135 89 45 61 9 8 14 205 78 23 3 0.589 ‐2.5 . . 0 . . .
0 0 0 0 21 8 4 144 107 35 77 6 6 15 2042 361 24 4 0.488 ‐3.3 . . 0 . . .
500 1 0 0 22 8 7 152 107 42 73 9 6 19 107 132 14 3 0.534 ‐2.8 . . 0 . . .
0 0 0 15 29 11 5 119 141 29 157 9 4 16 176 83 18 3 0.822 ‐0.8 . . 0 . . .
1000 2.5 0 0 17 7 11 102 64 37 37 8 3 15 87 102 41 4 0.545 ‐2.8 . . 0 . . .
500 2 20 2 18 8 4 176 53 35 114 8 4 22 90 42 29 3 0.669 ‐1.9 . . 0 . . .
0 0 5 0 26 7 6 108 95 27 55 6 7 14 722 100 24 4 0.651 ‐1.8 . . 0 . . .
0 0 10 15 26 9 6 102 111 36 37 8 3 19 873 97 17 4 1.06 0.9 . . 0 . . .
1000 1 1 5 25 7 8 105 49 34 62 8 4 24 324 69 31 4 0.605 ‐2.4 . . 0 . . .
1000 0.3 1 0 25 7 13 56 39 27 16 8 6 16 0.9 82 29 4 0.714 ‐1.6 0 0 0 . . .
0 0 4 0 22 7 4 156 148 30 87 8 6 16 0.9 56 24 4 0.601 ‐2.2 0 0 0 . . .
0 0 0 0 24 10 4 166 55 45 95 8 5 16 0.9 86 15 4 0.695 ‐1.4 . . 0 . . .
1000 1 5 17 . 5 6 108 44 46 39 9 5 15 0.9 120 27 3 0.571 ‐2.6 1 1 1 3 5 8
0 0 1 0 28 14 3 137 94 38 76 9 4 22 79 73 23 4 0.854 ‐0.6 1 0 0 . . .
0 0 5 0 24 11 4 82 75 32 30 8 4 23 152 72 28 4 . . 1 0 0 . . .
0 0 0 10 27 9 6 133 76 35 74 8 4 22 902 56 22 4 0.709 ‐1.6 1 1 0 . . .
1000 0.5 0 0 22 7 6 125 56 36 69 9 3 21 342 31 23 3 0.711 ‐1.6 5 3 0 . . .
500 1 4 0 22 10 2 142 72 47 73 8 4 20 542 . 18 4 0.626 ‐2 . . 0 . . .
0 0 6 0 22 13 5 188 224 29 104 8 3 28 287 118 34 4 0.719 ‐1.6 . . 0 . . .
0 0 3 0 20 13 2 154 102 31 91 9 4 18 145 96 24 4 0.614 ‐2.3 . . 0 . . .
0 0 30 0 25 12 3 94 81 29 46 8 4 24 533 98 30 4 0.706 ‐1.6 1 0 0 . . .
0 0 2 2 22 11 8 183 73 57 93 8 6 21 255 92 45 2 0.588 ‐2.5 1 0 0 . . .
1500 2.5 10 2 22 11 4 98 79 20 65 8 3 19 527 137 48 4 0.7 ‐1.7 1 0 0 . . .
1500 1 0 10 18 8 7 202 40 68 101 8 6 16 566 140 21 3 0.523 ‐3 4 1 0 . . .
1000 0.5 0 0 20 9 5 94 71 29 50 8 5 15 125 63 26 4 0.769 ‐1.2 3 1 0 . . .
0 0 1 0 27 8 14 104 157 33 36 7 9 15 502 61 21 4 0.679 ‐1.8 3 1 0 . . .
1000 0.1 25 20 21 8 6 210 255 26 118 9 4 20 357 67 19 4 0.606 ‐2.4 6 3 0 . . .
1000 2.5 7 0 24 7 7 348 241 47 221 10 7 21 59 88 20 2 0.756 ‐1.3 8 4 0 . . .
0 0 0 0 20 10 8 . . 49 35 8 5 18 358 122 18 4 0.961 0.2 0 0 0 . . .
0 0 5 0 25 6 10 . . . . 4 8 14 644 543 21 4 0.575 ‐2.6 . . 0 . . .
0 0 1 0 18 10 5 147 51 54 67 9 6 26 168 66 36 4 0.879 ‐0.4 1 0 0 . . .
0 0 1 0 17 8 13 159 108 43 83 6 10 19 781 102 20 4 0.754 ‐1.3 0 0 0 . . .
0 0 0 0 25 11 3 399 220 56 257 8 6 32 285 136 18 3 0.748 ‐1.3 4 2 0 . . .
0 0 1 0 30 13 2 206 174 31 128 9 4 21 147 72 28 4 1.72 ‐1.2 1 0 0 . . .
0 0 8 8 20 8 5 106 59 55 28 8 5 27 382 63 22 4 0.643 ‐2.1 1 0 0 . . .
0 0 10 5 26 14 3 187 177 30 121 9 4 24 138 67 26 5 0.684 ‐1.8 0 0 0 . . .
0 0 1 10 29 10 3 258 200 38 168 8 4 21 103 89 29 3 0.781 ‐0.6 3 2 0 . . .
0 0 0 0 16 13 3 139 56 52 66 9 4 25 238 130 . 5 . . 4 3 0 . . .
0 0 0 0 21 8 9 188 68 60 98 6 6 21 1042 176 . 4 . . 3 2 0 . . .
0 0 10 10 27 11 4 149 113 46 76 8 5 16 434 137 17 4 0.443 ‐3.7 1 0 0 . . .
0 0 1 0 . 7 8 140 57 58 72 9 6 16 770 105 16 4 . . 3 2 1 2 3 3
0 0 2 0 18 7 14 77 78 20 36 6 9 10 856 79 45 4 0.709 ‐1.6 0 0 0 . . .
0 0 0 0 21 10 3 190 163 27 128 9 3 26 251 139 35 4 0.655 ‐2 4 2 2 . . .
S.no H.No Age Res Sex Edu Occ Symp nkd dial gfr pain frac prur prox para smok alc sun amen milk diet vdur vdos bind bdur
54 584725d  24 3 1 3 1 4 4 3 19 1 0 1 1 0 0 0 0.5 . 0 2 0 0 4 0
55 585038d  32 2 1 5 4 2 1 3 11 0 0 0 0 0 0 0 1.5 . 0 2 0.3 2.5 1 0.6
56 584778d  60 3 1 1 6 1 2 3 5 1 0 0 0 0 0 1 1 . 0 2 0.5 3.25 1 0.5
57 589184d  37 3 1 5 4 3 6 3 15 0 0 0 0 0 0 0 1.5 . 100 1 0 0 4 0
58 589166d  27 2 2 5 1 6 1 3 17 0 0 1 0 0 0 0 0.5 0 0 2 0 0 4 0
59 539456d  65 11 1 3 1 1 2 3 19 0 0 0 0 0 1 1 1 . 200 2 0 0 4 0
60 589381d  65 8 1 1 1 2 2 3 11 1 0 0 0 0 1 0 0.5 . 0 2 2 15 4 0
61 593715d  56 2 1 4 4 3 2 3 28 1 0 1 1 0 0 0 1 . 0 1 0 0 4 0
62 593287d  30 2 1 3 6 3 1 3 10 1 0 1 0 0 1 0 3 . 100 2 0 0 4 0
63 594468d  40 3 1 2 2 2 1 3 18 0 0 0 0 0 0 0 2.5 . 200 2 0.1 0.5 1 0.6
64 593502d  58 1 2 1 1 1 1 3 18 0 0 0 0 0 0 0 0.5 240 300 2 0 0 4 0
65 590197d  60 2 2 3 1 6 4 3 4 0 0 1 0 0 0 0 0.5 120 0 2 0.1 2.5 4 0
66 579324d  56 3 1 3 4 0 2 3 17 1 0 0 0 0 1 0 1.5 . 200 2 0 0 4 0
67 594432d  45 3 2 6 4 2 1 3 3 0 0 0 0 0 0 0 1.5 0 200 1 0.5 7.5 1 0.5
68 592636d  46 1 1 2 2 6 2 3 7 0 0 1 0 0 1 1 1 . 200 1 0 0 4 0
69 589421d  44 2 1 3 7 2 2 3 20 0 0 1 1 0 1 0 2.5 . 100 2 0 0 4 0
70 587248d  49 6 2 3 1 2 2 3 11 0 0 0 1 0 0 0 1.5 0 500 1 1 7.5 1 0.5
71 585175d  22 3 1 5 1 1 1 3 19 0 0 0 0 0 0 0 3 . 200 2 0 0 3 0.5
72 588092d  55 1 1 3 1 1 2 3 15 0 0 0 0 0 1 0 0.5 . 200 2 0 0 4 0
73 589225d  24 3 1 3 2 1 4 3 5 0 0 0 0 0 0 0 2 . 200 2 0 0 1 1
74 593880d  29 3 1 2 2 1 4 1 4 1 0 0 0 0 1 0 1.5 . 150 2 0 0 1 0.5
75 592685d  40 7 2 1 1 1 1 3 15 0 0 0 0 0 0 0 1.5 0 0 1 0.5 0 4 0
76 593887d  52 3 1 5 4 1 2 3 6 0 0 0 0 0 0 0 5 . 500 1 0 0 4 0
77 593896d  25 2 1 2 2 1 2 3 8 0 0 0 0 0 0 0 3 . 200 2 0 0 4 0
78 593353d  27 14 2 5 1 1 1 3 5 0 0 0 0 0 0 0 0.5 0 100 2 0 0 1 0.5
79 587299d  55 3 1 5 4 1 6 3 16 0 0 0 0 0 0 0 0.5 . 0 2 1 22.5 4 0
80 593107d  65 1 2 1 1 0 1 3 17 0 0 0 0 0 0 0 0.5 120 0 1 0 0 4 0
81 589255d  35 6 2 3 1 1 1 3 14 1 0 1 1 0 0 0 0.5 . 500 1 0.5 1 4 0
82 671427d  33 6 2 3 1 2 1 3 21 0 0 1 0 0 0 0 1 0 100 2 0 0 4 0
83 642457d  37 2 1 3 6 1 1 3 9 1 0 1 0 0 0 0 10 . 100 2 0.5 1 4 0
84 666058c  56 3 2 2 1 1 2 3 10 0 0 0 0 0 0 0 1 180 200 1 0 0 4 0
85 667196d  53 3 2 2 1 3 1 3 12 0 0 1 0 0 0 0 1 60 200 2 0 0 4 0
86 667132d  55 15 1 5 4 1 2 3 15 0 0 0 0 0 0 0 1 . 0 2 0 0 4 0
87 668119d  48 2 1 3 1 3 1 3 4 0 0 0 0 0 0 0 0.5 . 250 2 0 0 4 0
88 666892d  55 2 1 3 6 1 1 3 5 0 0 1 1 0 0 0 1 . 250 2 0.66 1 4 0
89 671099d  31 5 1 3 2 1 1 3 5 0 0 0 0 0 0 0 1.5 . 0 2 0 0 4 0
90 668133d  52 12 1 3 4 1 1 3 28 0 0 0 1 0 0 0 5.5 . 500 2 1 0.5 4 0
91 670281d  68 3 1 3 1 0 1 3 6 0 0 0 0 0 0 0 1 . 250 2 0.1 1 4 0
92 671164d  60 3 1 1 3 1 6 3 8 0 0 0 0 0 0 0 3 . 0 2 0 0 3 1
93 671966d  44 8 1 3 6 1 1 3 9 0 0 0 0 0 0 0 3 . 0 2 0 0 4 0
94 670499d  66 3 1 3 1 12 2 3 7 0 0 1 0 0 1 0 0.5 . 200 1 0 0 4 0
95 670918d  45 2 2 3 1 0 1 3 16 0 0 0 1 0 0 0 0.5 0 150 2 0 0 1 1
96 677470d  50 1 2 1 1 1 2 3 10 0 0 0 0 0 0 0 0.5 60 0 2 0 0 4 0
97 679096d  69 6 1 4 1 1 2 3 19 0 0 0 0 0 0 0 1.5 . 0 1 0 0 4 0
98 677285d  59 11 1 3 1 12 2 3 17 0 0 1 1 0 0 0 0.5 . 500 1 0 0 4 0
99 670091d  32 2 1 5 4 0 1 3 7 0 0 1 0 0 0 0 0.5 . 200 2 2.5 9 4 0
100 672811d  43 3 1 5 6 1 2 3 12 1 0 0 1 0 0 0 1 . 200 2 2 15 4 0
101 681766d  27 2 2 3 1 18 4 3 8 0 0 0 0 0 0 0 0.5 0 0 2 0.5 15 4 0
102 694754d  42 2 1 3 6 2 1 3 12 0 0 0 0 0 0 0 0.5 . 0 2 0 0 4 0
103 688577d  51 3 1 5 4 1 2 3 26 0 0 0 0 0 0 0 0.5 . 1000 2 0 0 4 0
104 696229d  46 2 1 2 2 3 1 3 15 0 0 0 0 0 0 0 6 . 0 2 0 0 1 1.5
105 691477d  57 2 1 5 6 3 1 3 10 0 0 0 0 0 1 0 1 . 200 2 2 5 1 0.66























































cdos cdur ht dm bmi hb cr chol tg hdl ldl ca phosbic pth alp vitd alb bmd tscor echo1echo2 Xray ass apas apss
0 0 0 0 22 11 4 168 119 43 90 8 4 . 261 67 15 4 0.938 0.1 1 0 0 . . .
1500 0.6 0 0 27 9 6 . . . . 9 6 18 662 71 25 4 . . 1 0 0 . . .
1500 0.5 1 1 17 9 11 130 34 46 74 6 7 14 877 85 22 4 . . 3 2 2 . . .
0 0 1 0 24 9 5 121 99 28 61 9 4 17 1306 309 28 5 0.83 ‐0.7 1 0 2 . . .
0 0 1 0 25 7 4 126 56 42 66 7 5 13 532 77 25 3 . . 0 0 0 . . .
0 0 3 3 22 8 3 157 141 25 93 8 4 19 339 89 32 4 . . 2 1 0 . . .
1500 2 3 25 23 10 6 271 274 32 164 9 5 24 230 85 21 4 0.604 ‐2.4 3 1 2 . . .
0 0 3 3 28 12 2 185 119 36 128 9 4 23 315 87 11 4 . . 5 3 1 2 2 2
0 0 0 0 19 9 7 140 58 59 65 8 6 16 385 144 26 4 . . 1 0 0 . . .
1000 0.6 0 0 18 8 4 134 85 37 67 8 3 28 123 43 33 4 0.646 ‐2.1 0 0 0 . . .
0 0 3 0 25 10 3 146 70 49 88 9 5 20 636 81 29 5 . . . . 2 . . .
1000 0.1 6 0 17 6 11 184 155 48 102 6 9 13 1761 95 24 4 . . 3 1 0 . . .
0 0 9 9 26 11 4 147 137 32 76 7 5 19 509 71 36 4 . . . . 1 1 1 1
1000 0.5 0 0 25 9 14 137 89 63 44 9 5 15 303 119 23 3 . . 2 1 0 . . .
0 0 10 10 22 9 9 . . . . 9 6 16 378 98 16 3 . . 2 1 1 2 2 2
500 1 8 1 25 6 4 90 65 39 39 9 5 17 195 70 23 3 0.758 ‐1.3 4 2 0 . . .
0 0 7 7 27 10 5 143 100 45 66 8 6 17 1066 93 14 4 0.671 ‐1.6 1 0 0 . . .
0 0 0 0 21 13 4 115 107 32 59 8 5 20 152 62 22 5 1.06 1 . . 0 . . .
0 0 5 5 25 10 5 145 158 30 79 9 5 13 731 91 32 4 0.838 ‐0.7 . . 0 . . .
0 0 0 0 17 8 12 128 59 58 55 8 8 14 360 76 19 4 0.678 ‐1.9 0 0 0 . . .
0 0 0 0 21 9 16 164 200 36 85 8 7 28 236 63 27 4 0.934 0 6 4 0 . . .
1000 1 3 0 24 8 4 124 117 34 68 9 4 21 67 44 38 4 0.951 ‐0.4 0 0 0 . . .
0 0 0 12 27 9 10 139 80 45 67 7 5 20 0.9 99 19 4 0.676 ‐1.9 2 1 0 . . .
0 0 3 3 21 7 8 160 135 68 58 7 7 15 599 162 18 3 0.566 ‐2.7 1 0 0 . . .
0 0 3 0 26 8 10 245 306 35 142 9 5 24 280 103 16 4 0.863 0.1 . . 0 . . .
1000 1 10 0 22 11 4 223 231 29 132 9 5 19 1036 208 25 4 0.667 ‐1.9 3 2 0 . . .
0 0 3 0 27 13 3 138 137 27 76 8 4 21 225 . 20 4 0.469 ‐3.4 0 0 0 . . .
1000 1 5 0 16 7 4 144 69 44 81 8 6 17 230 60 30 4 0.59 ‐2.3 . . 0 . . .
0 0 0 0 25 10 3 142 261 29 71 9 3 20 281 133 16 5 0.755 ‐0.8 6 2 0 . . .
1000 0.5 1 0 20 7 6 332 148 37 239 9 5 . 75 85 23 4 0.701 ‐1.7 4 2 0 . . .
0 0 5 5 30 8 6 170 173 34 106 6 5 19 601 153 16 4 0.51 ‐3.1 . . 1 1 2 2
0 0 5 0 27 8 5 210 93 44 163 5 7 17 470 314 12 4 0.647 ‐1.8 3 2 0 . . .
0 0 3 25 26 8 4 158 185 34 101 8 4 17 149 76 19 4 0.936 0 . . 0 . . .
0 0 1 0 20 5 12 131 88 48 77 7 7 15 709 88 25 4 0.76 ‐0.8 4 2 0 . . .
1000 0.7 5 0 25 8 11 100 103 25 60 8 6 16 587 83 22 3 0.643 ‐2.1 2 1 0 . . .
0 0 0 0 19 7 14 191 92 44 131 8 7 15 373 74 30 4 0.932 0 . . 0 . . .
0 0 2 0 21 11 3 120 98 34 67 8 4 22 26 61 28 4 0.639 ‐2.1 6 3 0 . . .
1000 0.1 0 0 . 11 10 145 231 30 77 9 5 20 113 67 32 4 0.711 ‐1.6 . . 0 . . .
0 0 0 0 19 7 7 82 43 26 44 8 7 11 285 45 34 4 0.71 ‐1.6 6 3 0 . . .
0 0 3 0 27 10 7 186 259 24 115 8 4 17 255 107 20 4 0.742 ‐1.4 . . 0 . . .
0 0 5 5 23 10 8 . . . . 8 8 13 496 69 21 4 0.564 ‐2.7 7 3 1 2 3 3
1500 1 0 0 23 9 4 146 109 32 92 8 3 18 538 177 16 4 0.639 ‐1.9 . . 0 . . .
0 0 15 1 30 11 5 175 272 34 97 9 5 18 256 118 8 3 0.7 ‐1.3 5 2 0 . . .
0 0 6 6 25 9 4 133 143 39 69 9 5 17 110 97 17 4 0.445 ‐3.6 5 2 0 . . .
0 0 5 20 22 9 4 175 105 45 110 . . 16 391 170 10 3 0.555 ‐2.8 2 1 0 . . .
0 0 0 0 22 10 9 124 178 22 74 7 6 16 239 87 26 5 0.993 0.5 9 4 0 . . .
0 0 1 6 31 8 6 . . . . 8 6 19 182 121 20 4 0.935 0 7 3 0 . . .
1000 0.5 0 0 18 7 7 151 63 54 89 8 6 20 60 66 21 4 0.839 ‐0.1 8 3 2 . . .
0 0 1 0 16 10 5 168 104 62 68 8 3 28 70 116 25 5 0.771 ‐1.2 5 3 0 . . .
0 0 3 18 24 10 3 167 274 30 93 9 4 25 201 121 15 3 0.646 ‐2.1 4 2 0 . . .
1000 1.5 0 0 17 9 4 135 80 35 83 9 4 23 79 71 23 4 0.614 ‐2.3 5 3 0 . . .
1000 0.7 15 0 23 11 6 65 76 27 29 8 4 . 247 . 15 5 0.573 ‐2.6 5 2 1 2 2 2
0 0 0 0 18 10 3 124 91 38 67 9 3 21 29 97 29 4 0.639 ‐2.1 5 3 0 . . .
S.no H.No Age Res Sex Edu Occ Symp nkd dial gfr pain frac prur prox para smok alc sun amen milk diet vdur vdos bind bdur
107 624075d  41 2 2 5 1 3 1 3 3 1 0 0 0 0 0 0 0.5 0 0 2 0 0 4 0
108 587594d  47 2 1 3 4 6 1 3 28 1 0 0 0 0 1 0 1 . 0 2 0 0 4 0
109 622383d  55 2 1 3 3 12 2 3 10 0 0 1 0 0 0 1 7 . 0 2 0 0 4 0
110 617925d  15 2 2 3 1 0 1 3 29 0 0 0 0 0 0 0 1 . 100 1 1 15 4 0
111 622827d  51 10 2 5 1 12 1 3 11 0 0 1 0 0 0 0 0.5 48 0 1 1 30 4 0
112 628794d  56 2 1 3 3 3 1 1 4 1 0 0 0 0 1 0 1 . 500 2 0 0 4 0
113 627706d  56 3 1 3 6 1 1 3 6 0 0 0 0 0 0 0 1.5 . 200 2 0.5 3.5 2 0.5
114 619150d  51 2 1 1 4 1 1 3 9 0 0 0 0 0 1 0 7 . 0 2 0 0 1 0.24
115 627506d  42 2 1 3 6 2 1 1 4 0 0 0 0 0 0 0 1.5 . 200 2 0.5 3.75 4 0
116 629460d  46 10 2 3 1 6 1 3 12 1 0 0 0 0 0 0 1.5 0 0 1 0 0 4 0
117 647558d  30 3 2 5 1 0 1 3 15 0 0 1 0 0 0 0 0.5 0 250 2 0.5 3.75 1 0.5
118 646038d  36 2 1 2 2 0 1 3 11 1 0 0 1 0 0 0 1 . 0 2 1 30 4 0
119 626336d  53 2 1 3 6 3 2 3 20 0 0 0 0 0 1 0 1.5 . 200 2 0 0 4 0
120 650484d  63 3 1 3 1 2 2 3 9 1 0 0 1 0 1 0 1 . 300 2 0 0 4 0
121 619985d  59 2 1 6 6 0 1 3 7 0 0 0 0 0 0 0 1.5 . 0 2 0 0 4 0
122 621867d  16 16 1 3 1 1 1 1 10 0 0 0 0 0 0 0 2 . 100 2 0.5 2.5 3 0.5
123 618374d  54 6 2 1 1 6 1 3 26 1 1 1 1 0 0 0 0.5 60 0 2 0 0 4 0
124 621281d  43 5 2 5 7 36 2 3 5 0 0 0 0 0 0 0 0.5 0 0 2 0 0 4 0
125 600078d  43 2 2 6 1 6 4 3 14 1 0 0 0 0 0 0 0.5 0.1 0 2 0 0 4 0
126 615581d  58 1 2 5 4 12 1 3 11 0 0 0 0 0 0 0 0.5 120 200 1 0.66 20 1 0.6
127 621445d  37 2 1 2 2 1 1 1 3 0 0 0 1 0 0 0 5 . 0 2 0 0 1 0.3
128 623752d  52 15 1 5 5 1 2 3 21 0 0 1 0 0 0 0 5 . 500 2 0.5 3.5 4 0
129 627275d  40 2 1 3 6 2 1 3 6 0 0 0 0 0 0 0 1.5 . 200 2 0 0 4 0
130 624971d  56 2 2 3 1 4 2 3 14 0 0 0 0 0 0 0 0.5 60 200 1 0 0 4 0
131 627030d  62 3 1 3 1 2 2 1 9 1 0 0 0 0 0 0 1 . 200 2 0.5 3.5 2 0.5
132 624265d  45 6 1 6 6 1 2 3 20 0 0 0 0 0 0 0 1.5 . 250 2 0 0 2 0.3
133 630844d  37 8 2 3 1 2 1 3 3 0 0 0 0 0 0 0 1 0 0 2 1 7.5 4 0
134 646067d  51 11 1 3 5 1 2 3 30 0 0 1 0 0 1 0 0.5 . 250 2 0 0 4 0
135 647606d  60 2 1 2 6 2 5 3 23 1 0 0 0 0 1 0 0.5 . 0 2 0 0 4 0
136 649752d  38 8 1 3 2 3 1 3 6 0 0 1 1 0 0 0 5.5 . 100 2 1 3.75 4 0
137 650076d  59 2 1 3 4 3 2 3 18 1 0 0 1 0 0 0 1 . 300 1 0.3 5 4 0
138 650207d  35 10 1 3 4 1 2 1 7 0 1 1 0 1 0 0 0.5 . 150 1 0 0 4 0
139 650498d  80 3 1 3 1 0 1 3 8 1 0 1 1 0 0 0 0.5 . 250 2 1 3.75 1 1
140 650604d  45 2 2 3 1 0 1 3 9 0 0 0 0 0 0 0 3 0 200 1 0 0 1 1
141 621553d  37 2 2 5 1 3 1 3 8 1 0 0 0 0 0 0 1 0 200 2 2 30 4 0
142 617403d  38 2 1 3 6 12 2 3 15 0 0 0 0 0 0 0 2.5 . 0 1 0 0 4 0
143 621210d  57 3 1 5 4 2 1 3 8 0 0 0 0 0 0 0 0.5 . 0 2 0 0 4 0
144 613713d  47 9 1 5 4 1 1 3 13 1 0 0 0 0 0 0 1.5 . 100 2 0 0 2 0.3
145 618027d  30 2 2 3 1 1 1 3 20 0 0 0 0 0 0 0 0.5 0 100 2 0 0 4 0
146 251544b  50 2 1 5 4 0 4 3 26 1 0 1 1 0 0 0 2.5 . 0 2 0 0 4 0
147 618962d  37 6 2 2 1 2 1 3 6 1 0 0 1 0 0 0 0.5 120 200 2 1 7.5 4 0
148 619048d  27 8 1 5 1 6 1 3 3 1 0 1 1 0 0 0 1.5 . 250 2 0 0 4 0
149 618970d  47 1 1 3 6 24 2 3 4 1 0 1 1 0 0 0 0.5 . 0 1 0 0 4 0
150 618874d  53 13 1 4 3 2 1 3 17 0 0 0 0 0 1 0 7 . 500 1 0 0 2 0.3
151 617658d  34 8 1 2 1 3 1 3 3 0 0 0 0 0 0 0 2 . 250 2 0 0 4 0
152 662540d  24 2 1 5 2 2 1 3 9 1 0 0 0 0 0 0 6 . 0 2 0 0 1 2
153 662266d  38 2 2 6 5 0 4 3 7 0 0 0 0 0 0 0 2 0 200 2 0 0 4 0
154 621410d  29 2 1 5 5 1 1 3 7 1 0 0 0 0 0 0 0.5 . 100 2 0.3 1.75 1 0.3
155 636656d  53 3 2 2 1 36 2 3 14 0 0 0 1 0 0 0 0.5 120 100 2 0 0 4 0
156 716076d  37 6 1 5 5 3 1 3 14 0 0 0 0 0 0 0 0.5 . 200 2 2 15 1 2
157 751158d  43 3 2 2 1 3 1 3 11 1 0 0 0 0 0 0 0.5 0 500 1 1 7.5 4 0
158 756798d  26 1 1 2 2 0 1 3 23 0 0 0 0 0 0 1 4 . 0 2 0 0 4 0























































cdos cdur ht dm bmi hb cr chol tg hdl ldl ca phosbic pth alp vitd alb bmd tscor echo1echo2 Xray ass apas apss
0 0 8 0 22 4 16 108 159 26 47 5 10 10 808 92 20 5 0.656 ‐1.7 1 1 0 . . .
0 0 10 0 20 13 3 162 202 32 97 9 4 27 161 78 19 5 0.572 ‐2.6 . . 0 . . .
0 0 1 7 23 7 6 174 58 53 99 8 5 17 160 63 18 3 0.792 ‐1 5 2 0 . . .
500 1 0 0 14 8 2 143 61 48 82 5 6 13 697 310 12 4 0.507 . 4 2 0 . . .
1000 1 28 0 26 7 4 133 68 51 27 9 4 16 317 92 54 3 0.553 ‐2.7 2 1 0 . . .
0 0 0 0 19 7 14 175 253 17 64 6 7 14 296 157 18 4 0.727 ‐1.5 3 2 0 . . .
0 0 5 0 21 10 10 124 106 24 74 5 6 18 671 172 11 4 0.557 ‐2.7 3 2 0 . . .
1000 0.3 0 0 23 8 7 202 211 40 122 9 4 19 443 132 30 5 0.846 ‐0.6 3 2 0 . . .
1500 0.5 1 0 24 8 16 125 115 29 76 8 6 25 357 63 19 4 0.688 ‐1.8 . . 0 . . .
0 0 1 0 36 8 4 103 84 36 48 9 6 19 159 100 16 4 0.751 ‐0.9 4 1 0 . . .
1000 0.5 0 0 18 8 4 107 67 40 58 7 5 12 721 90 21 4 0.568 ‐2.5 4 2 0 . . .
1000 1 5 0 20 9 6 153 45 46 76 9 5 18 0.9 . . 4 . . . . 2 . . .
0 0 1 6 19 10 3 163 83 38 102 8 3 22 722 122 12 4 0.495 ‐3.2 . . 0 . . .
500 0.3 3 1 21 9 7 231 89 53 126 8 5 23 513 70 19 3 0.72 . 5 3 0 . . .
0 0 10 15 22 9 8 150 50 57 67 8 6 22 232 61 20 4 0.724 ‐1.5 . . 2 . . .
0 0 0 0 21 6 8 117 147 27 30 9 4 17 274 131 15 3 1.17 . 7 3 0 . . .
0 0 10 10 . 10 2 300 349 38 177 8 5 22 133 72 . 5 0.416 ‐3.9 1 1 0 . . .
0 0 3 5 27 9 9 122 70 42 61 8 4 19 296 . . 4 . . 4 2 2 . . .
0 0 1 0 21 9 4 230 96 70 133 9 4 22 79 56 11 4 0.725 ‐1.1 1 1 0 . . .
1000 0.6 0 0 32 9 5 192 134 34 121 8 3 15 1241 264 5 4 0.512 ‐3 1 1 0 . . .
1000 0.3 0 0 27 6 7 171 72 67 66 8 7 17 696 150 17 4 0.631 ‐2.2 4 2 0 . . .
1500 0.5 2 12 23 9 3 188 208 34 113 8 4 19 71 163 12 3 0.699 ‐1.7 3 1 0 . . .
0 0 4 0 21 8 10 221 180 42 128 9 7 30 758 94 5 4 0.697 ‐1.7 0 0 0 . . .
0 0 3 10 26 10 5 235 190 59 127 8 4 23 740 162 4 4 0.444 ‐3.7 7 3 1 4 4 5
0 0 3 22 20 11 5 197 250 27 104 9 6 18 53 546 16 4 0.735 ‐1.4 2 1 0 . . .
1000 0.3 1 10 21 9 4 260 182 40 173 9 3 22 96 149 11 2 0.709 ‐1.6 3 2 0 . . .
1000 1 2 0 22 7 20 168 143 25 108 8 9 9 261 130 23 5 0.857 0.1 2 1 0 . . .
0 0 3 10 21 2 109 95 36 45 9 3 29 45 74 17 3 0.708 ‐1.6 2 2 0 . . .
0 0 2 1 22 10 3 137 88 32 93 8 3 23 86 91 25 5 0.704 ‐1.7 4 3 0 . . .
0 0 0 0 24 7 10 178 207 25 116 8 6 16 155 80 30 4 . . . . 0 . . .
1000 0.3 2 13 22 14 4 246 223 51 153 9 3 27 322 184 19 3 0.585 ‐2.5 6 3 0 . . .
0 0 8 8 38 10 8 . . . . 8 5 18 265 78 . 3 . . . . 2 . . .
1500 1 20 0 26 13 7 180 116 41 91 9 3 25 378 87 9 3 0.521 ‐3 7 4 1 4 6 8
1000 1 1 0 24 8 5 233 433 35 147 9 4 21 246 72 17 4 . . . . 2 . . .
1000 2 0 0 24 9 6 166 85 41 91 8 6 19 357 56 24 4 0.86 0.1 5 3 0 . . .
0 0 1 10 24 9 5 240 653 26 100 8 3 20 459 195 29 5 . . . . 0 . . .
0 0 12 0 18 5 8 190 128 79 76 6 6 9 601 65 15 3 . . 5 3 0 . . .
0 0 6 0 24 10 5 219 169 33 114 9 3 22 257 132 23 4 0.662 ‐2 5 2 0 . . .
0 0 1 0 21 9 3 155 153 38 84 8 3 25 117 80 8 4 0.761 ‐0.8 3 2 0 . . .
0 0 7 14 24 10 3 213 184 47 121 10 4 25 16 43 15 4 0.694 ‐1.7 3 1 1 3 4 5
500 1 2 0 29 11 8 177 254 20 102 7 7 23 360 84 6 4 . . 3 2 0 . . .
0 0 1 0 . 6 20 195 174 37 120 8 11 10 0.9 68 28 3 . . 3 1 0 . . .
0 0 3 15 21 6 14 123 106 24 72 6 5 12 582 123 27 4 0.64 ‐2.1 . . 2 . . .
0 0 5 1 23 11 4 136 103 47 42 9 5 30 27 72 24 4 0.875 ‐0.4 6 2 0 . . .
0 0 1 0 . 8 19 130 193 35 47 8 9 16 457 48 19 4 0.885 ‐0.3 . . 0 . . .
1000 2 0 0 18 10 8 . . . . . . . 180 . 21 4 0.727 ‐1.5 6 3 0 . . .
0 0 0 0 24 9 7 220 175 37 159 9 5 . 341 68 11 3 0.66 ‐1.7 3 1 0 . . .
1000 0.3 1 0 25 9 10 168 126 41 97 7 8 19 422 71 6 4 0.795 ‐1 2 1 0 . . .
0 0 3 8 . 6 4 111 63 52 37 8 4 18 265 83 26 4 0.483 ‐3.3 3 3 0 . . .
1500 2 1 0 22 12 5 125 95 34 82 10 3 25 24 56 . 5 . . 5 2 0 . . .
1000 1 1 0 25 8 5 106 118 27 61 8 4 16 0.9 . . 4 . . . . 2 . . .
0 0 0 0 17 13 4 . . . . 9 4 24 114 84 25 4 . . . . 2 . . .
0 0 7 0 22 11 4 225 163 43 158 9 5 27 222 . . 3 . . 4 1 0 . . .
S.no H.No Age Res Sex Edu Occ Symp nkd dial gfr pain frac prur prox para smok alc sun amen milk diet vdur vdos bind bdur
160 752034d  66 2 1 3 3 1 1 3 11 0 0 0 0 0 0 0 6 . 0 1 2 15 4 0
161 748727d  31 6 1 5 5 0 1 3 26 0 0 0 1 0 0 0 0.5 . 250 1 2 7.5 1 2
162 750710d  31 6 1 3 4 1 1 3 13 0 0 0 1 0 0 0 3.5 . 500 2 1 15 4 0
163 758347d  42 6 1 5 4 4 2 3 12 1 0 0 0 0 0 0 1.5 . 0 2 0 0 4 0
164 760651d  20 5 1 3 1 1 5 3 12 0 0 0 0 0 0 0 3 . 200 2 0 0 1 1
165 760342d  33 3 1 3 3 4 1 3 2 0 0 0 0 0 0 0 3 . 0 2 0 0 4 0
166 745955d  24 5 2 3 7 6 6 3 9 0 0 0 0 0 0 0 1 . 0 2 1 0.5 4 0
167 738932d  70 5 1 5 1 3 1 3 16 0 0 0 0 0 0 0 0.5 . 0 2 0 0 4 0
168 745681d  40 2 1 2 1 2 1 3 6 0 0 0 0 0 0 0 5.5 . 0 2 0.66 5 1 0.66
169 738189d  72 2 1 3 1 2 2 3 27 0 0 0 0 0 0 0 1 . 100 2 0 0 4 0
170 733184d  39 2 1 5 4 1 2 3 12 0 0 0 0 0 0 0 1.5 . 200 2 0 0 4 0
171 736995d  35 3 2 2 1 2 2 3 28 1 0 0 0 0 0 0 0.5 0 200 2 0 0 4 0
172 728370d  52 1 2 3 1 0 1 3 28 0 0 0 0 0 0 0 0.5 0 100 2 0 0 4 0
173 716844d  67 1 2 3 1 6 1 3 20 1 0 0 0 0 0 0 1 60 250 2 0 0 4 0
174 732411d  58 3 1 6 4 1 2 3 6 0 0 1 0 0 0 0 1 . 200 2 0.5 3.75 3 0.5
175 733567d  57 11 2 3 1 6 1 3 18 1 0 0 1 0 0 0 0.5 72 0 1 1 3.75 4 0
176 730889d  57 12 1 5 4 1 6 3 16 0 0 0 1 0 1 0 1 . 200 2 0 0 4 0
177 731394d  16 1 2 3 1 2 1 3 7 1 0 0 1 0 0 0 1 0 100 2 0 0 4 0
178 729281d  45 2 1 3 6 10 2 3 20 0 0 0 0 0 0 0 1 . 500 2 0 0 4 0
179 730903d  56 2 1 5 4 1 1 3 29 0 0 0 0 0 0 0 1 . 0 2 0.5 3.75 4 0
180 687081d  63 2 1 3 1 6 2 3 23 0 0 0 1 0 0 0 1 . 250 2 0 0 4 0
181 726874d  48 3 1 3 3 2 1 3 29 0 0 0 0 0 0 0 1.5 . 500 2 0 0 4 0
182 730610d  46 2 1 3 6 1 1 3 5 0 0 0 0 0 0 0 2.5 . 100 2 0 0 4 0
183 727239d  58 2 1 5 5 0 1 3 26 1 0 0 0 0 1 0 3 . 500 2 0 0 4 0
184 729115d  59 6 2 2 1 7 1 3 8 1 0 0 1 0 0 0 0.5 144 500 2 0 0 4 0
185 761775d  62 6 1 2 1 2 1 3 20 0 0 0 0 0 0 0 1 . 0 2 0 0 4 0
186 761842d  60 2 1 3 1 1 1 1 9 0 0 1 1 0 0 0 0.5 . 0 2 0 0 1 1
187 761379d  44 3 2 2 1 3 1 3 7 0 0 0 0 0 0 0 0.5 0 200 2 2 15 1 2
188 727211d  55 2 1 2 1 2 1 1 7 0 0 0 0 0 1 0 0.55 . 200 2 0 0 4 0
189 721966d  67 5 1 6 1 2 1 3 12 0 0 0 0 0 1 0 2.5 . 400 2 0 0 4 0
190 727176d  44 2 2 3 4 1 1 3 8 0 0 0 0 0 0 0 0.5 0 0 2 0 0 1 1
191 731359d  38 2 2 3 1 1 1 3 7 1 0 0 0 0 0 0 0.5 0 0 2 0 0 4 0
192 102837d  61 3 1 5 4 0 2 3 26 0 0 0 0 0 0 0 1.5 . 0 2 0 0 4 0
193 745907d  48 2 2 4 1 0 2 3 5 0 0 0 1 0 0 0 0 24 0 2 0 0 4 0
194 749245d  52 16 1 3 4 2 1 1 5 0 0 1 1 0 0 0 5 . 300 2 0.5 3.75 4 0
195 717281d  56 13 1 5 6 0 1 3 12 1 0 0 1 0 0 0 0.5 . 100 2 0 0 4 0
196 745398d  46 17 1 3 4 6 1 3 19 1 0 0 0 0 0 0 1.5 . 0 2 0 0 4 0
197 734041d  65 11 1 3 1 1 2 3 8 0 0 0 0 0 0 0 0.5 . 250 2 1 7.5 4 0
198 743393d  54 12 1 3 4 6 1 3 23 0 0 0 0 0 0 0 1.5 . 200 2 0 0 4 0
199 734173d  46 3 1 5 6 0 1 3 9 0 0 0 0 0 0 0 3 . 500 2 0 0 2 0.5
200 740957d  55 2 1 2 6 2 2 3 9 1 0 1 1 0 1 0 0.5 . 250 2 0 0 4 0
201 745791d  24 2 1 3 2 1 1 3 9 0 0 0 0 0 1 0 2.5 . 200 2 0.5 3.75 4 0
202 740435d  30 8 1 3 3 12 1 3 2 1 0 1 1 0 0 0 8 . 250 2 1 7.5 4 0
203 740575d  58 2 1 3 1 9 2 3 22 1 0 0 1 0 0 0 4.5 . 250 2 0 0 4 0
204 741098d  40 2 1 3 6 3 1 3 8 1 0 0 1 0 1 0 0.5 . 0 2 0 0 4 0
205 758436d  29 2 1 3 2 1 1 3 6 0 0 0 0 0 0 0 1.5 . 200 2 0 0 4 0
206 474187d  60 5 1 6 1 0 1 3 28 0 0 0 0 0 1 0 2 . 100 2 0 0 4 0
207 741923d  48 9 1 5 4 0 1 3 28 0 0 0 1 0 0 0 0.5 . 200 1 0 0 4 0
208 747406d  36 2 2 3 1 4 1 3 9 1 0 1 0 0 0 0 0.5 0 0 2 2 7.5 3 2
209 751138d  55 2 2 3 1 0 1 3 17 1 0 0 1 0 0 0 0.5 0 250 1 0 0 4 0
210 752432d  29 2 1 3 1 1 1 3 3 0 0 0 1 0 1 0 0.5 . 0 1 0 0 1 1
211 752075d  32 2 1 3 1 1 1 3 27 0 0 1 1 0 0 0 0.5 . 0 1 0 0 4 0























































cdos cdur ht dm bmi hb cr chol tg hdl ldl ca phosbic pth alp vitd alb bmd tscor echo1echo2 Xray ass apas apss
0 0 10 2 30 8 6 102 125 27 56 8 5 17 0.9 . . 5 . . 6 2 0 . . .
1000 2 2 0 23 12 3 . . . . 8 3 26 106 73 18 5 . . . . 0 . . .
1000 1 1 0 23 11 6 102 171 29 45 9 5 22 0.9 . . 4 . . . . 2 . . .
0 0 3 3 21 9 6 135 157 35 73 9 6 12 40 . 23 4 . . . . 2 . . .
1500 1 0 0 18 9 6 . . . . 9 5 17 317 . 20 4 . . . . 0 . . .
0 0 0 0 . 5 30 . . . . 4 9 12 0.9 . . 4 . . . . 2 . . .
1000 1 1 0 19 11 6 . . . . 8 3 19 349 91 39 4 . . 7 2 0 . . .
0 0 0 30 14 8 4 91 88 27 43 9 4 17 76 75 42 4 . . . . 0 . . .
1000 0.7 0 0 22 8 10 109 69 39 57 8 5 24 0.9 . . 5 . . . . 2 . . .
0 0 0 7 18 12 3 143 88 45 78 8 4 26 127 143 . 3 0.879 ‐0.4 8 4 0 . . .
0 0 1 5 23 12 6 165 179 31 106 9 5 24 250 87 15 4 . . 6 3 0 . . .
0 0 1 7 27 9 2 337 371 34 237 8 5 12 556 201 17 2 . . 2 1 0 . . .
0 0 3 0 24 12 2 192 303 35 116 9 2 28 70 105 15 5 . . 9 4 0 . . .
0 0 0 0 29 11 3 220 141 42 157 9 3 25 254 117 20 4 . . 6 2 1 1 1 2
1500 0.5 7 3 22 9 10 106 73 32 52 9 6 19 642 . . 4 . . . . 2 . . .
0 0 20 0 17 9 3 120 122 57 47 9 4 22 349 66 13 4 . . 5 2 0 . . .
0 0 1 0 20 8 4 141 83 38 85 8 4 14 314 105 . 4 . . 4 2 0 . . .
0 0 0 0 17 7 8 142 71 61 70 7 5 10 1324 . . 4 . . . . 2 . . .
0 0 13 13 27 8 4 175 229 25 110 . . . 0.9 85 . 4 . . . . 2 . . .
500 0.5 8 0 22 13 3 248 247 34 177 9 3 24 0.9 . . 4 . . . . 2 . . .
0 0 8 8 20 7 3 185 201 40 110 8 4 . 59 114 17 4 . . . . 2 . . .
0 0 2 12 23 11 3 287 109 57 200 9 5 25 47 81 18 3 . . 4 1 0 . . .
0 0 1 0 23 7 13 . . . . 6 7 14 1036 121 17 4 . . . . 2 . . .
0 0 3 14 23 9 3 152 95 47 85 9 4 20 0.9 . . 3 . . . . 2 . . .
0 0 15 0 18 10 6 216 158 34 148 9 6 21 0.9 . . 4 . . 11 4 0 . . .
0 0 0 0 23 4 3 52 78 14 25 10 5 18 24 66 22 3 0.638 ‐2.1 6 3 0 . . .
1000 1 8 0 20 9 9 . . . . 9 6 16 281 . . 4 0.71 ‐1.3 . . 2 . . .
1500 2 0 0 21 8 7 160 124 49 97 8 5 15 476 155 28 4 0.521 ‐3 6 3 0 . . .
0 0 0 0 21 8 8 195 77 43 125 8 5 15 233 73 29 4 0.843 ‐0.6 . . 0 . . .
0 0 1 0 20 10 5 132 120 26 84 8 4 21 240 88 29 5 0.611 ‐2.8 6 3 0 . . .
1500 1 4 0 28 11 . 121 80 35 69 9 4 23 334 90 21 5 0.804 ‐0.4 6 3 0 . . .
0 0 2 0 19 6 7 228 135 52 140 8 5 15 0.9 . . 4 0.624 ‐2 6 3 0 . . .
0 0 5 15 25 9 3 97 64 35 48 8 4 16 283 108 12 4 0.61 ‐2.4 . . 0 . . .
0 0 5 7 25 9 . 165 159 37 105 9 5 19 335 119 27 3 0.731 ‐1.1 4 2 0 . . .
0 0 2 0 19 6 12 103 140 17 52 8 4 16 367 . 23 2 0.646 ‐2.1 9 4 0 . . .
0 0 15 0 21 9 5 75 74 22 40 8 3 16 83 77 33 4 0.629 ‐2.2 7 3 0 . . .
0 0 5 0 33 9 4 152 144 35 91 8 4 29 348 66 15 4 0.77 ‐1.2 6 2 0 . . .
1000 1 15 15 20 9 7 135 137 42 75 8 6 25 619 . 17 3 . . 12 4 1 1 1 1
0 0 0 0 21 8 3 149 128 40 88 8 2 22 94 . 58 4 . . 4 1 0 . . .
0 0 1 0 21 9 7 155 58 42 98 8 5 19 338 108 29 5 . . 9 4 0 . . .
0 0 1 15 22 10 7 186 121 39 133 8 4 24 570 . 16 4 . . . . 0 . . .
0 0 0 0 18 9 8 155 98 34 117 8 6 14 0.9 . . 4 . . . . 2 . . .
0 0 1 0 17 8 25 102 163 26 51 8 12 12 0.9 . . 4 . . . . 2 . . .
0 0 5 5 26 9 3 165 208 30 102 9 4 22 154 110 31 5 . . 2 1 0 . . .
0 0 6 0 26 8 8 121 90 39 62 5 5 . 584 103 18 5 . . 5 3 0 . . .
0 0 0 0 21 9 11 117 138 27 71 5 8 16 406 . 18 4 . . . . 0 . . .
0 0 4 12 25 10 3 169 154 28 104 9 4 14 98 . . 4 . . . . 2 . . .
0 0 0 10 27 10 2 196 134 36 138 8 3 23 137 85 19 5 . . . . 2 . . .
0 0 4 0 31 10 6 103 65 30 73 8 6 13 376 85 15 4 . . 7 3 0 . . .
0 0 0 0 23 9 3 202 186 32 141 8 4 16 683 . 19 5 . . 5 2 2 . . .
1000 1 0 0 20 8 18 . . . . 9 8 15 143 69 . 4 . . . . 0 . . .
0 0 1 1 22 9 3 133 343 24 54 7 4 19 293 80 . 4 . . . . 2 . . .
1000 1 1 3 . 6 10 . . . . 8 6 . 467 126 15 3 . . 11 4 0 . . .
S.no H.No Age Res Sex Edu Occ Symp nkd dial gfr pain frac prur prox para smok alc sun amen milk diet vdur vdos bind bdur
213 751242d  43 2 1 2 3 1 1 3 10 0 0 0 0 0 1 0 8 . 300 2 1 7.5 4 0
214 748459d  35 8 1 2 2 2 1 1 4 0 0 1 0 0 0 0 6.5 . 0 2 0 0 4 0
215 756044d  66 2 2 3 1 2 2 3 23 1 0 1 1 0 0 0 0.5 264 200 2 0 0 4 0
216 752170d  65 1 1 3 1 0 1 3 26 0 0 0 0 0 0 0 0.5 . 100 2 0 0 4 0
217 756596d  42 2 1 5 5 6 2 3 6 0 0 0 1 0 0 0 4 . 0 1 0 0 4 0
218 736067d  32 3 1 5 1 1 1 3 4 0 0 0 0 0 0 0 3 . 0 2 1 3.75 1 1
219 735826d  69 2 2 4 1 1 2 3 16 1 0 0 0 0 0 0 1 24 100 2 0 0 4 0
220 727211d  55 2 1 2 1 2 1 1 7 0 0 0 0 0 1 0 0.5 . 200 2 0 0 4 0
221 724424d  33 16 1 2 3 6 1 1 7 0 0 1 0 0 0 0 0.5 . 0 2 0.3 5 4 0
222 729071d  47 6 1 3 3 1 2 3 8 0 0 0 0 0 1 0 8 . 250 2 0 0 4 0
223 766257d  62 6 1 3 3 6 5 3 7 0 0 0 0 0 0 0 2 . 250 2 0 0 4 0
224 729208d  65 2 1 3 1 24 2 3 28 0 0 0 0 0 1 0 2 . 0 2 0 0 4 0
225 729664d  36 2 1 3 6 0 1 3 20 0 0 0 0 0 0 0 7 . 0 2 0 0 4 0
226 732013d  58 2 2 3 1 3 2 3 17 0 0 0 0 0 0 0 0.5 . 100 2 0 0 4 0
227 732128d  35 18 1 5 6 1 1 3 18 0 0 0 0 0 1 0 1.5 . 200 2 0.3 5 4 0
228 737355d  22 2 2 3 1 3 1 3 23 1 0 1 1 0 0 0 0.5 . 100 1 1.5 11.3 4 0
229 736831d  50 6 1 5 4 1 1 3 6 0 0 1 1 0 0 0 2.5 . 500 2 0 0 1 0.5
230 731874d  48 12 2 3 1 3 1 3 5 0 0 0 1 0 0 0 0.5 18 500 2 1 15 4 0
231 738012d  53 2 2 2 1 12 2 3 7 1 0 1 0 0 0 0 0.5 72 0 2 1 7.5 4 0
232 738256d  56 3 1 5 1 2 1 3 10 1 0 0 1 0 0 0 0.5 . 200 2 0 0 4 0
233 738780d  50 2 2 2 1 24 1 3 16 0 0 0 0 0 0 0 0.5 24 0 2 0 0 4 0
234 734358d  45 1 2 3 2 0 1 3 15 1 0 0 1 0 0 0 0.5 0 200 2 0 0 4 0
235 737580d  45 3 1 3 6 2 2 3 7 0 0 0 1 0 0 0 6 . 200 2 0.5 3.75 1 0.5
236 737371d  48 3 1 6 7 1 1 3 3 0 0 0 1 0 1 0 2.5 . 250 1 0.3 2.5 1 0.3
237 732730d  40 18 2 2 1 1 2 3 11 0 0 0 1 0 0 0 0.5 0 100 1 0 0 4 0
238 733028d  65 2 1 2 1 12 1 3 13 0 0 0 0 0 0 0 8 . 500 1 0 0 4 0
239 731568d  50 11 1 3 4 0 1 3 25 1 0 0 1 0 0 0 0.5 . 0 2 0 0 4 0
240 722007d  52 2 1 3 6 2 2 3 17 0 0 0 0 0 0 0 0.5 . 250 2 0 0 4 0
241 877257b  37 2 1 3 3 1 1 3 13 0 0 0 0 0 0 0 8 . 0 2 0 0 1 0.5
242 721513d  40 3 2 3 1 0 1 3 12 0 0 0 0 0 0 0 0.5 0 200 1 0.5 7.5 4 0
243 725495d  50 6 2 1 1 2 1 3 4 1 0 1 1 0 0 0 0.5 60 100 2 0.3 1.75 1 0.3
244 729823d  43 2 1 3 4 3 1 3 6 1 0 0 0 0 0 0 0.5 . 500 2 0 0 4 0
245 726040d  55 2 1 3 4 0 2 3 17 0 0 0 0 0 0 0 1 . 0 2 0 0 2 1
246 726797d  35 6 2 3 1 1 1 3 15 0 0 0 0 0 0 0 0.5 0 100 2 0 0 4 0
247 731610d  56 2 1 2 2 2 1 3 14 0 0 0 0 0 0 0 8 . 100 2 0 0 4 0
248 738597d  45 1 1 5 5 4 1 3 4 0 0 1 0 0 0 0 0.5 . 500 2 0 0 1 0.3
249 750907d  13 1 1 3 1 2 1 3 10 1 0 0 0 0 0 0 1 . 150 2 1 7.5 4 0
250 759557d  52 5 1 6 5 1 2 3 13 1 0 1 1 0 0 0 0.5 . 50 2 0 0 4 0
251 752186d  32 2 1 5 6 3 1 3 9 1 0 1 0 0 0 0 2 . 0 2 0 0 4 0
252 749062d  60 3 1 3 6 1 1 3 11 0 0 1 0 0 1 0 1 . 100 1 2 18 3 2
253 750683d  42 3 1 3 3 0 1 3 14 0 0 0 0 0 0 0 0.5 . 0 2 0 0 4 0
254 743606d  60 6 1 5 1 3 2 3 12 0 0 0 0 0 1 1 0.1 . 0 2 0 0 4 0
255 743886d  58 2 1 3 6 1 2 3 23 1 0 0 0 0 0 0 0.5 . 0 2 0 0 4 0
256 751127d  67 2 1 5 1 2 1 3 18 0 0 0 0 0 1 0 0.5 . 100 2 0 0 4 0
257 747031d  55 9 1 5 4 6 1 3 8 0 0 0 0 0 0 0 0.5 . 0 2 0 0 4 0
258 749694d  30 6 1 2 2 2 1 3 6 0 0 0 1 0 0 0 11 . 500 2 1 7.5 4 0
259 748759d  25 3 2 3 1 1 1 3 8 0 0 0 0 0 0 0 0.5 0 0 2 0 0 4 0
260 757904d  54 6 2 3 1 3 2 3 15 1 0 1 0 0 0 0 0.5 72 100 2 0 0 2 0.5
261 748202d  56 2 1 3 6 1 2 3 10 0 0 0 0 0 0 0 0.5 . 500 2 1 15 4 0
262 757065d  55 19 1 3 6 1 1 3 8 0 0 1 0 0 0 0 0.5 . 100 1 0.5 7.5 4 0
263 745650d  59 1 1 5 1 3 1 3 11 0 0 1 1 0 0 0 0.5 . 150 2 0 0 4 0
264 752707d  72 3 1 5 1 0 2 3 28 0 0 0 0 0 0 0 3 . 400 2 0 0 4 0























































cdos cdur ht dm bmi hb cr chol tg hdl ldl ca phosbic pth alp vitd alb bmd tscor echo1echo2 Xray ass apas apss
500 1 1 0 17 7 7 . . . . 7 5 . 266 102 46 4 . . 5 2 0 . . .
0 0 1 0 23 7 16 111 97 31 66 8 7 14 0.9 . . 4 . . . . 2 . . .
0 0 0 20 35 8 3 115 106 48 49 7 4 21 0.9 . . 4 . . . . 2 . . .
0 0 15 10 . 11 3 173 128 32 120 8 4 23 114 . . 5 . . . . 2 . . .
0 0 1 15 23 7 10 . . . . 9 6 10 186 132 12 3 0.597 ‐2.4 0 0 0 . . .
1500 1 0 0 20 8 15 129 84 31 84 6 10 12 408 . 19 3 0.962 ‐1.2 6 2 2 . . .
0 0 20 12 24 8 3 127 217 42 50 8 3 . 181 . 9 4 0.56 ‐2.6 . . 0 . . .
0 0 0 0 21 8 8 195 77 43 125 8 5 15 233 73 29 4 0.843 ‐0.6 11 3 0 . . .
1000 0.3 0 0 20 8 9 145 194 27 87 8 5 19 168 84 22 3 0.865 ‐0.5 10 4 0 . . .
0 0 5 12 28 8 8 250 182 44 161 8 9 13 137 74 16 3 0.605 ‐2.4 6 3 2 . . .
0 0 10 0 21 7 15 . . . . 7 5 . 625 124 16 4 . . . . 2 . . .
0 0 0 5 18 8 3 . . . . 8 3 23 86 203 21 3 0.685 ‐1.8 5 2 0 . . .
0 0 7 0 26 12 4 178 257 24 108 7 3 27 552 156 16 5 0.789 ‐1 . . 0 . . .
0 0 15 15 25 7 3 186 386 30 99 8 4 18 211 111 23 4 0.59 ‐2.3 6 3 0 . . .
0 0 1 0 25 12 4 120 141 24 70 8 5 19 255 69 20 5 0.933 0 6 2 0 . . .
500 1.5 0 . 18 10 4 189 190 40 117 9 4 25 365 69 15 4 0.857 0.1 8 3 0 . . .
1000 0.5 0 0 25 6 9 122 150 50 49 4 8 10 414 296 14 4 0.668 ‐1.9 . . 2 . . .
100 1 6 0 25 9 9 168 211 28 104 8 6 17 444 82 19 5 0.671 ‐1.6 5 2 0 . . .
0 0 10 10 22 8 7 116 56 42 65 12 6 . 2 49 22 4 0.773 ‐0.7 9 4 0 . . .
0 0 8 8 39 10 6 202 91 58 122 7 4 30 645 125 7 5 0.662 ‐2 . . 2 . . .
0 0 0 0 22 8 3 203 138 38 134 9 3 23 482 91 18 4 0.564 ‐2.6 2 2 0 . . .
0 0 1 0 22 11 4 . . . . 8 4 22 454 78 25 4 0.71 ‐1.3 3 2 0 . . .
100 0.5 2 4 20 10 8 135 133 48 60 8 6 16 504 . 33 3 0.624 ‐2.2 8 3 0 . . .
1500 0.3 1 0 28 8 16 96 165 23 48 5 8 15 662 191 . 5 0.754 ‐1.3 2 1 0 . . .
0 0 1 10 17 9 5 221 83 64 132 8 6 23 130 78 18 4 0.648 ‐1.8 . . 2 . . .
0 0 10 0 18 6 5 94 98 39 35 9 6 13 77 . . 4 0.612 ‐2.8 7 3 0 . . .
0 0 15 0 21 10 3 145 112 47 84 8 4 19 164 92 26 4 0.509 ‐3.1 . . 2 . . .
0 0 1 1 20 9 4 168 77 62 86 9 4 21 279 60 12 4 0.575 ‐3 7 3 0 . . .
1000 0.5 0 0 18 10 5 123 204 21 67 10 5 16 17 72 32 4 0.667 ‐1.9 7 3 0 . . .
1000 0.5 0 0 24 11 4 137 75 46 72 8 5 21 742 73 13 4 0.722 ‐1.1 . . 0 . . .
1500 0.3 0 0 19 9 10 201 193 22 146 11 6 23 3 . 10 5 0.589 ‐2.3 . . 0 . . .
0 0 1 0 19 7 11 81 26 33 40 7 5 12 594 113 29 5 0.779 ‐1.1 2 2 2 . . .
0 0 1 10 24 11 4 200 125 39 134 9 3 26 206 107 10 3 0.769 ‐1.2 7 3 1 2 3 4
0 0 3 0 26 11 4 173 140 44 106 9 5 22 374 131 12 4 0.837 ‐0.1 8 3 0 . . .
0 0 10 0 19 8 5 135 52 46 72 8 5 25 326 71 30 4 0.756 ‐1.3 1 2 0 . . .
1000 0.3 8 0 19 6 16 142 115 34 94 5 7 10 1332 245 15 4 0.466 ‐3.4 9 3 0 . . .
500 1 0 0 15 5 8 . . . . 9 7 . 1174 195 35 4 0.635 . 4 2 0 . . .
0 0 0 17 . 8 5 . . . . . . 18 159 71 9 3 0.459 ‐3.5 . . 0 . . .
0 0 0 0 19 11 6 . . . . 9 4 . 170 84 21 4 0.801 ‐0.9 6 3 0 . . .
0 0 0 0 20 12 6 101 83 27 63 8 5 16 234 92 24 4 0.595 ‐2.5 5 3 1 1 1 1
0 0 5 0 . 9 5 104 72 35 57 8 5 17 316 122 19 4 0.882 ‐0.4 . . 2 . . .
0 0 1 20 23 10 6 234 140 59 149 9 4 22 224 80 22 3 0.683 ‐1.8 6 3 0 . . .
0 0 20 20 31 8 3 168 196 31 103 8 3 19 245 108 14 3 0.686 ‐1.8 5 2 0 . . .
0 0 0 0 22 9 4 191 410 26 99 8 3 . 147 61 35 4 0.791 ‐1 4 2 0 . . .
0 0 9 0 26 9 8 117 47 58 45 8 5 16 0.9 98 25 3 0.572 ‐2.6 6 3 0 . . .
500 1 0 0 19 8 11 . . . . 8 5 . 742 93 27 5 0.69 ‐1.8 . . 2 . . .
0 0 0 0 21 9 7 172 134 43 108 9 5 16 1004 84 11 4 0.528 ‐2.9 . . 2 . . .
0 0 5 20 26 10 3 264 283 51 166 9 4 24 123 123 13 4 0.677 ‐1.5 . . 0 . . .
1000 1 2 15 24 9 6 . . . . 8 5 23 200 87 21 5 0.845 ‐0.6 9 3 0 . . .
1000 0.5 6 0 20 8 7 . . . . 9 6 13 129 75 20 3 0.688 ‐1.8 . . 0 . . .
0 0 10 0 26 11 6 . . . . 8 5 19 223 104 15 4 0.595 ‐2.5 4 2 0 . . .
0 0 10 10 20 10 2 . . . . 9 3 27 37 73 24 4 0.705 ‐1.7 7 2 1 1 1 1
0 0 10 10 21 8 4 . . . . 8 4 20 425 114 9 4 0.513 ‐3 4 1 1 3 5 10
S.no H.No Age Res Sex Edu Occ Symp nkd dial gfr pain frac prur prox para smok alc sun amen milk diet vdur vdos bind bdur
266 733995d  47 2 1 3 7 0 1 3 8 0 0 0 1 0 0 0 0.5 . 250 1 0 0 4 0
267 737012d  21 3 2 5 1 2 1 3 19 1 0 1 1 0 0 0 0.5 0 200 1 1 15 4 0
268 759211d  26 18 2 5 7 6 1 1 2 0 0 0 0 0 0 0 0.5 0 200 2 0 0 4 0
269 761099d  60 2 1 2 1 1 2 3 11 1 0 0 1 0 0 0 0.5 . 500 2 0 0 4 0
270 763972d  37 2 1 3 3 1 1 1 4 0 0 0 0 0 0 0 3 . 200 2 0 0 2 0.5
271 671705d  69 2 2 2 1 1 1 3 3 1 0 1 1 0 0 0 0.5 240 250 2 0 0 1 2
272 671183d  48 18 2 3 1 2 2 3 18 0 0 0 1 0 0 0 0.5 120 500 2 0 0 4 0
273 679901d  59 2 1 3 3 3 2 3 6 0 0 0 0 0 1 0 1.5 . 0 2 0 0 4 0
274 677605d  51 1 1 5 7 36 2 3 6 0 0 0 0 0 0 0 0.5 . 200 2 0 0 4 0
275 679587d  29 3 1 6 1 1 1 1 5 0 0 0 0 0 0 0 1.5 . 0 2 0.5 3.25 1 0.5
276 679523d  36 6 1 3 3 1 1 3 10 0 0 0 0 0 0 0 5 . 200 2 0 0 4 0
277 677741d  38 8 1 6 6 0 1 3 9 0 0 1 0 0 1 0 0.5 . 100 2 1 22.5 4 0
278 678532d  62 2 1 4 1 12 1 3 5 0 0 0 0 0 0 0 1 . 200 2 0 0 4 0
279 688751d  30 2 1 3 7 1 1 3 4 1 0 0 0 0 0 0 0.5 . 0 2 0 0 4 0
280 672608d  25 2 1 3 7 6 1 3 11 0 0 0 0 0 0 0 0.5 . 0 2 1 7.5 1 1
281 672659d  47 2 1 2 6 1 1 3 6 0 0 0 0 0 0 0 4 . 50 2 0.5 3.25 1 0.5
282 681707d  29 3 2 3 1 1 1 3 6 1 0 0 1 0 0 0 0.5 . 200 1 0 0 2 0.3
283 697080d  39 3 2 2 1 12 1 3 5 1 0 0 0 0 0 0 1.5 0 0 1 0 0 1 0.3
284 693002d  58 2 1 3 4 3 1 3 2 1 0 1 0 0 0 0 0.5 . 0 2 0 0 4 0
285 675063d  50 16 1 4 3 1 1 3 9 0 0 0 0 0 1 1 3 . 0 2 0 0 4 0
286 655031d  33 2 1 5 6 1 1 3 7 0 0 0 0 0 0 1 3 . 0 2 0 0 4 0
287 673273d  59 2 1 3 4 0 1 3 8 0 0 0 0 0 0 0 1 . 100 2 0 0 4 0
288 673193d  52 15 1 3 6 8 2 3 9 0 0 0 0 0 0 0 1 . 0 2 0 0 4 0
289 665867d  54 2 2 2 1 3 3 3 15 1 0 1 0 0 0 0 0.5 224 0 2 0 0 4 0
290 694710d  55 3 1 3 4 3 1 3 13 0 0 0 0 0 0 0 1.5 . 100 2 0.5 7.5 4 0
291 695463d  43 3 2 6 1 1 1 3 8 0 0 0 0 0 0 0 0.5 . 350 2 0.5 3.25 4 0
292 695557d  51 20 1 6 4 12 2 3 15 0 0 0 0 0 0 0 1 . 200 2 0 0 4 0
293 697616d  49 3 1 3 6 3 1 3 25 0 0 0 0 0 0 0 1.5 . 0 2 0 0 4 0
294 698732d  61 1 1 3 1 1 1 3 7 0 0 0 0 0 0 0 1 . 100 2 0 0 4 0
295 612008d  44 2 1 1 3 36 2 3 20 0 0 0 0 0 0 0 0.5 . 0 2 0 0 4 0
296 627065d  49 21 1 5 4 6 1 3 7 0 0 0 0 0 0 0 1.5 . 0 2 0.25 0.75 1 0.25
297 626965d  22 2 2 3 1 6 1 3 2 0 0 1 1 0 0 0 0.5 6 0 2 0.3 5 4 0
298 629295d  57 2 1 3 4 3 2 3 16 0 0 1 0 0 0 1 1.5 . 200 2 0 0 4 0
299 627010d  57 3 1 5 4 1 2 3 26 0 0 0 0 0 0 0 1.5 . 0 2 0 0 4 0
300 627782d  38 3 2 3 1 1 1 3 25 0 0 0 0 0 0 0 1.5 0 0 2 0 0 4 0
301 680954d  41 6 2 4 4 6 1 3 15 0 0 0 0 0 0 0 1 36 100 1 0 0 4 0
302 683015d  52 3 1 6 4 1 1 3 2 0 0 0 0 0 0 0 1.5 . 100 2 0.5 1.62 1 0.5
303 682379d  52 2 2 5 4 0 1 3 11 0 0 0 0 0 0 0 0.5 0 50 2 1 15 1 1
304 677314d  43 2 2 1 1 1 3 3 21 0 0 1 1 0 0 0 1 0 0 2 1 15 4 0
305 676155d  61 3 1 3 3 2 1 3 21 0 0 0 0 0 0 0 0.5 . 500 2 0 0 4 0
306 680177d  36 1 2 4 1 6 1 3 6 1 0 0 0 0 0 0 1.5 0 200 2 2 15 4 0
307 676276d  44 2 1 3 7 1 2 3 8 0 0 0 0 0 1 0 2.5 . 0 1 0 0 4 0
308 681965d  35 2 2 3 1 12 1 3 5 0 0 0 1 0 0 0 0 0 0 2 1 22.5 4 0
309 682106d  61 2 2 6 1 6 2 3 8 0 0 0 0 0 0 0 0 156 500 2 1.5 25.3 4 0
310 672243d  24 16 2 3 1 6 1 3 18 0 0 0 0 0 0 0 1.5 36 0 2 0 0 4 0
311 202661d  57 2 1 5 7 10 2 3 22 1 0 0 0 0 0 0 0 . 250 2 0 0 4 0
312 689750d  30 10 1 3 6 0 1 3 6 0 0 0 0 0 0 0 1.5 . 100 1 1 22.5 4 0
313 692548d  68 2 1 3 1 1 1 3 10 1 0 0 0 0 1 0 1 . 0 2 0.3 2.5 4 0
314 673840d  18 3 2 5 1 6 1 3 7 0 0 0 0 0 0 0 1 0 0 1 0 0 4 0
315 678106d  45 6 1 4 6 1 2 3 9 0 0 0 0 0 0 0 1.5 . 0 2 0 0 4 0
316 668580d  52 2 2 3 1 0 2 3 16 0 0 0 0 0 0 0 0.5 108 400 2 0 0 4 0
317 676434d  67 2 1 3 1 0 1 3 16 0 0 1 0 0 0 0 0 . 0 2 0 0 4 0























































cdos cdur ht dm bmi hb cr chol tg hdl ldl ca phosbic pth alp vitd alb bmd tscor echo1echo2 Xray ass apas apss
0 0 0 0 22 10 7 168 166 24 116 8 5 20 245 117 15 4 0.465 ‐3.4 4 3 0 . . .
1000 1 0 0 18 8 3 130 160 33 74 9 5 24 280 104 25 3 0.862 0.1 8 3 0 . . .
0 0 1 0 16 10 23 . . . . 8 9 10 602 39 . 4 . . . . 2 . . .
0 0 10 10 21 8 6 . . . . 8 5 16 250 . 15 4 0.549 ‐2.8 8 3 2 . . .
0 0 0 0 21 8 17 92 26 50 41 9 4 22 155 71 40 4 . . . . 2 . . .
1500 2 10 0 21 8 7 128 131 35 77 8 5 16 60 45 17 4 . . . . 2 . . .
0 0 2 20 23 7 4 168 210 26 103 8 4 17 226 171 12 3 . . 9 4 0 . . .
0 0 2 2 15 7 10 135 70 47 73 8 5 13 0.9 . . 4 . . . . 2 . . .
0 0 3 3 26 9 10 113 98 32 66 6 5 17 1196 114 26 4 . . . . 2 . . .
1000 0.5 2 0 23 8 12 128 95 33 71 6 6 16 866 112 8 4 . . . . 2 . . .
0 0 1 0 21 12 6 140 93 39 82 8 6 15 213 100 23 5 . . . . 0 . . .
1000 1 0 0 23 10 8 169 75 32 108 8 8 11 514 35 . 4 . . . . 2 . . .
0 0 15 0 23 10 10 100 59 32 59 8 4 19 274 70 28 5 . . 6 3 1 2 3 3
0 0 1 0 21 7 14 107 96 26 64 7 11 11 0.9 . . 4 . . . . 2 . . .
1000 1 1 0 25 7 7 115 152 38 56 8 4 14 191 100 . 4 . . . . 2 . . .
1500 0.5 0 0 18 8 10 . . . . 7 5 10 789 115 25 4 . . 7 3 0 . . .
0 0 0 0 18 7 8 153 171 40 91 8 9 19 0.9 . . 4 . . 4 2 0 . . .
1000 0.3 0 0 22 7 10 . . . . 8 6 16 1445 133 16 4 . . . . 2 . . .
0 0 0 0 21 5 24 114 99 29 64 9 10 7 579 75 27 3 . . . . 0 . . .
0 0 0 0 18 8 7 197 125 49 41 8 6 17 326 153 23 4 . . 7 3 0 . . .
0 0 0 0 17 7 9 130 113 40 78 7 9 . 362 . 15 4 . . 4 1 0 . . .
0 0 2 1 20 5 8 132 41 55 74 6 6 9 499 121 23 3 . . 9 4 0 . . .
1000 0.3 1 10 26 11 7 195 158 34 139 8 5 19 959 108 13 3 . . 6 2 0 . . .
0 0 1 0 20 11 3 . . . . 8 4 25 154 68 28 4 . . 7 3 1 1 1 2
1000 0.5 0 0 17 7 5 95 127 21 48 7 4 20 211 183 39 3 . . 4 2 0 . . .
500 0.5 0 0 23 10 6 76 62 17 45 7 5 8 723 176 21 4 . . 2 2 0 . . .
0 0 10 20 28 10 4 140 256 27 75 9 3 . 183 . 7 4 . . 6 3 0 . . .
0 0 15 0 17 16 3 . . . . . . . 0.9 . 12 . . . 5 2 0 . . .
0 0 0 0 23 6 9 145 65 38 85 8 5 12 601 130 28 4 . . . . 2 . . .
0 0 5 1 18 9 3 278 251 48 202 9 4 . 180 122 8 3 . . . . 0 . . .
1000 0.3 6 0 22 9 9 209 238 29 133 9 6 17 330 78 26 4 . . 5 2 0 . . .
500 0.3 0 0 19 3 23 167 162 29 73 7 15 16 561 56 12 3 . . 1 1 0 . . .
0 0 5 10 19 11 4 155 129 50 69 8 3 22 674 248 7 3 . . 5 2 0 . . .
0 0 2 14 . 9 3 181 95 34 121 8 4 21 195 156 6 3 . . . . 2 . . .
0 0 1 0 19 10 2 179 80 56 93 9 4 15 134 126 13 4 . . . . 0 . . .
0 0 15 0 22 8 3 . . . . 8 5 16 823 130 8 4 . . 5 2 0 . . .
1000 0.5 0 0 36 8 24 172 290 26 91 7 9 16 1010 130 . 5 . . . . 2 . . .
1000 1 7 0 24 9 5 236 . 36 155 9 5 21 69 70 13 3 . . 5 2 0 . . .
1000 1 20 0 31 10 3 179 102 56 105 9 4 . 149 99 26 4 . . . . 2 . . .
0 0 3 0 21 10 3 163 181 30 99 8 3 24 232 70 19 4 . . 6 3 1 1 1 1
0 0 0 0 24 7 9 . . . . 8 5 13 1289 134 20 4 . . 7 3 0 . . .
0 0 0 2 30 10 6 181 93 38 125 9 4 16 194 78 24 3 . . 6 3 0 . . .
1000 1 0 0 22 9 10 136 72 36 79 9 5 22 317 83 21 4 . . . . 2 . . .
1000 1.5 3 15 27 8 6 114 97 37 66 8 5 22 285 168 19 4 . . 5 2 0 . . .
0 0 0 0 19 8 3 . . . . 9 5 15 76 83 15 4 . . 5 2 0 . . .
0 0 16 4 24 10 3 178 165 50 106 9 3 26 111 111 12 3 . . 5 2 0 . . .
1500 1 0 0 21 9 10 70 53 21 38 7 6 13 433 138 18 4 . . 4 2 0 . . .
500 0.3 12 0 16 8 6 135 125 38 76 9 6 12 337 98 14 4 . . 4 2 1 4 5 8
0 0 1 0 16 7 8 103 92 35 55 8 7 15 1745 219 15 4 . . 5 2 0 . . .
0 0 1 6 28 10 7 236 131 40 172 9 6 17 552 116 4 3 . . 8 4 0 . . .
0 0 1 1 31 9 3 243 167 59 148 8 4 19 256 148 18 4 . . 2 1 0 . . .
0 0 0 0 21 9 4 208 114 39 147 8 4 12 145 93 29 4 . . . . 0 . . .
0 0 5 20 26 9 5 172 65 43 115 8 3 16 407 107 18 4 . . 7 3 0 . . .
S.no H.No Age Res Sex Edu Occ Symp nkd dial gfr pain frac prur prox para smok alc sun amen milk diet vdur vdos bind bdur
319 678380d  51 2 1 2 1 7 1 3 29 0 0 0 0 0 1 0 1 . 0 2 0 0 4 0
320 678322d  39 2 1 3 2 6 1 3 5 0 0 0 1 0 0 0 6 . 100 2 1 7.5 4 0
321 677802d  62 3 1 3 1 1 2 3 12 1 0 0 0 0 1 0 2 . 0 1 0.5 3.25 1 0.5
322 747182d  73 11 1 3 5 1 1 3 10 1 0 1 1 0 0 0 0 . 200 2 0 0 4 0
323 754275d  56 3 1 5 7 1 2 3 8 1 0 1 1 0 0 0 0 . 200 2 1 7.5 4 0
324 755617d  47 3 1 3 7 4 2 3 27 1 0 1 1 0 0 0 0 . 100 2 0 0 4 0
325 722650d  46 6 1 5 5 6 2 3 10 0 0 0 0 0 0 0 1.5 . 200 2 2 15 4 0
326 720321d  39 10 1 5 4 1 1 3 10 0 0 0 0 0 1 1 2.5 . 200 2 0 0 4 0
327 719138d  32 6 1 5 5 3 4 3 13 0 0 0 0 0 0 0 3 . 200 2 0 0 4 0
328 682830d  51 2 2 1 7 1 6 3 13 0 0 0 0 0 0 0 1 60 250 2 1 15 4 0
329 682270d  60 13 2 2 1 2 1 3 14 1 0 0 1 0 0 0 0 120 250 2 0 0 4 0
330 679645d  69 2 1 5 6 6 1 3 15 0 0 0 0 0 0 0 1 . 200 2 0 0 4 0
331 683335d  30 3 2 5 1 6 1 3 6 1 0 1 1 0 0 0 0 . 0 1 0 0 1 0.3
332 685214d  51 3 1 3 6 1 2 3 26 1 0 0 0 0 0 0 5.5 . 0 1 1.5 1 4 0
333 714991d  31 8 1 6 4 3 1 3 8 0 0 0 1 0 1 1 0 . 0 2 0 0 4 0
334 714060d  50 11 1 3 4 12 2 3 23 0 0 0 0 0 0 0 2 . 300 2 0 0 4 0
335 725145d  41 2 2 3 1 2 1 3 5 1 0 1 0 0 0 0 0 0 200 2 0.5 10.8 4 0
336 722043d  22 2 2 3 1 3 1 3 8 1 0 0 0 0 0 0 1 0 299 2 0 0 4 0
337 718078d  59 5 1 5 1 3 2 3 6 0 0 0 1 0 0 1 0 . 250 2 0 0 4 0
338 762158d  39 2 2 3 1 2 6 3 17 0 0 0 0 0 0 0 0 0 200 2 0 0 4 0
339 761300d  61 2 1 3 1 0 1 3 13 0 0 1 1 0 0 0 0 . 200 2 0 0 4 0
340 763878d  32 11 1 6 7 1 1 3 4 0 0 0 1 0 0 0 1 . 200 2 1 7.5 4 0
341 666875d  46 3 1 2 1 1 1 3 7 0 0 0 0 0 0 0 1 . 0 2 0.3 7.5 1 0.3
342 663818d  48 2 1 3 6 2 2 3 19 0 0 1 0 0 0 0 0.5 . 250 1 0 0 4 0
343 671723d  34 1 2 6 1 0 1 3 6 0 0 0 0 0 0 0 1 0 200 2 0 0 1 0.5
344 667069d  53 2 1 3 6 12 2 3 23 0 0 0 0 0 0 0 1.5 . 200 2 0 0 4 0
345 671509d  42 2 1 2 3 1 5 3 4 0 0 0 0 0 0 0 1.5 . 200 2 0 0 4 0
346 670273d  55 3 1 1 1 0 1 3 7 0 0 0 0 0 0 0 0 . 250 1 0 0 1 1
347 309578b  21 18 1 5 1 1 1 1 3 0 0 0 0 0 0 0 2 . 100 2 0 0 2 0.5
348 670144d  41 10 2 6 4 3 1 3 4 0 0 1 0 0 0 0 0 0 200 1 0 0 3 0.5
349 670267d  67 8 1 5 4 0 2 3 28 0 0 0 0 0 1 1 1.5 . 0 2 1.5 10.3 4 0
350 709871d  65 6 1 4 1 12 1 3 26 1 0 0 0 0 0 0 1.5 . 500 2 0 0 4 0
351 715195d  75 3 2 1 1 3 1 3 10 1 0 1 0 0 0 0 0.5 240 0 1 0 0 4 0
352 715903d  35 9 2 2 1 1 1 3 3 1 0 0 0 0 0 0 1 0 0 2 1 3.25 4 0
353 715769d  35 2 1 5 4 1 1 3 10 1 0 0 0 0 0 0 2 . 200 2 0.5 7.5 4 0
354 709739d  57 2 1 4 7 0 2 3 30 0 0 0 0 0 0 0 1.5 . 200 1 0 0 4 0
355 713707d  38 2 2 3 1 0 2 3 30 0 0 0 0 0 0 0 1 . 0 2 0 0 4 0
356 714707d  52 2 1 3 4 0 2 3 8 0 0 0 0 0 0 1 0.5 . 0 2 1 15 4 0
357 709742d  27 1 1 3 6 2 1 3 4 0 0 0 0 0 0 0 0.5 . 200 2 0 0 4 0
358 705739d  50 3 1 5 3 48 7 3 8 0 0 0 0 0 0 0 3 . 200 2 0 0 4 0
359 714254d  48 3 1 6 4 6 1 3 12 0 0 0 0 0 0 0 0.5 . 250 2 2 15 3 2
360 713130d  49 13 2 5 1 1 1 3 5 0 0 0 0 0 0 0 0.5 0 0 2 0 0 4 0
361 837410c  54 1 2 2 1 12 6 3 17 1 0 0 0 0 0 0 0.5 0 200 2 0 0 4 0
362 711546d  63 2 1 5 1 6 2 3 8 0 0 0 0 0 0 0 0.5 . 0 2 0 0 4 0
363 707559d  59 2 1 3 4 48 1 3 12 0 0 1 0 0 0 0 0.5 . 0 1 0 0 4 0
364 709982d  40 6 1 5 6 2 2 3 9 0 0 0 1 0 0 1 10 . 250 2 0 0 4 0
365 707678d  62 3 1 3 3 1 2 3 6 0 0 0 0 0 0 0 4 . 250 1 0 0 4 0
366 704563d  57 3 1 3 6 3 1 3 5 0 0 0 0 0 0 1 0.5 . 250 2 1 7.5 1 1
367 710684d  34 2 1 1 2 2 1 3 3 1 0 1 1 0 0 0 12 . 0 1 0 0 4 0
368 702979d  23 2 2 3 1 2 1 3 4 0 0 0 1 0 0 0 3 0 0 2 0 0 4 0
369 699199d  72 2 1 4 1 2 1 3 26 0 0 0 0 0 0 0 1 . 200 2 0 0 1 1
370 697201d  65 6 1 4 6 3 2 3 28 1 0 0 0 0 0 0 1.5 . 200 2 0 0 4 0























































cdos cdur ht dm bmi hb cr chol tg hdl ldl ca phosbic pth alp vitd alb bmd tscor echo1echo2 Xray ass apas apss
0 0 8 0 20 12 3 152 72 63 74 8 4 24 63 82 39 5 . . 5 2 0 . . .
500 0 1 0 20 6 12 149 134 36 80 5 8 13 470 125 29 4 . . 5 2 0 . . .
1500 0.5 2 2 23 10 5 98 163 34 38 8 5 22 85 102 4 4 . . . . 0 . . .
0 0 8 0 21 11 6 . . . . 9 5 25 126 76 31 4 0.691 ‐1.8 7 3 2 . . .
500 1 3 13 20 10 8 . . . . 8 4 25 459 84 10 4 0.689 ‐1.8 4 3 0 . . .
0 0 1 15 23 3 109 71 54 34 9 4 18 0.9 . . 3 0.749 ‐1.3 6 3 0 . . .
0 0 2 8 26 9 7 127 68 38 71 8 5 23 0.9 . . 3 . . 7 2 0 . . .
0 0 2 0 24 12 7 97 118 24 53 8 5 17 77 71 14 5 . . 6 3 0 . . .
0 0 2 0 22 8 5 96 107 33 45 8 5 20 320 71 13 4 . . 2 1 0 . . .
1000 1 0 0 19 8 4 98 50 35 49 7 4 10 782 348 22 4 . . 5 2 0 . . .
0 0 0 0 19 7 4 . . . . 9 4 18 264 84 19 4 . . . . 0 . . .
0 0 20 20 20 9 4 147 75 43 94 8 4 18 110 100 17 4 . . 6 2 1 4 6 8
1000 0.3 0 0 22 7 8 121 167 40 67 5 5 17 859 312 23 4 . . 5 2 0 . . .
1000 1 0 17 18 12 3 158 163 30 102 8 3 22 322 207 . 4 . . 4 2 2 . . .
0 0 0 0 20 10 9 119 128 29 69 7 3 18 0.9 . . 4 0.887 ‐1.9 . . 2 . . .
0 0 12 15 25 14 3 216 370 32 127 10 5 19 60 77 16 4 . . 5 2 0 . . .
1000 0.5 2 0 25 8 10 183 155 37 116 8 5 12 226 80 17 4 . . 6 3 0 . . .
0 0 0 0 18 9 7 170 144 50 95 9 5 17 442 75 22 3 . . . . 0 . . .
0 0 0 18 18 8 9 169 144 23 121 9 6 10 0.9 . . 4 . . . . 2 . . .
0 0 0 0 17 9 4 . . . . 8 4 15 1150 192 15 4 0.517 ‐3 5 3 0 . . .
0 0 7 0 20 7 5 87 47 40 39 8 5 17 0.9 . . 5 . . . . 2 . . .
0 0 0 0 22 7 16 . . . . 6 7 12 663 55 16 4 0.849 ‐0.6 6 3 0 . . .
1000 0.3 0 0 29 8 7 152 68 42 95 8 6 19 247 . 18 3 . . . . 0 . . .
0 0 1 12 20 9 4 95 90 27 57 8 4 15 184 93 20 4 . . 4 2 0 . . .
500 0.5 2 0 42 9 8 133 130 37 74 8 8 19 228 73 12 4 . . 2 2 0 . . .
0 0 3 22 25 11 3 227 156 42 155 8 4 22 187 . 14 4 . . . . 2 . . .
0 0 0 0 22 10 15 105 129 28 54 7 11 16 0.9 . . 4 . . . . 2 . . .
1000 1 2 0 23 6 9 89 66 31 48 8 5 19 0.9 . . 4 . . . . 2 . . .
0 0 1 0 23 8 19 89 30 30 53 4 8 9 562 70 19 4 0.941 ‐1.4 5 2 0 . . .
0 0 15 0 30 8 11 135 73 36 77 10 6 15 0.9 . . 4 . . . . 2 . . .
0 0 15 15 25 13 3 104 79 36 56 8 4 22 78 54 24 4 . . . . 1 3 5 6
0 0 1 0 25 11 3 124 46 48 71 8 3 19 148 75 27 5 . . 5 2 0 . . .
0 0 4 0 20 9 5 207 112 50 137 9 5 29 294 98 15 4 . . 5 2 0 . . .
500 1 0 0 21 8 15 98 166 18 53 8 8 14 233 105 15 4 . . . . 0 . . .
1000 0.5 1 0 24 12 7 123 45 29 69 6 5 19 652 204 8 5 . . . . 0 . . .
0 0 8 2 24 12 2 190 180 32 123 9 4 20 105 81 26 5 . . . . 0 . . .
0 0 2 12 21 7 2 162 111 51 89 9 4 20 117 92 17 4 . . . . 0 . . .
1000 1 12 12 24 10 7 184 117 48 112 8 5 20 410 95 25 4 . . 5 2 0 . . .
0 0 0 0 29 7 14 . . . . 8 7 . 0.9 . . 4 . . . . 2 . . .
0 0 0 0 21 10 7 . . . . 7 5 17 637 154 18 4 . . 5 2 0 . . .
1000 2 1 0 18 9 5 107 63 33 59 8 5 13 168 62 24 4 . . 6 3 0 . . .
0 0 10 0 28 7 9 93 61 37 46 8 6 13 762 102 12 4 . . 7 2 0 . . .
0 0 4 0 23 10 3 150 135 30 97 8 4 19 162 56 20 4 . . . . 2 . . .
0 0 15 15 19 8 7 206 108 63 116 9 5 14 0.9 . . 3 . . . . 2 . . .
0 0 0 10 22 11 5 163 146 36 93 9 3 19 238 99 18 4 . . 8 3 2 . . .
0 0 0 5 17 8 7 138 167 33 76 8 4 13 281 109 17 5 . . 10 4 0 . . .
0 0 0 5 18 7 9 110 90 36 55 5 9 11 691 93 11 4 . . 12 4 0 . . .
1000 1 1 0 22 8 11 74 68 31 31 6 6 11 0.9 . . 5 . . . . 2 . . .
0 0 0 0 22 6 19 150 121 36 73 8 11 10 0.9 . . 4 . . . . 2 . . .
0 0 0 0 20 8 12 97 62 36 46 9 10 14 0.9 . . 4 . . . . 2 . . .
1000 1 2 0 20 3 . . . . 8 3 19 177 140 17 5 . . . . 0 . . .
0 0 29 14 25 9 4 161 150 35 96 8 5 20 505 . 15 4 . . . . 2 . . .
0 0 0 0 21 11 8 114 62 25 82 9 6 21 132 75 18 5 . . . . 2 . . .
S.no H.No Age Res Sex Edu Occ Symp nkd dial gfr pain frac prur prox para smok alc sun amen milk diet vdur vdos bind bdur
372 662540d  24 2 1 4 1 2 1 3 11 0 0 0 0 0 0 0 0.5 . 0 2 0 0 1 2
373 659318d  50 18 1 6 4 24 2 3 7 1 0 0 0 0 1 1 12 . 200 2 0 0 4 0
374 659670d  41 2 1 2 2 24 1 3 9 1 0 0 0 0 1 0 4 . 200 2 0 0 4 0
375 660370d  24 3 1 2 1 2 1 3 8 1 0 0 0 0 0 0 6 . 0 2 0 0 4 0
376 665631d  17 2 2 3 1 1 1 3 5 1 0 0 1 0 0 0 0 0 0 2 0 0 4 0
377 667189d  56 1 1 3 2 6 1 3 3 1 0 1 1 0 0 0 4 . 200 2 0 0 4 0
378 664643d  31 3 1 3 3 2 1 3 2 0 0 0 1 0 0 0 6 . 0 2 0 0 1 0.6
379 667259d  53 2 1 3 4 1 8 3 19 0 0 0 0 0 1 0 1 . 0 2 0 0 4 0
380 668218d  44 2 1 3 4 12 2 3 4 1 0 1 1 0 0 0 8 . 200 2 2 15 1 2
381 665247d  47 2 1 3 5 12 1 3 5 1 0 0 1 0 0 0 8 . 0 2 1 7.5 4 0
382 668007d  63 6 1 3 1 12 7 3 6 0 0 1 0 0 0 0 0.5 . 500 2 1 15 4 0
383 703851d  36 2 1 5 4 2 1 3 3 1 0 1 0 0 0 0 1.5 . 100 1 0 0 4 0
384 697614d  26 8 1 5 4 2 1 3 9 1 0 1 0 0 0 0 1.5 . 200 2 2 15 4 0
385 698207d  49 9 1 2 3 3 1 1 4 0 0 0 0 0 0 0 3 . 0 2 1 15 4 0
386 696251d  28 2 1 1 7 4 1 3 5 0 0 0 0 0 0 0 1.5 . 200 2 1 7.5 4 0
387 6.76d  56 2 1 4 4 6 7 3 6 0 0 0 0 0 0 0 1 . 250 2 0 0 4 0
388 710801d  46 1 2 3 1 1 1 3 14 0 0 0 0 0 0 0 1 0 200 2 0 0 4 0
389 705697d  52 2 1 1 3 2 6 3 13 0 0 0 0 0 0 0 8 . 0 2 0 0 4 0
390 706358d  53 2 1 3 4 1 2 3 24 0 0 0 0 0 0 0 0.5 . 500 2 0 0 4 0
391 707838d  28 8 2 5 4 2 1 3 3 0 0 0 0 0 0 0 1.5 0 100 2 0 0 4 0
392 692376d  67 1 2 5 1 1 5 3 26 0 0 0 0 0 0 0 0.5 0 200 2 0 0 4 0
393 700699d  80 1 2 2 1 1 1 3 14 1 0 0 0 0 0 0 0.5 210 100 2 0 0 4 0
394 698550d  54 2 1 6 4 1 2 3 13 0 0 0 0 0 1 0 1.5 . 200 2 1 15 4 0
395 6.87d  28 6 1 2 1 1 4 3 4 0 0 0 0 0 0 0 1 . 0 1 1 15 4 0
396 715495d  33 2 2 3 1 6 1 3 1 1 0 0 0 0 0 0 1 . 200 2 0 0 4 0
397 707590d  58 6 1 5 6 3 1 3 9 0 0 0 0 0 0 0 1.5 . 200 2 0 0 4 0
398 713351d  46 2 2 3 1 48 1 3 14 0 0 0 0 0 0 0 1 0 0 1 2 30 4 0
399 672911d  72 11 1 3 1 0 2 3 28 0 0 0 0 0 1 0 1.5 . 500 2 0 0 4 0
400 684604d  46 3 2 3 1 12 1 3 11 0 0 0 0 0 0 0 1 24 200 2 0.5 7.5 4 0
401 672596d  46 6 2 6 1 2 1 3 9 0 0 0 0 0 0 0 0.5 0 150 2 0 0 3 1
402 684779d  30 3 2 3 1 24 1 3 13 1 0 0 0 0 0 0 0.5 0 250 2 0 0 4 0
403 685007d  67 1 1 6 1 6 2 3 18 0 0 1 0 0 0 0 0.5 . 100 1 0 0 4 0
404 690061d  56 2 2 2 1 24 6 3 12 1 0 1 0 0 0 0 0.5 60 0 2 0 0 4 0
405 689552d  45 2 2 2 1 1 1 3 7 1 0 0 0 0 0 0 0.5 0 250 2 0 0 4 0
406 691682d  51 3 2 2 1 1 7 1 9 0 0 0 0 0 0 0 1 48 200 2 0.3 1.75 1 0.3
407 691172d  43 3 2 2 1 1 1 3 9 1 0 0 0 0 0 0 1 0 200 2 0 0 4 0
408 843441a  34 1 2 3 1 1 2 3 12 0 0 0 0 0 0 0 1.5 0 200 2 0 0 4 0
409 691123d  36 1 1 3 1 12 2 3 15 0 0 0 0 0 0 0 1 . 0 1 0 0 4 0
410 690186d  62 2 1 5 1 6 1 3 26 0 0 0 0 0 0 0 1 . 0 2 0 0 1 0.5
411 689713d  54 2 2 3 1 1 2 3 19 1 0 1 0 0 0 0 1 4 250 2 0 0 4 0
412 688797d  46 9 1 3 3 1 1 3 15 0 0 0 0 0 1 0 8 . 0 2 0 0 4 0
413 690023d  38 2 1 3 1 2 1 3 4 1 0 1 1 0 0 0 0.5 0 0 2 1 15 4 0
414 690641d  20 2 1 2 2 3 1 3 5 0 0 0 0 0 1 1 9 . 0 1 0 0 1 2
415 690992d  68 2 1 5 6 0 1 3 23 0 0 0 0 0 0 0 1 . 300 2 0 0 1 2
416 682810d  48 3 2 2 1 1 4 3 26 0 0 0 0 0 0 0 0.5 24 100 1 0 0 4 0
417 689218d  45 1 1 2 2 2 1 3 5 1 0 1 1 0 0 1 4 . 0 2 0 0 4 0
418 682636d  28 15 2 5 4 24 1 3 17 1 0 0 0 0 0 0 0.5 0 0 2 0.3 5 4 0
419 690932d  39 8 1 5 6 24 1 3 4 1 0 0 1 0 1 0 2 . 100 2 0.3 5 4 0
420 689714d  57 3 1 3 2 1 1 3 6 0 0 1 0 0 0 0 0.5 . 0 2 0 0 4 0
421 690520d  66 2 1 1 3 2 1 3 11 0 0 1 0 0 1 0 8 . 100 2 0.3 2.5 1 0.3
422 682368d  71 2 1 5 1 2 1 3 12 0 0 0 0 0 1 0 0.5 . 500 2 0 0 4 0
423 681167d  37 2 1 3 7 60 1 3 9 0 0 0 0 0 1 0 4.5 . 0 2 0 0 1 1























































cdos cdur ht dm bmi hb cr chol tg hdl ldl ca phosbic pth alp vitd alb bmd tscor echo1echo2 Xray ass apas apss
1500 2 1 0 17 10 8 . . . . . . . 180 21 . . . . . . 0 . . .
0 0 3 20 22 8 9 215 105 41 150 8 7 20 179 51 25 4 . . 7 3 0 . . .
0 0 2 0 19 11 7 176 95 51 108 8 6 16 258 110 26 4 . . . . 0 . . .
0 0 0 0 18 10 9 110 124 27 65 8 6 19 336 83 25 5 . . 4 3 0 . . .
0 0 0 0 18 6 10 113 101 41 55 8 6 10 605 89 26 3 . . 7 3 0 . . .
0 0 5 0 22 8 20 85 79 20 49 7 10 14 434 58 21 4 . . 5 2 0 . . .
1000 0.6 0 0 23 5 25 127 112 38 62 8 12 20 576 56 17 4 . . 7 3 0 . . .
0 0 10 0 27 13 4 146 227 28 99 8 3 17 231 108 15 4 . . 3 2 2 . . .
1000 2 2 10 24 7 13 152 65 59 98 9 5 18 502 103 28 4 . . 8 3 0 . . .
0 0 0 0 24 10 12 151 75 24 105 7 5 15 440 99 25 4 . . . . 0 . . .
1000 1 1 10 21 9 10 179 96 41 106 9 5 18 318 64 30 3 . . 7 3 0 . . .
0 0 1 0 22 6 22 131 57 50 63 8 8 9 531 144 25 4 . . . . 2 . . .
1500 2 2 0 21 10 10 182 223 28 118 9 4 24 53 45 29 5 . . . . 2 . . .
1000 1 0 0 18 6 15 106 108 34 46 8 6 10 191 78 25 4 . . . . 2 . . .
1000 1 0 0 24 10 12 116 73 48 62 7 8 19 589 . 26 5 . . . . 2 . . .
0 0 0 0 20 8 10 . . . . 7 5 10 569 106 . 4 . . . . 2 . . .
0 0 0 0 25 9 4 188 110 42 124 10 4 27 203 52 4 4 . . 5 3 0 . . .
0 0 0 0 18 9 5 . . . . 8 5 16 58 64 33 4 . . 10 4 1 2 2 3
0 0 1 5 27 11 3 166 175 39 96 8 4 21 89 78 16 4 . . 6 3 0 . . .
0 0 0 0 19 10 17 186 201 32 101 6 9 10 1012 90 12 5 . . . . 2 . . .
0 0 5 0 34 11 2 . . . . 9 4 24 0.9 83 19 4 . . . . 2 . . .
0 0 0 0 19 11 3 191 142 50 107 8 4 26 163 98 30 5 . . . . 2 . . .
1000 1 5 20 21 11 6 184 124 33 129 8 5 20 344 142 21 5 . . . . 0 . . .
1000 1 1 0 18 8 18 80 62 24 47 7 10 9 1331 115 28 4 . . . . 2 . . .
0 0 0 0 17 8 35 . . . . 7 14 10 0.9 51 14 4 . . 8 3 0 . . .
0 0 1 0 19 9 7 130 61 52 68 8 4 16 269 100 12 4 . . 6 2 0 . . .
1000 2 4 0 20 10 4 124 101 44 63 8 4 16 356 76 28 4 . . 6 2 0 . . .
0 0 2 20 22 10 2 131 112 34 74 8 3 . 37 85 20 4 . . 5 2 1 1 1 1
1000 0.5 5 0 19 9 4 187 132 42 116 7 7 19 1158 221 13 5 . . 9 3 0 . . .
1000 1 4 0 24 9 5 110 104 33 66 9 5 19 729 99 10 5 . . . . 0 . . .
0 0 0 0 18 9 4 104 70 43 41 7 3 17 741 227 18 4 . . . . 0 . . .
0 0 25 23 24 11 4 111 60 34 67 8 3 . 396 97 14 5 . . . . 2 . . .
0 0 10 10 24 8 4 129 212 28 66 6 4 15 1000 256 15 5 . . 2 1 0 . . .
0 0 5 0 22 7 7 183 250 30 114 4 11 12 483 134 4 4 . . 3 1 0 . . .
1000 0.3 10 0 19 9 4 176 118 70 80 7 4 22 405 150 24 4 . . 7 3 0 . . .
0 0 5 0 36 7 6 102 95 32 55 7 5 15 1016 126 15 4 . . 3 1 0 . . .
0 0 1 5 21 8 5 111 124 30 60 9 6 23 248 122 24 4 . . 6 3 0 . . .
0 0 1 10 22 6 5 105 39 49 45 9 4 10 78 146 20 2 . . . . 0 . . .
1000 0.5 12 0 16 7 3 163 117 36 113 9 4 29 96 116 17 4 . . 8 3 1 4 6 11
0 0 1 12 18 9 3 124 170 29 57 9 5 24 15 253 16 3 . . 4 1 0 . . .
0 0 1 0 19 7 7 185 149 41 112 8 5 17 507 94 25 4 . . 10 4 0 . . .
1000 1 1 0 27 5 13 118 101 18 77 8 8 14 386 56 18 3 . . . . 0 . . .
500 2 0 0 20 9 7 222 36 47 196 7 10 . 72 21 3 5 . . 5 2 0 . . .
500 1 3 0 23 8 3 165 156 27 110 8 4 18 125 115 22 4 . . 6 3 2 . . .
0 0 5 0 23 11 3 136 162 34 75 8 5 20 126 118 22 4 . . 5 2 0 . . .
0 0 0 0 25 11 12 80 123 21 42 7 6 12 294 173 26 4 . . 7 2 0 . . .
1000 0.3 2 0 18 11 4 164 100 52 99 7 3 16 477 111 16 4 . . 2 2 0 . . .
1000 0.3 2 0 25 10 16 . . . . 6 8 13 463 . . 5 . . . . 2 . . .
0 0 0 0 17 10 10 135 95 36 76 8 6 17 149 71 30 5 . . 11 4 0 . . .
1000 0.3 0 0 17 10 6 151 177 34 84 9 5 20 5 72 43 5 . . 8 3 0 . . .
0 0 2 5 18 12 5 239 140 140 46 . . 15 154 . . . . . 10 3 1 1 1 2
1000 1 1 0 18 10 7 134 101 40 65 8 3 16 228 184 28 5 . . . . 0 . . .
1000 1 0 0 20 11 4 116 131 30 67 8 5 19 151 64 22 4 . . . . 0 . . .
S.no H.No Age Res Sex Edu Occ Symp nkd dial gfr pain frac prur prox para smok alc sun amen milk diet vdur vdos bind bdur
425 687156d  30 2 1 3 2 8 1 3 12 0 0 1 0 0 0 0 4 . 0 2 1 15 1 1
426 687024d  28 3 1 3 2 1 1 1 9 1 0 1 1 0 0 1 8 . 100 1 0 0 2 0.5
427 690180d  27 1 2 5 4 2 1 3 7 0 0 0 0 0 0 0 0.5 0 250 1 0.5 1.86 4 0
428 689741d  42 12 1 5 4 1 7 1 6 0 0 0 0 0 0 0 0.5 . 250 2 0 0 4 0
429 690406d  47 3 2 2 1 3 2 3 23 0 0 1 1 0 0 0 7 1 250 2 0 0 4 0
430 678669d  76 6 1 3 1 24 2 3 21 1 0 0 0 0 0 0 0.5 . 500 1 0 0 4 0
431 670184d  37 2 1 5 4 2 1 3 5 0 0 1 0 0 1 0 0.5 . 0 2 0 0 4 0
432 675900d  52 1 1 3 1 12 2 3 11 0 0 0 0 0 1 0 0.5 . 0 2 0 0 4 0
433 676652d  33 7 2 3 1 3 1 3 3 1 0 0 0 0 0 0 1 0 0 1 0 0 3 0.5
434 671203d  32 2 1 3 6 1 4 3 19 0 0 0 0 0 0 0 0.5 . 0 2 0 0 4 0
435 675979d  42 9 2 3 1 1 1 1 9 0 0 0 0 0 0 0 1 0 0 1 0.3 0.75 1 0.3
436 676079d  52 5 1 5 4 1 2 3 28 0 0 0 0 0 0 1 0 . 100 2 0 0 4 0
437 676243d  35 2 2 5 1 3 1 3 7 0 0 1 0 0 0 0 0.5 0 100 2 0 0 1 0.5
438 675270d  56 3 1 3 6 2 2 3 14 0 0 1 1 0 0 0 0.5 . 0 2 0.3 2.5 1 0.3
439 675797d  50 2 1 3 5 1 1 3 11 0 0 0 1 0 0 0 2 . 100 2 0 0 4 0
440 675472d  50 22 2 3 6 12 1 3 2 0 0 0 1 0 0 0 0.5 12 100 1 1 15 1 1
441 672000d  77 2 1 3 1 1 5 3 9 0 0 0 0 0 0 0 0.5 . 0 1 0 0 4 0
442 676781d  28 8 1 4 5 1 1 3 10 1 0 0 0 0 0 0 3 . 0 2 0.5 3.65 4 0
443 677175d  30 1 1 6 5 1 1 3 15 0 0 0 0 0 0 0 3 . 0 2 0 0 4 0
444 676833d  46 8 2 2 1 60 6 3 12 0 0 0 0 0 0 0 1 48 0 2 0 0 4 0
445 672765d  22 3 2 5 4 2 1 3 7 0 0 0 0 0 0 0 1.5 0 0 2 0 0 4 0
446 672746d  41 12 1 3 5 1 1 3 16 0 0 1 0 0 1 0 0.5 . 0 2 1 7.5 4 0
447 670019d  55 5 1 3 7 3 2 3 6 0 0 0 0 0 0 0 1 . 300 2 2.5 22.5 1 2.5
448 672762d  34 2 2 2 1 4 1 1 5 0 0 0 0 0 0 0 0.5 0 0 2 0.5 3.65 1 0.5
449 629300d  50 2 1 2 3 6 2 3 29 0 0 0 1 0 0 0 2.5 . 100 1 0 0 4 0
450 634875d  39 2 1 4 6 1 1 3 22 0 0 1 0 0 1 0 2 . 100 2 0 0 4 0
451 634990d  58 13 1 5 6 6 2 3 14 0 0 1 1 0 0 0 0.5 . 200 1 0 0 4 0
452 633919d  53 11 1 5 4 0 2 3 9 1 0 0 0 0 0 1 0.5 . 100 2 1 3.25 4 0
453 633493d  51 1 1 1 2 6 2 1 6 0 0 1 0 0 0 0 12 . 200 2 0 0 4 0
454 628025d  61 1 1 3 6 1 2 3 7 0 0 1 0 0 0 0 1 . 200 2 0 0 2 0.5
455 634385d  48 10 2 2 1 24 2 1 7 1 0 1 1 0 0 0 1 0 200 2 0 0 4 0
456 634119d  23 2 1 3 7 0 1 1 5 1 0 1 1 0 0 0 1 . 250 2 0 0 4 0
457 638741d  50 8 1 3 6 7 2 3 12 1 0 1 0 0 1 0 3 . 150 2 0 0 4 0
458 637961d  60 2 1 1 6 24 1 3 29 1 0 1 0 0 0 0 4 . 250 2 0 0 4 0
459 637948d  34 2 1 5 7 2 1 3 13 0 0 0 0 0 1 0 5 . 0 2 0 0 4 0
460 961788c  56 3 1 5 1 0 2 3 19 0 0 0 0 0 0 0 1 . 250 2 0.3 0.75 4 0
461 429946d  55 5 1 2 2 3 1 3 21 1 0 1 0 0 0 0 4.5 . 50 2 0 0 4 0
462 636755d  39 1 1 2 2 0 8 3 28 0 0 0 0 0 0 0 10 . 200 2 0 0 4 0
463 636981d  34 3 1 3 3 1 1 3 3 1 0 1 0 0 0 0 10 . 0 1 0 0 1 0.3
464 640464d  48 1 2 3 2 1 1 3 3 1 0 0 0 0 0 0 8 0 50 2 0 0 4 0
465 637978d  48 2 2 3 1 2 1 3 8 1 0 1 1 0 0 0 4 120 0 2 1 7.5 4 0
466 637732d  22 2 2 5 1 5 1 3 6 1 0 0 1 0 0 0 0.5 . 0 2 1 7.5 4 0
467 642103d  32 6 1 5 1 3 1 3 7 0 0 0 0 0 0 0 3 . 250 2 0 0 1 1
468 646705d  50 10 2 6 1 24 1 3 7 0 0 0 0 0 0 0 1 . 100 2 1 15 4 0
469 645904d  51 15 1 6 4 0 2 3 10 0 0 1 0 0 0 0 0.5 . 250 2 0 0 4 0
470 663359d  40 2 1 3 2 0 1 1 6 0 0 0 0 0 0 0 10 . 100 2 0 0 3 0.5
471 664392d  48 3 1 5 4 0 1 3 14 0 0 0 0 0 0 0 0.5 . 50 2 0 0 2 1
472 665701d  33 2 1 3 2 9 1 3 2 1 0 1 1 0 0 0 10 . 200 2 0 0 4 0
473 663778d  54 3 2 1 1 12 2 3 14 1 0 0 1 0 0 0 0.5 48 100 1 0 0 4 0
474 621825d  40 2 2 5 1 12 4 3 19 1 0 0 0 0 0 0 0.5 0 200 2 0 0 4 0
475 623845d  62 3 1 1 1 6 2 3 21 0 0 0 0 0 0 0 0.5 . 200 2 0 0 4 0
476 622333d  55 3 1 3 1 3 2 3 23 0 0 0 0 0 1 1 5 . 200 2 0 0 4 0























































cdos cdur ht dm bmi hb cr chol tg hdl ldl ca phosbic pth alp vitd alb bmd tscor echo1echo2 Xray ass apas apss
1000 1 1 0 21 10 6 162 69 56 87 9 5 18 110 61 24 4 . . 6 2 0 . . .
0 0 0 0 18 9 10 178 172 30 112 7 6 19 1025 109 18 4 . . 6 1 2 . . .
0 0 0 0 29 9 8 138 128 32 87 8 8 12 833 80 16 5 . . 8 3 0 . . .
0 0 4 15 . 6 10 62 109 20 25 8 7 9 260 150 18 4 . . 10 4 0 . . .
0 0 0 15 . 6 2 86 141 27 45 9 4 17 18 95 48 4 . . 4 2 2 . . .
0 0 20 20 25 10 3 182 97 59 104 8 4 19 231 177 8 4 . . 10 3 0 . . .
0 0 0 0 22 8 13 175 184 29 84 7 12 10 564 46 16 4 . . 9 4 2 . . .
0 0 7 20 23 8 6 . . . . 8 4 21 263 98 28 4 . . 4 1 1 2 4 5
0 0 1 0 19 8 16 269 165 29 198 9 10 12 255 86 12 4 . . 6 2 0 . . .
0 0 2 0 36 . 4 157 73 49 84 8 4 21 281 55 20 4 . . . . 2 . . .
1000 0.3 3 0 23 8 7 149 92 47 91 8 4 26 751 84 12 4 . . 6 2 2 . . .
0 0 0 10 19 10 3 206 225 26 123 9 3 18 105 174 12 4 . . . . 0 . . .
1000 0.5 1 0 23 8 7 193 312 41 103 9 4 23 0.9 . . 3 . . . . 2 . . .
1000 0.3 1 20 24 8 5 96 92 28 55 7 6 18 471 111 17 4 . . 5 2 0 . . .
0 0 17 0 28 9 6 123 132 39 66 8 6 17 387 68 23 4 . . 4 2 0 . . .
1000 1 5 0 22 6 19 106 46 40 64 6 10 10 738 139 15 4 . . 4 2 0 . . .
0 0 0 0 18 7 6 . . . . 7 3 15 118 47 26 3 . . . . 0 . . .
1000 0.5 0 0 18 8 7 230 258 31 144 8 4 15 162 53 24 4 . . 5 2 0 . . .
0 0 0 0 28 12 5 169 94 32 126 8 4 25 799 50 17 5 . . 5 2 0 . . .
0 0 5 0 25 11 4 175 97 47 113 9 5 26 113 64 10 5 . . 5 2 0 . . .
0 0 2 0 18 8 6 128 136 32 76 8 6 15 351 76 20 4 . . 5 2 0 . . .
1000 1 1 0 20 10 4 158 103 58 88 9 3 22 83 67 24 4 . . 7 1 0 . . .
1000 2.5 6 10 29 9 10 214 114 56 129 8 5 18 649 101 7 3 . . . . 0 . . .
1000 0.5 0 0 21 10 10 192 204 40 131 9 5 26 201 83 29 5 . . . . 0 . . .
0 0 14 1 21 9 3 313 143 60 210 9 5 21 82 . 10 3 . . . . 0 . . .
0 0 15 0 18 12 3 141 146 31 77 9 5 23 227 97 26 4 . . 2 1 0 . . .
0 0 8 4 27 10 5 125 72 46 56 9 4 17 444 162 11 4 . . 2 1 0 . . .
0 0 15 15 26 7 7 122 71 39 62 7 5 22 854 94 17 4 . . 3 2 0 . . .
1000 1 15 15 24 10 11 170 144 35 113 8 6 25 403 69 19 4 . . 3 2 1 2 2 3
0 0 20 7 21 7 9 201 78 45 141 8 5 18 512 102 18 3 . . 4 2 0 . . .
0 0 14 10 25 8 8 201 177 40 119 8 5 26 834 . 6 3 . . 2 2 0 . . .
0 0 0 0 18 7 13 174 203 23 97 6 4 14 935 184 24 3 . . 1 1 0 . . .
0 0 4 18 22 11 6 358 232 29 268 8 5 23 878 152 13 4 . . 5 3 0 . . .
0 0 0 24 24 10 2 131 253 25 63 8 4 23 326 71 12 4 . . . . 0 . . .
0 0 0 0 . 13 6 187 272 29 110 9 4 22 324 137 56 5 . . 2 1 0 . . .
0 0 20 2 22 10 4 169 150 42 99 6 5 25 385 120 8 4 . . 3 2 0 . . .
0 0 2 0 19 7 3 117 133 27 67 8 4 17 45 67 33 4 . . . . 0 . . .
0 0 2 0 22 12 3 146 76 45 82 8 5 19 175 71 27 4 . . 5 2 0 . . .
1000 0.3 2 0 19 9 21 150 110 47 79 8 14 12 317 87 20 3 . . 2 2 2 . . .
0 0 0 0 24 9 16 183 228 21 116 8 8 19 0.9 . . 4 . . . . 0 . . .
0 0 2 0 23 6 7 112 32 36 67 9 5 20 509 93 22 3 . . 1 1 0 . . .
1000 1 0 0 14 7 7 156 84 68 67 8 5 12 0.9 . . 4 . . . . 0 . . .
1000 1 10 0 19 8 8 148 68 51 83 8 6 15 402 59 19 4 . . 5 2 0 . . .
1000 1 8 18 27 10 7 226 79 67 141 9 4 21 359 78 18 3 . . . . 0 . . .
0 0 6 6 25 8 6 171 176 29 117 6 5 15 171 86 21 4 0.94 ‐1.2 . . 2 . . .
0 0 0 0 23 8 10 120 49 41 69 8 7 14 146 46 21 4 . . . . 0 . . .
0 0 5 0 23 10 5 111 92 32 57 8 5 12 250 114 25 4 . . 3 2 0 . . .
0 0 1 0 21 5 25 104 106 30 54 9 9 14 212 52 26 4 . . 10 4 0 . . .
0 0 2 20 24 9 4 201 185 50 108 9 4 19 181 139 15 4 . . 5 3 0 . . .
0 0 1 0 25 10 3 223 151 35 133 7 4 21 504 87 4 3 . . 4 2 0 . . .
0 0 5 10 25 9 3 204 123 76 94 9 6 29 107 84 11 2 . . 3 2 0 . . .
0 0 3 7 22 8 3 164 95 39 87 8 5 15 204 188 28 4 . . 6 3 0 . . .
0 0 1 0 23 5 18 128 136 20 78 6 11 7 0.9 . . 4 . . . . 2 . . .
S.no H.No Age Res Sex Edu Occ Symp nkd dial gfr pain frac prur prox para smok alc sun amen milk diet vdur vdos bind bdur
478 623948d  49 2 1 3 4 0 1 3 6 0 0 0 0 0 0 0 1.5 . 0 2 0 0 1 1
479 623760d  38 3 1 5 6 1 1 3 5 0 0 0 0 0 1 0 1.5 . 100 2 0 0 4 0
480 614080d  69 1 1 3 2 1 1 3 7 0 0 0 0 0 1 0 1 . 0 2 0 0 4 0
481 624328d  31 8 1 3 5 1 1 3 5 1 0 0 0 0 0 0 1.5 . 500 2 1 7.5 4 0
482 627810d  60 2 1 3 1 36 2 3 7 0 0 0 0 0 0 0 1.5 . 0 2 0 0 4 0
483 624583d  56 2 1 4 5 1 2 3 27 0 0 0 0 0 0 0 1 . 0 2 0 0 4 0
484 620179d  50 1 1 3 6 0 1 3 23 0 0 0 0 0 0 0 1.5 . 200 2 0 0 4 0
485 624568d  56 3 1 4 2 1 2 3 16 0 0 0 0 0 0 0 5 . 200 2 0.5 7.5 4 0
486 624796d  43 8 1 5 5 1 1 3 6 0 0 0 0 0 1 0 3 . 200 2 1 7.5 4 0
487 581405d  55 21 1 3 7 3 2 3 17 1 0 0 0 0 1 1 3 . 200 2 0 0 4 0
488 623396d  60 3 1 5 5 1 2 3 11 0 0 0 0 0 0 0 1.5 . 0 2 0.3 1.75 3 0.3
489 627049d  57 13 1 3 4 1 8 1 5 0 0 0 0 0 0 0 1.5 . 200 2 0.3 2.5 1 0.3
490 627621d  65 1 1 3 1 1 1 3 6 1 0 0 0 0 1 0 0.5 . 200 2 0 0 4 0
491 626083d  59 3 1 3 4 3 2 1 8 0 0 0 0 0 1 0 1 . 200 2 1 7.5 1 1
492 624794d  48 2 1 3 3 3 2 3 10 0 0 0 0 0 0 0 1 . 0 2 0 0 4 0
493 626354d  26 2 1 3 7 2 1 1 6 0 0 0 0 0 0 0 3 . 100 2 0.5 7.5 4 0
494 623621d  54 1 2 1 1 1 1 3 6 0 0 0 0 0 0 0 1.5 180 200 2 0 0 4 0
495 628456d  55 3 1 4 4 1 7 1 6 0 0 0 0 0 0 0 1.5 . 200 1 0.3 1.75 1 0.3
496 633688d  54 3 2 1 1 1 2 3 17 1 0 0 0 0 0 0 2 . 500 2 0.6 10 4 0
497 631774d  32 8 1 4 5 12 1 3 12 1 0 1 1 0 0 0 12 . 100 2 2 7.5 4 0
498 631236d  53 6 1 4 6 1 2 3 21 0 0 0 0 0 0 1 2 . 250 2 0 0 4 0
499 629240d  30 3 1 4 1 1 1 3 7 1 0 0 0 0 0 0 1.5 . 100 2 1 7.5 2 1
500 633145d  28 2 1 2 2 2 1 3 6 0 0 1 0 0 0 0 2 . 100 2 1 3.25 4 0
501 653410d  65 1 1 2 1 24 1 3 6 1 0 0 0 0 1 0 1 . 500 2 0 0 4 0
502 648010d  65 1 1 2 3 12 2 3 22 0 0 0 1 0 0 0 8 . 250 2 0 0 4 0
503 629654d  59 2 1 3 1 1 1 3 23 1 0 0 0 0 0 0 5.5 . 100 1 0 0 4 0
504 620464d  60 1 1 6 5 24 2 3 17 1 0 1 0 0 0 0 0 . 150 2 0 0 4 0
505 634185d  58 2 1 3 2 2 1 3 12 1 0 0 1 0 1 0 12 . 100 2 1 15 4 0
506 634330d  59 2 1 5 1 4 2 3 7 0 0 0 1 0 1 0 2 . 250 1 0 0 1 1
507 631286d  23 2 1 5 4 1 1 3 20 1 0 0 0 0 0 0 2 . 100 2 0 0 1 1
508 633228d  48 2 2 1 1 1 1 3 7 0 0 0 1 0 0 0 1 180 0 2 1.5 22.5 4 0
509 633833d  24 2 1 3 1 2 1 1 6 0 0 1 0 0 0 0 8 . 100 2 1 3.75 1 1
510 635189d  64 3 1 3 1 6 2 3 12 1 0 0 1 0 0 0 1 . 50 2 1 7.5 4 0
511 634046d  51 2 1 3 3 0 2 3 9 0 0 0 0 0 0 0 10 . 200 2 0 0 4 0
512 635790d  25 2 1 2 2 1 1 3 5 0 0 0 0 0 0 0 8 . 50 1 0 0 3 0.5
513 636189d  67 11 1 5 1 1 1 3 10 0 0 0 1 0 0 0 2 . 0 1 0 0 1 1
514 634514d  32 3 1 5 4 1 1 3 10 0 0 0 1 0 0 0 10 . 200 1 0 0 4 0
515 637009d  34 2 1 2 7 2 1 3 6 1 0 1 1 0 0 0 0 . 100 1 0 0 4 0
516 636961d  52 1 1 2 2 2 8 3 15 0 0 0 0 0 0 0 8 . 200 2 0 0 4 0
517 631250d  60 1 1 1 3 0 1 3 26 1 0 0 1 0 0 0 8 . 500 1 0 0 4 0
518 633025d  64 1 1 1 2 6 1 3 15 0 0 0 1 0 0 0 12 . 50 2 0 0 4 0
519 621590d  50 2 1 3 4 3 1 3 21 0 0 0 0 0 1 1 5 . 0 2 0 0 4 0
520 623432d  22 2 1 6 5 1 1 1 6 0 0 0 0 0 1 0 1.5 . 0 2 0.3 3 1 0.3
521 621837d  16 3 1 4 1 1 4 3 15 0 0 0 0 0 0 0 1.5 . 100 2 0 0 4 0
522 654987d  44 2 1 2 6 0 1 3 6 0 0 0 0 0 0 0 4 . 0 2 0 0 4 0
523 657799d  41 2 1 3 2 1 2 3 7 1 0 1 1 0 0 0 6 . 250 2 0 0 4 0
524 658244d  55 2 1 3 4 1 1 3 3 1 0 0 0 0 0 0 7 . 0 2 0.5 7.5 4 0
525 657934d  30 3 1 5 4 1 1 1 5 1 0 1 0 0 0 0 2.5 . 200 2 0.5 7.5 4 0
526 657882d  45 3 1 1 6 6 1 3 7 0 0 0 1 0 0 0 3.5 . 250 2 0 0 4 0
527 176739c  58 1 2 2 1 0 2 3 17 0 0 0 0 0 0 0 1 84 0 2 0 0 4 0
528 623831d  22 3 1 2 3 3 1 1 7 0 0 0 0 0 0 0 1.5 . 200 2 0.5 3.75 1 0.5
529 657526d  51 8 1 3 1 6 2 3 14 1 0 0 1 0 0 0 0.5 . 0 2 2 15 4 0























































cdos cdur ht dm bmi hb cr chol tg hdl ldl ca phosbic pth alp vitd alb bmd tscor echo1echo2 Xray ass apas apss
1000 1 2 17 22 7 10 148 112 23 99 9 5 22 234 81 13 4 . . 3 1 2 . . .
500 1 0 0 22 8 13 104 59 33 50 8 7 20 0.9 . . 3 . . . . 2 . . .
0 0 0 0 16 8 8 194 224 40 112 8 8 14 622 98 12 3 . . . . 0 . . .
1000 1 6 0 25 10 12 110 144 25 58 9 8 18 180 60 20 4 . . 3 1 0 . . .
0 0 3 20 22 7 8 76 76 29 20 8 6 15 0.9 119 . 4 . . 1 0 0 . . .
0 0 5 5 24 11 3 286 131 68 175 9 4 23 331 126 6 3 . . 2 1 0 . . .
0 0 2 0 21 10 3 168 139 34 85 8 4 21 59 70 24 4 . . 7 3 0 . . .
1000 0.5 0 7 21 8 6 117 180 20 58 9 5 15 38 93 14 4 . . 3 1 0 . . .
1500 1 2 0 26 9 11 142 59 34 90 9 6 18 212 47 18 4 . . 5 3 0 . . .
0 0 0 2 21 9 4 138 164 26 72 9 4 19 70 . 36 4 . . 2 1 0 . . .
0 0 3 3 22 8 6 159 62 33 109 5 7 20 276 83 7 3 . . . . 0 . . .
1500 0.3 0 0 23 10 11 129 95 55 41 9 6 25 194 73 . 5 . . . . 2 . . .
0 0 0 0 25 11 9 225 166 25 154 7 5 18 748 410 12 4 . . . . 2 . . .
1000 1 3 6 21 10 7 145 112 44 71 8 5 18 0.9 . . 3 . . . . 2 . . .
0 0 2 4 24 9 7 188 218 38 98 8 6 22 83 83 17 3 . . 1 0 0 . . .
0 0 0 0 21 6 11 108 94 25 58 7 9 14 0.9 . . 3 . . . . 2 . . .
0 0 6 0 21 6 7 264 143 36 184 8 5 13 596 130 15 4 . . 3 2 0 . . .
1500 0.3 2 7 23 12 10 165 178 29 94 5 6 20 869 162 10 4 . . 9 4 0 . . .
1000 0.6 5 10 21 13 4 152 85 91 34 8 4 25 1071 83 17 4 . . 3 1 0 . . .
0 0 10 0 26 10 6 270 349 37 167 9 7 21 0.9 . . 4 . . . . 2 . . .
0 0 0 10 22 8 3 127 130 40 64 8 4 20 173 88 18 4 . . 1 0 0 . . .
0 0 0 0 15 10 10 193 292 27 116 4 14 14 1241 335 18 4 . . 4 2 0 . . .
0 0 0 0 28 8 11 222 186 34 139 9 7 17 0.9 . . 4 . . . . 2 . . .
0 0 0 12 25 13 10 . . . . 10 6 9 7 178 . 3 . . . . 0 . . .
0 0 2 6 18 11 3 . . . . 8 4 25 0.9 . . 4 . . 6 3 0 . . .
0 0 5 0 22 10 3 100 161 27 47 8 3 28 170 76 24 3 . . 2 2 0 . . .
0 0 20 20 23 15 4 110 229 23 53 8 3 28 120 112 12 5 . . . . 0 . . .
1000 1 2 0 17 7 5 114 21 51 52 8 6 17 487 178 34 4 . . . . 0 . . .
1000 1 13 8 22 9 8 136 103 30 77 8 6 24 351 68 14 4 . . . . 0 . . .
500 1 1 0 17 12 5 175 97 64 87 8 5 17 130 84 17 5 . . 2 1 2 . . .
1000 1.5 0 0 19 4 7 151 104 53 84 7 6 14 886 126 22 5 . . 1 1 0 . . .
1000 1 0 0 19 10 12 125 113 48 49 9 8 20 157 96 4 4 0.764 ‐2.8 2 2 0 . . .
500 1 2 1 24 7 5 144 167 33 86 6 5 15 376 171 22 4 . . 1 1 0 . . .
0 0 3 12 21 6 7 140 86 51 65 9 7 16 0.9 . . 4 . . . . 2 . . .
0 0 2 0 19 5 14 96 59 32 50 7 8 15 488 99 23 4 . . 2 2 0 . . .
1000 1 20 0 28 9 6 92 95 37 34 8 4 18 439 88 22 4 . . . . 0 . . .
0 0 0 0 33 12 7 189 269 34 106 7 5 17 1312 107 13 4 . . 0 0 0 . . .
0 0 2 0 23 7 10 184 71 63 106 8 8 12 886 140 26 3 . . . . 2 . . .
0 0 15 15 34 13 5 553 275 43 427 9 5 19 221 60 19 2 . . 2 1 0 . . .
0 0 0 0 22 13 3 147 82 38 87 . . 25 0.9 . . . . . 1 1 0 . . .
0 0 5 0 20 11 4 . . . . 8 4 15 227 108 48 4 . . 3 1 0 . . .
0 0 6 0 25 11 3 136 112 22 88 8 3 24 205 138 25 4 . . 1 1 0 . . .
1500 0.3 0 0 19 10 11 242 276 35 145 9 4 22 358 217 8 4 . . 4 2 0 . . .
0 0 0 0 15 7 6 153 227 24 88 9 9 19 1164 87 12 4 . . 4 3 0 . . .
0 0 2 0 23 8 10 159 163 25 102 7 11 . 711 70 25 4 . . . . 2 . . .
0 0 2 2 21 6 9 92 95 35 43 9 8 16 138 67 15 3 . . . . 2 . . .
1000 0.5 0 0 22 8 18 . . . . 8 10 10 0.9 59 . 4 . . . . 2 . . .
1000 0.5 0 0 22 8 12 222 210 34 149 9 8 23 350 65 11 3 . . . . 0 . . .
0 0 0 0 23 9 8 132 81 39 79 8 6 14 398 159 22 4 . . . . 0 . . .
0 0 5 10 29 9 3 151 135 18 102 9 3 24 180 135 27 4 . . 4 2 1 4 7 10
1000 0 0 0 . 8 10 165 350 33 68 9 6 23 36 98 7 3 . . 2 2 0 . . .
1500 2 1 21 21 10 5 141 561 18 52 9 4 23 48 74 22 4 . . 7 3 0 . . .
0 0 3 20 23 11 3 114 100 26 69 9 3 23 123 63 20 4 . . 5 2 0 . . .
S.no H.No Age Res Sex Edu Occ Symp nkd dial gfr pain frac prur prox para smok alc sun amen milk diet vdur vdos bind bdur
531 656867d  55 13 1 5 6 3 2 1 6 0 0 1 0 0 0 0 0.5 . 150 2 0 0 4 0
532 659061d  40 2 1 3 4 24 4 3 26 0 0 1 0 0 0 0 0.5 . 250 2 0 0 4 0
533 659084d  56 2 2 2 1 24 1 3 8 0 0 1 1 0 0 0 8 84 0 2 0 0 4 0
534 653086d  39 3 1 6 6 3 1 3 18 0 0 1 1 0 0 0 0.5 . 1000 1 1 22.5 4 0
535 653079d  48 6 1 5 4 0 1 3 27 0 0 0 0 0 0 0 0.5 . 250 2 0 0 4 0
536 652319d  26 3 1 3 7 1 1 3 4 0 0 0 0 0 0 0 4 . 500 2 0.3 2.5 4 0
537 652168d  45 2 1 3 6 3 1 3 11 0 0 0 0 0 0 0 0 . 200 2 0 0 1 1
538 646801d  67 1 1 3 1 6 2 3 22 1 0 1 0 0 0 0 0.5 . 100 1 0 0 4 0
539 944660b  65 1 1 3 1 36 2 3 22 0 0 1 1 0 0 0 0.5 . 400 2 0 0 4 0
540 648881d  29 5 1 6 5 2 1 3 3 0 0 1 0 0 1 1 0.5 . 200 2 2 15 4 0
541 645134d  66 2 1 5 1 36 1 3 6 1 0 0 1 0 0 0 0.5 . 0 2 1 7.5 1 1
542 644703d  46 3 1 3 7 2 2 3 10 0 0 0 0 0 0 1 1 . 250 1 0 0 4 0
543 644634d  20 2 1 3 1 2 1 1 6 1 0 1 1 0 0 0 1 . 100 1 0 0 4 0
544 645803d  40 2 1 5 4 1 1 3 7 0 0 0 0 0 0 0 1 . 250 2 0 0 4 0
545 642668d  64 3 1 5 1 3 2 3 8 1 0 1 1 0 0 0 2 . 250 2 0 0 4 0
546 644865d  60 2 1 5 5 3 2 3 17 1 0 0 1 0 1 0 4 . 0 2 0 0 4 0
547 640730d  23 2 2 3 1 12 1 3 9 0 0 1 1 0 0 0 1 0 0 2 0 0 4 0
548 637937d  22 6 1 3 4 2 4 3 18 0 0 0 1 0 0 0 7 . 0 2 0 0 4 0
549 638088d  25 2 1 5 5 2 1 1 5 1 0 1 0 0 0 0 10 . 0 2 0 0 4 0
550 635210d  37 3 2 1 1 0 1 3 8 0 0 0 0 0 0 0 4 . 0 2 1 7.5 2 1
551 637922d  65 2 1 5 1 1 2 3 9 0 0 0 1 0 0 0 1 . 200 2 0 0 1 2
552 635918d  26 2 2 2 1 6 1 3 1 1 0 0 0 0 0 0 10 0 0 2 0 0 4 0
553 634092d  54 10 1 5 4 12 8 3 17 0 0 1 1 0 0 0 1.5 . 150 1 0 0 3 1.5
554 637669d  39 2 2 3 1 36 1 3 21 1 0 0 0 0 0 0 1 . 250 2 2 15 1 2
555 634471d  51 6 1 6 4 3 2 3 9 0 0 0 0 0 0 0 2 . 200 2 2 15 3 2
556 635651d  54 1 2 1 1 1 2 3 9 1 0 1 0 0 0 0 1 . 200 1 0 0 4 0
557 634108d  47 2 1 1 6 8 1 3 3 1 0 0 1 0 0 0 8 . 250 1 2 30 4 0
558 633349d  58 11 1 3 4 1 2 3 12 1 0 1 1 0 1 1 2.5 . 250 2 1.5 22.5 4 0
559 633600d  34 16 1 5 4 0 1 3 4 0 0 0 0 0 0 0 10 . 0 2 0 0 4 0
560 636340d  57 1 1 3 7 2 7 3 7 1 0 0 1 0 1 1 1 . 250 2 0 0 4 0
561 614740d  61 1 2 2 1 2 1 3 21 0 0 1 0 0 0 0 1 120 50 1 0 0 4 0
562 640435d  52 2 1 3 6 1 2 3 19 1 0 0 0 0 1 1 2 . 50 2 0 0 4 0
563 643980d  58 2 1 5 5 4 2 3 17 0 0 0 0 0 1 0 1 . 1000 1 0 0 4 0
564 640708d  55 6 2 3 1 2 2 3 11 1 0 0 1 0 0 0 8 72 200 2 0 0 4 0
565 639914d  52 2 1 6 5 36 2 3 22 0 0 1 0 0 0 0 3.5 . 50 2 0 0 4 0
566 636152d  39 11 1 3 4 3 6 3 23 0 0 0 0 0 0 0 10 . 200 1 1 7.5 4 0
567 621522d  38 2 1 3 6 2 6 3 14 1 0 0 1 0 0 0 1 . 50 2 0 0 4 0
568 635186d  49 2 2 1 1 1 1 3 6 1 0 0 1 0 0 0 1 60 50 2 0 0 4 0
569 641594d  41 2 2 2 1 12 1 3 12 1 0 0 0 0 0 0 1 108 0 2 1 15 4 0
570 639473d  36 10 1 5 6 2 2 1 6 1 0 0 1 0 0 0 2.5 . 200 2 0 0 4 0
571 639924d  48 2 1 5 4 2 1 3 6 0 0 1 0 0 0 0 1 . 1000 2 0.5 7.5 4 0
572 638659d  64 3 1 3 5 3 2 3 22 1 0 0 1 0 0 0 6 . 1000 2 0 0 1 2
573 641033d  46 3 1 3 5 6 1 3 11 1 0 1 1 0 0 0 1 . 250 2 0.3 1.75 1 0.3
574 639089d  41 2 1 5 7 2 1 3 10 1 0 1 1 0 1 0 8 . 250 2 0.5 7.5 4 0
575 639251d  58 3 1 3 4 24 2 3 20 1 0 1 1 0 0 0 0.5 . 250 2 0 0 4 0
576 641434d  62 2 1 3 4 1 2 3 24 1 0 0 0 0 0 0 1 . 500 2 0 0 4 0
577 644633d  38 3 1 3 6 12 2 3 18 0 0 0 1 0 0 0 1 . 150 1 0 0 1 0.5
578 633011d  45 2 1 3 4 2 2 3 20 0 0 0 1 0 1 0 1 . 300 1 1 7.5 4 0
579 641328d  54 2 1 3 3 1 6 3 22 0 0 1 0 0 0 0 0 . 0 1 1 15 2 1
580 586481c  36 2 1 3 4 2 1 3 15 0 0 0 0 0 1 0 0.5 . 100 1 0 0 4 0
581 377098c  60 11 1 3 1 0 2 3 21 0 0 0 0 0 0 0 0.5 . 0 2 0.3 5 4 0
582 647849d  65 3 2 3 1 24 2 3 11 1 0 0 1 0 0 0 2 120 0 2 1 15 3 1























































cdos cdur ht dm bmi hb cr chol tg hdl ldl ca phosbic pth alp vitd alb bmd tscor echo1echo2 Xray ass apas apss
0 0 7 28 21 8 9 204 303 32 118 7 4 20 0.9 . . 3 . . . . 2 . . .
0 0 0 0 19 14 4 184 232 47 109 9 4 21 108 82 17 5 . . 2 1 0 . . .
0 0 6 0 24 9 6 235 79 60 101 9 6 22 0.9 124 32 4 . . 4 2 0 . . .
1000 1 1 0 22 7 6 80 94 22 36 9 4 . 123 98 25 3 . . 5 2 0 . . .
0 0 1 0 21 9 3 136 174 23 81 8 3 18 135 112 31 4 . . . . 2 . . .
0 0 0 0 18 8 17 148 211 32 78 8 10 12 0.9 . . 4 . . . . 2 . . .
1500 1 2 0 23 10 6 134 108 43 74 8 5 18 158 99 20 5 . . 5 2 0 . . .
0 0 15 6 29 11 3 109 57 30 68 8 4 18 205 147 23 4 . . . . 0 . . .
0 0 2 15 23 10 3 165 98 47 91 10 3 24 55 21 20 3 . . 7 4 1 3 4 6
0 0 0 0 22 10 18 191 146 35 124 9 7 20 385 73 14 4 . . 5 2 0 . . .
1000 1 8 0 25 6 9 177 212 34 115 8 5 10 447 72 15 4 . . . . 0 . . .
0 0 0 3 25 9 6 125 93 27 81 8 5 16 0.9 . . 4 . . . . 0 . . .
0 0 0 0 21 10 12 171 51 64 87 9 7 15 167 139 17 5 . . 2 1 0 . . .
0 0 0 0 15 10 8 218 135 84 109 4 7 16 1114 292 15 4 . . 1 1 0 . . .
0 0 10 20 23 9 7 83 133 28 36 8 5 15 276 273 21 3 . . 3 1 0 . . .
0 0 15 15 24 8 4 148 90 38 85 9 4 29 147 210 10 3 . . 4 2 0 . . .
0 0 1 0 . 6 8 160 119 28 111 9 8 12 0.9 . . 4 . . . . 2 . . .
0 0 0 0 16 13 3 . . . . 8 3 23 64 . 44 4 . . 4 1 0 . . .
0 0 0 0 19 7 14 112 121 19 50 10 4 17 233 68 19 3 . . 6 3 0 . . .
0 0 0 0 23 11 5 132 74 36 80 8 3 20 362 85 31 4 . . 3 1 0 . . .
1000 2 4 4 22 9 5 121 84 47 55 8 5 17 297 76 15 3 . . 1 1 0 . . .
0 0 0 0 18 7 29 125 179 23 49 10 11 14 0.9 . . 3 . . . . 2 . . .
0 0 4 0 26 12 4 188 164 32 126 8 5 26 189 93 16 5 . . 3 2 0 . . .
1000 2 16 0 21 9 3 106 40 47 58 8 5 17 74 57 29 4 . . 1 1 0 . . .
0 0 14 14 24 10 7 243 144 63 147 9 4 20 218 61 6 3 . . 3 1 0 . . .
0 0 3 8 25 9 7 . . . . 8 7 16 235 . . 4 . . . . 2 . . .
1000 2 0 0 22 5 17 95 98 23 51 7 11 7 2500 250 35 4 . . 7 3 0 . . .
1000 1.5 9 23 20 8 5 178 140 48 114 8 4 27 488 191 23 3 . . 5 2 0 . . .
0 0 15 0 21 6 14 115 37 45 60 5 8 6 903 76 21 4 . . 1 1 0 . . .
0 0 10 0 23 7 9 169 117 36 111 6 6 12 897 148 22 4 . . 4 2 0 . . .
0 0 3 0 19 9 3 114 83 32 65 10 4 21 27 61 45 4 . . 4 2 0 . . .
0 0 8 15 25 7 4 83 141 31 25 9 5 16 153 79 14 4 . . 3 2 0 . . .
0 0 0 3 21 10 4 139 101 49 69 9 4 25 198 127 7 2 . . . . 2 . . .
0 0 0 5 31 5 4 123 117 32 58 5 5 16 567 170 14 4 . . 5 2 0 . . .
0 0 5 0 26 12 3 164 266 28 77 9 4 23 272 74 15 3 . . 4 2 1 1 1 2
1000 1 3 0 18 10 3 146 74 43 80 8 3 23 123 57 34 4 . . 5 2 0 . . .
0 0 0 0 28 11 5 151 399 20 68 9 5 24 157 70 40 4 . . . . 0 . . .
0 0 0 0 21 6 9 150 119 47 78 7 8 20 0.9 . . 4 . . . . 0 . . .
1000 1 2 0 18 10 4 180 158 43 100 8 4 23 519 133 27 5 . . 2 2 0 . . .
0 0 0 0 25 8 11 111 162 17 55 6 6 21 720 79 16 4 . . 2 2 0 . . .
1000 0.5 3 0 25 9 10 104 104 34 59 7 7 18 523 85 31 5 . . 2 1 0 . . .
1000 2 8 8 19 10 3 114 47 47 51 8 4 17 95 85 19 4 . . 5 2 0 . . .
1000 0.3 10 0 30 10 6 67 73 23 29 9 5 15 361 103 37 5 . . 3 2 0 . . .
1000 0.5 0 0 17 7 6 196 79 49 118 8 5 13 0.9 106 39 4 . . . . 0 . . .
0 0 11 11 20 11 3 169 155 31 108 8 3 23 369 159 19 4 . . 3 2 0 . . .
0 0 2 6 23 10 3 200 354 27 113 8 3 18 189 44 12 5 . . 0 0 0 . . .
1000 0.5 1 15 19 8 4 159 126 33 95 8 4 15 238 371 34 1 . . 5 2 0 . . .
2000 1 10 2 22 9 3 94 48 40 40 8 5 24 170 93 47 4 . . 6 3 0 . . .
500 1 5 0 18 8 3 96 71 23 61 9 3 16 0.9 . . 4 . . . . 2 . . .
0 0 1 10 22 6 4 133 77 31 77 8 5 16 157 113 48 3 . . 6 3 0 . . .
1000 0.3 7 18 26 7 6 142 85 24 84 8 5 20 587 180 25 4 . . 3 1 0 . . .
1500 1 2 2 27 10 7 102 130 29 49 8 5 21 164 104 10 4 . . 4 2 0 . . .
0 0 12 7 19 13 7 169 117 26 117 9 5 15 16 82 22 4 . . . . 0 . . .
S.no H.No Age Res Sex Edu Occ Symp nkd dial gfr pain frac prur prox para smok alc sun amen milk diet vdur vdos bind bdur
584 646982d  54 1 2 1 2 2 1 3 4 1 0 1 0 0 0 0 0 84 250 1 0 0 4 0
585 646273d  30 11 1 3 2 3 1 3 7 1 0 0 0 0 0 0 3 . 50 2 0.5 3.75 4 0
586 646773d  51 2 1 2 4 3 2 3 12 0 0 0 0 0 0 0 0.5 . 100 2 0.3 5 4 0
587 646450d  50 2 1 1 2 6 1 3 14 1 0 0 0 0 0 0 8 . 0 2 0 0 4 0
588 646524d  23 2 1 5 1 36 1 3 4 1 0 0 0 0 0 0 5 . 250 2 0 0 4 0
589 642739d  62 2 1 3 1 24 2 3 15 0 0 1 0 0 0 0 0.5 . 100 2 0 0 4 0
590 643853d  59 2 1 5 4 3 1 3 25 1 0 0 0 0 0 0 0.5 . 100 1 0 0 4 0
591 651759d  54 2 1 3 5 1 2 3 5 0 0 1 0 0 0 0 1 . 0 2 0 0 4 0
592 648128d  56 1 1 3 2 1 1 3 4 1 0 1 0 0 1 0 4 . 50 2 0 0 4 0
593 649149d  20 2 1 3 7 3 1 3 11 0 0 0 1 0 0 0 6 . 50 2 0 0 4 0
594 647711d  61 2 2 2 1 0 2 3 25 0 0 0 0 0 0 0 1 180 100 2 0 0 4 0
595 633442d  38 3 1 5 5 2 1 3 30 0 0 1 0 0 0 0 0.5 . 500 2 2 15 1 2
596 647576d  53 2 1 2 6 12 1 3 5 1 0 1 0 0 1 0 1 . 50 1 0 0 4 0
597 650427d  29 13 1 3 6 3 1 3 7 0 0 0 1 0 0 0 0.5 . 250 1 1 15 4 0
598 647859d  18 2 1 3 1 6 1 3 4 1 0 1 1 0 0 0 0.5 . 100 2 0 0 4 0
599 652329d  55 3 2 1 1 3 1 3 21 1 0 0 0 0 0 0 0.5 60 100 2 1 7.5 4 0
600 653116d  44 2 2 3 1 120 1 3 13 1 0 0 0 0 0 0 0 0 100 2 0 0 4 0
601 638508d  37 1 1 3 2 1 1 3 15 0 0 0 0 0 0 0 10 . 100 2 0 0 4 0
602 637348d  48 3 2 3 1 0 2 3 24 0 0 0 0 0 0 0 0.5 0 200 2 0 0 3 0.5
603 648647d  47 11 1 3 5 60 2 3 16 0 0 1 1 0 0 0 2 . 50 2 0 0 2 2
604 636907d  55 2 2 5 1 6 2 3 16 1 0 0 0 0 0 0 0.5 24 250 2 0 0 4 0
605 649312d  31 11 1 3 2 2 1 1 6 0 0 0 0 0 1 0 0.5 . 50 2 1 7.5 2 1
606 645830d  50 2 1 3 4 0 6 3 8 0 0 0 0 0 1 0 1 . 100 2 0 0 1 1
607 647678d  68 2 1 5 1 18 2 3 12 1 0 1 1 0 1 0 0.5 . 0 2 0 0 4 0
608 653874d  64 3 1 3 1 1 1 3 7 0 0 0 1 0 0 0 2 . 200 2 1 15 4 0
609 224421c  59 1 1 5 1 0 2 3 24 0 0 1 0 0 0 0 1 . 200 2 0 0 4 0
610 657510d  14 1 1 1 1 1 1 3 7 0 0 1 0 0 0 0 0.5 . 200 1 0 0 4 0
611 654787d  39 10 1 5 6 24 1 3 3 1 0 0 0 0 1 1 2 . 100 2 0 0 1 0.3
612 655183d  47 6 1 3 6 1 2 3 7 0 0 0 0 0 1 0 0.5 . 0 1 0 0 4 0
613 650849d  62 2 2 2 1 12 1 3 8 1 0 1 1 0 0 0 0.5 240 100 1 1 7.5 4 0
614 652642d  36 6 1 5 5 0 1 3 14 0 0 0 0 0 0 0 1.5 . 150 2 0 0 4 0
615 653677d  31 19 1 6 5 3 4 3 14 0 0 1 0 0 0 0 0.5 . 100 2 0 0 4 0
616 655271d  54 1 1 1 1 60 2 3 14 1 0 0 0 0 0 0 3 . 50 2 0 0 4 0
617 585823d  54 15 1 6 7 12 1 3 24 0 0 1 0 0 1 0 1 . 150 2 0 0 4 0
618 655188d  49 6 1 1 1 2 3 3 22 1 0 0 0 0 0 0 2 . 0 2 0 0 1 1
619 655931d  42 2 2 3 1 1 1 3 20 1 0 0 0 0 0 0 8 0 50 2 0.5 3.75 1 0.5
620 655023d  44 3 1 2 6 1 1 3 6 0 0 1 0 0 0 0 0.5 . 250 2 0 0 4 0
621 657910d  32 1 1 5 4 1 1 3 13 1 0 0 0 0 0 0 0.5 . 300 2 1 15 4 0
622 657442d  73 11 1 6 1 0 1 3 26 0 0 0 0 0 0 0 2 . 200 2 0 0 4 0
623 662118d  37 2 2 2 7 0 2 3 16 0 0 0 0 0 0 0 0.5 0 0 2 0 0 1 0.5
624 722712d  60 16 1 5 3 3 1 3 8 0 0 0 0 0 0 0 1.5 . 200 2 0 0 4 0
625 717420d  53 2 1 3 6 1 1 3 7 0 0 0 0 0 0 0 1 . 0 2 1 7.5 1 1
626 725325d  33 2 2 3 1 6 1 3 6 0 0 0 0 0 0 0 0.5 0 500 2 0 0 4 0
627 705240d  62 6 1 5 1 3 2 3 6 0 0 1 0 0 1 1 0.5 . 400 1 0 0 4 0
628 722933d  40 2 1 3 4 3 1 3 11 0 0 0 1 0 0 0 0.5 . 0 2 1 7.5 1 1
629 723654d  52 1 1 6 5 3 5 3 5 0 0 0 0 0 0 0 0.5 . 400 2 0 0 4 0
630 718599d  55 2 1 3 5 2 2 3 13 0 0 0 1 0 0 0 0.5 . 300 2 0 0 1 1
631 688624d  60 1 2 3 1 7 2 3 6 0 0 0 0 0 0 0 0.5 120 0 2 0 0 4 0
632 447032c  49 1 1 3 2 1 2 3 22 0 0 0 0 0 0 0 1.5 . 200 2 0 0 4 0
633 721002d  45 7 1 2 3 12 1 3 7 0 0 0 0 0 0 0 2.5 . 200 2 0 0 4 0
634 721707d  52 2 1 3 3 12 1 3 11 1 0 0 0 0 1 0 2 . 0 2 0 0 4 0
635 716404d  39 9 2 3 1 4 1 3 16 0 0 0 0 0 0 0 0.5 . 0 1 0 0 4 0























































cdos cdur ht dm bmi hb cr chol tg hdl ldl ca phosbic pth alp vitd alb bmd tscor echo1echo2 Xray ass apas apss
0 0 8 0 21 10 12 217 131 52 139 8 6 17 461 83 . 4 . . 11 4 0 . . .
0 0 0 0 17 8 10 138 106 49 68 9 8 10 376 100 26 4 . . . . 0 . . .
500 0.3 4 5 18 7 6 159 271 32 84 9 4 23 224 67 28 4 . . 2 2 0 . . .
0 0 0 0 18 8 5 116 39 53 54 9 5 18 63 101 22 4 . . 3 2 0 . . .
0 0 0 0 20 7 16 147 107 36 87 8 7 21 973 109 15 5 . . 8 4 0 . . .
0 0 8 15 27 8 4 160 75 46 103 9 4 23 118 151 14 3 . . . . 0 . . .
0 0 10 20 25 12 3 175 137 33 110 8 3 23 0.9 102 18 4 . . 1 1 1 3 5 5
0 0 3 3 20 7 11 203 77 63 123 8 6 17 483 83 20 3 . . 4 2 2 . . .
0 0 0 0 24 10 13 . . . . 8 5 12 225 . . 4 . . . . 2 . . .
0 0 1 0 18 7 7 113 57 37 61 8 6 17 363 60 21 3 . . 4 3 0 . . .
0 0 5 15 26 10 3 194 426 40 72 9 4 20 292 118 10 3 . . . . 2 . . .
500 2 0 0 26 12 3 154 175 26 93 8 3 17 356 282 24 5 . . 5 3 2 . . .
0 0 3 0 19 8 11 163 81 39 103 7 8 9 1062 159 27 4 . . 5 3 0 . . .
1500 1 0 0 22 7 10 207 58 41 129 9 5 14 258 79 23 4 . . 6 3 0 . . .
0 0 0 0 24 6 13 153 86 43 97 5 9 . 0.9 . . 3 . . . . 2 . . .
1000 1 0 0 21 9 3 146 153 26 86 8 5 19 148 . 31 5 . . 6 2 0 . . .
0 0 5 0 26 9 4 156 80 46 91 8 6 12 128 50 20 5 . . 6 3 0 . . .
0 0 0 0 24 11 5 143 233 18 82 . . . 0.9 . . . . . . . 2 . . .
0 0 13 13 25 11 2 392 412 49 237 9 4 . 189 68 7 3 . . 5 2 0 . . .
0 0 3 14 27 9 4 261 396 33 163 9 4 19 192 182 10 3 . . 3 1 0 . . .
0 0 2 13 . 8 3 180 153 45 114 9 4 . 0.9 133 . 4 . . 6 3 2 . . .
0 0 0 0 17 10 11 139 121 35 79 8 5 20 213 83 17 5 . . . . 0 . . .
1000 1 3 3 23 8 8 168 64 60 89 7 5 15 434 155 27 3 . . 8 4 0 . . .
0 0 1 25 20 8 5 131 60 51 65 7 5 11 338 136 22 4 . . 4 2 1 2 2 3
1000 1 8 0 22 9 8 178 124 67 74 8 6 18 270 97 26 4 . . 7 3 0 . . .
0 0 10 10 20 11 3 143 87 51 60 9 4 21 184 97 19 4 . . 6 3 0 . . .
0 0 1 0 . 4 11 132 139 28 81 5 10 12 517 84 22 3 . . 4 1 2 . . .
1000 0.3 2 0 25 7 17 104 98 21 67 4 7 14 504 362 23 5 . . 6 2 2 . . .
500 1 1 10 22 9 9 . . . . 8 6 13 116 80 24 4 . . 6 2 0 . . .
500 1 0 0 25 10 5 136 70 36 80 8 4 19 504 162 35 4 . . 5 1 0 . . .
0 0 0 0 23 9 5 124 80 39 67 8 4 18 261 77 16 4 . . 8 3 0 . . .
0 0 4 0 20 10 5 138 89 41 78 8 4 21 456 80 10 5 . . 8 4 0 . . .
0 0 8 15 23 9 5 153 178 23 99 8 3 20 561 111 . 4 . . . . 2 . . .
0 0 1 0 25 7 3 . . . . 7 4 14 508 186 16 4 . . 4 2 0 . . .
1000 1 3 0 26 12 3 118 165 34 54 9 3 20 103 83 18 5 . . 2 1 0 . . .
1000 0.5 0 0 16 8 4 178 109 59 95 9 7 15 53 56 25 4 . . 6 2 0 . . .
0 0 1 0 24 8 9 197 280 32 120 9 6 17 0.9 . . 4 . . . . 2 . . .
1000 1 2 1 20 13 5 136 111 23 93 8 4 16 458 96 28 3 . . . . 0 . . .
0 0 29 0 24 10 3 128 97 35 75 7 3 24 146 70 19 4 . . 4 2 0 . . .
1000 0.5 1 12 17 11 4 138 148 35 74 9 4 30 119 398 14 4 . . 3 1 0 . . .
0 0 0 0 21 8 8 124 52 39 73 7 6 . 439 159 25 5 0.972 0.3 5 2 0 . . .
500 1 1 0 21 10 9 205 151 40 135 8 4 17 601 179 14 5 . . 6 3 0 . . .
0 0 3 0 24 8 9 154 84 43 97 5 7 13 0.9 . . 4 . . . . 2 . . .
0 0 3 8 25 8 9 99 75 29 54 7 5 13 595 145 22 4 . . 7 3 0 . . .
1000 1 7 0 21 10 6 205 118 52 118 9 4 17 343 90 16 4 0.775 ‐1.1 9 3 0 . . .
0 0 0 0 23 8 12 127 103 27 74 6 7 6 607 85 13 5 . . 5 2 0 . . .
1000 1 1 12 21 7 5 99 65 43 35 8 5 22 299 136 17 4 0.616 ‐2.3 9 3 0 . . .
0 0 8 25 33 11 8 231 139 29 174 9 6 22 1009 127 7 3 . . 6 3 0 . . .
0 0 5 5 29 10 3 168 154 25 113 8 6 21 71 75 21 3 . . . . 0 . . .
0 0 12 0 23 11 9 124 89 24 87 7 7 14 515 108 26 5 . . 8 3 0 . . .
0 0 13 0 22 10 6 . . . . 8 5 17 361 97 17 4 . . 1 1 0 . . .
0 0 0 0 17 11 3 158 133 52 73 9 5 14 42 86 23 4 . . 4 1 0 . . .
0 0 3 3 21 11 6 95 121 23 50 8 3 13 140 101 . 4 . . 3 1 0 . . .
S.no H.No Age Res Sex Edu Occ Symp nkd dial gfr pain frac prur prox para smok alc sun amen milk diet vdur vdos bind bdur
637 697286d  39 2 1 3 4 6 1 3 21 0 0 1 0 0 0 0 2 . 0 2 0 0 4 0
638 718257d  45 2 2 2 1 6 1 3 7 1 0 0 0 0 0 0 0.5 0 0 2 1 15 1 1
639 717713d  55 3 1 2 2 6 1 3 23 0 0 0 0 0 0 0 0.5 . 0 2 0 0 4 0
640 717821d  65 5 1 2 2 1 1 3 20 0 0 0 0 0 0 0 1 . 0 2 0 0 4 0
641 722537d  35 1 2 5 1 0 2 3 9 0 0 0 0 0 0 0 0.5 0 0 2 0 0 4 0
642 663309d  34 4 1 3 6 0 2 1 8 0 0 0 0 0 0 0 0.5 . 300 2 1 7.5 4 0
643 662887d  71 22 1 3 1 3 1 3 10 0 0 1 0 0 0 0 0.5 . 0 2 0 0 4 0
644 657184d  52 2 1 3 7 48 1 3 23 0 0 0 1 0 1 0 0.5 . 0 2 0 0 4 0
645 662004d  26 3 1 3 3 1 1 3 7 1 0 0 1 0 0 0 0.5 . 1000 2 0 0 4 0
646 659670d  41 12 1 5 6 12 1 3 9 0 0 1 1 0 0 0 0.5 . 100 2 0 0 2 1
647 658882d  48 18 1 3 6 2 1 3 4 1 0 1 1 0 0 0 0.5 . 0 2 0.5 7.5 4 0
648 659166d  28 6 2 3 1 12 1 3 4 1 0 1 1 0 0 0 0.5 0 0 2 0.5 7.5 4 0
649 659557d  27 11 1 5 5 24 1 3 27 1 0 0 1 0 0 0 0.5 . 100 2 0 0 4 0
650 656676d  58 2 1 5 5 2 2 3 11 1 0 1 1 0 0 0 0.5 . 0 2 0 0 4 0
651 656150d  26 2 1 3 3 3 1 1 5 1 0 0 1 0 0 0 5 . 250 2 0.5 7.5 4 0
652 654051d  51 2 1 3 6 2 1 3 2 0 0 0 1 0 1 0 0.5 . 0 2 0 0 4 0
653 652703d  52 8 2 3 1 3 1 3 9 0 0 1 0 0 0 0 0.5 36 200 2 0.66 5 4 0
654 653867d  62 2 1 2 1 0 1 3 24 0 0 0 0 0 0 0 8 . 500 2 0 0 4 0
655 653518d  58 4 1 3 4 48 2 3 9 1 0 0 0 0 1 1 10 . 200 2 0 0 4 0
656 641358d  40 2 2 3 1 36 3 3 9 1 0 0 0 0 0 0 0.5 0 500 1 0 0 4 0
657 650272d  66 3 1 3 1 3 2 3 23 1 0 0 1 0 0 0 0.5 . 500 2 1 7.5 1 1
658 645123d  58 2 1 5 4 24 2 3 14 0 0 1 0 0 1 0 0.5 . 200 2 0 0 4 0
659 600684d  49 1 1 3 2 1 2 3 3 0 0 1 0 0 0 0 1 . 100 2 0 0 4 0
660 581452d  50 9 1 1 3 0 1 3 18 1 0 0 0 0 0 0 0 . 0 2 0 0 4 0
661 922331a  39 1 2 2 1 2 1 3 4 1 0 0 0 0 0 0 0 0 0 2 0 0 4 0
662 593954d  62 1 1 2 1 1 1 2 3 0 0 0 0 0 0 1 1 . 0 2 0 0 4 0
663 600409d  30 8 1 5 5 1 1 1 3 0 0 0 0 0 0 0 0 . 100 2 1.5 11.3 4 0
664 511883c  55 2 1 5 5 3 2 3 27 0 0 1 0 0 0 1 0 . 100 2 0 0 4 0
665 600423d  42 2 1 3 3 2 1 3 18 1 0 1 0 0 0 0 0 . 100 2 0 0 1 0.3
666 600359d  45 2 2 3 1 36 1 3 4 0 0 1 0 0 0 0 0 60 0 1 0 0 4 0
667 599819d  30 3 1 5 4 2 5 1 5 0 0 0 0 0 0 0 0 . 100 2 1 15 4 1
668 5.83d  62 2 1 1 3 3 2 3 15 0 0 1 1 0 0 1 0 . 200 2 0.3 1.75 4 0.3
669 600805d  37 2 1 5 3 6 1 3 9 1 0 0 0 0 0 1 0 . 250 2 0 0 4 0
670 600763d  40 1 1 3 4 3 1 3 7 0 0 0 0 0 0 0 0 . 200 2 2 30 1 1
671 595225d  52 15 1 5 4 6 2 3 8 1 0 1 0 0 0 1 1 . 100 2 0.1 2.5 4 0
672 596705d  57 3 1 5 4 2 2 1 8 0 0 0 0 0 0 1 0 . 200 2 0.1 0.5 4 0
673 600010d  52 2 1 3 1 3 2 3 8 0 1 0 0 0 0 0 0 . 0 2 0 0 4 0
674 596450d  75 3 1 3 6 2 1 3 22 0 0 0 0 0 0 0 0 . 400 2 0 0 3 0.3
675 598204d  33 13 1 3 5 2 1 3 5 0 0 0 0 0 0 1 1 . 400 2 0 0 4 0
676 599256d  46 3 1 2 1 2 2 3 15 0 0 0 0 0 0 0 0 . 200 2 0.5 3.75 1 0.5
677 601513d  51 2 1 4 4 24 2 3 13 1 0 1 0 0 0 0 0 . 500 2 1 7.5 4 0
678 602933d  51 9 2 3 1 1 1 3 28 0 0 0 0 0 0 0 0 . 0 2 0 0 4 0
679 604675d  61 9 1 2 3 2 2 3 13 1 0 1 0 0 0 0 0 . 0 1 0.3 7.5 4 0
680 600914d  52 6 2 1 1 0 2 3 23 1 0 0 0 0 0 0 0 . 500 1 0 0 4 0
681 601873d  44 2 1 5 5 6 1 3 24 0 0 1 0 0 0 0 0 . 0 1 0 0 4 0
682 604726d  26 5 1 6 1 1 1 3 2 0 0 0 0 0 0 0 0 . 0 2 0 0 4 0
683 602342d  23 2 2 4 4 1 1 3 5 0 0 0 1 0 0 0 0 . 500 2 0 0 4 0
684 580242d  42 1 2 3 1 0 1 3 25 1 0 0 0 0 0 0 0 2 100 2 0 0 4 0
685 600476d  17 1 1 3 1 1 1 1 4 0 0 0 0 0 0 0 0 . 100 2 0 0 4 0
686 599617d  58 2 2 3 1 6 1 3 6 1 0 1 1 0 0 0 0 60 0 2 0 0 4 0
687 599034d  27 16 2 5 5 2 1 1 8 0 0 0 1 0 0 0 0 0 200 2 0 0 4 0
688 596675d  52 2 1 5 5 6 2 3 15 0 0 0 0 0 0 1 0 . 100 2 0 0 4 0























































cdos cdur ht dm bmi hb cr chol tg hdl ldl ca phosbic pth alp vitd alb bmd tscor echo1echo2 Xray ass apas apss
0 0 0 0 20 10 4 138 237 24 72 9 2 . 0.9 66 . 4 . . . . 2 . . .
1000 1 1 0 26 8 7 122 85 30 80 9 7 12 1086 100 20 4 . . 5 2 0 . . .
0 0 0 0 23 7 3 164 101 41 98 8 4 21 70 66 20 4 . . . . 0 . . .
0 0 18 8 21 12 3 . . . . 9 3 . 0.9 . . 4 . . 9 3 0 . . .
0 0 8 8 35 8 6 126 88 37 64 7 3 14 345 106 11 4 . . 6 2 0 . . .
1000 1 0 5 24 11 8 255 245 28 191 9 5 22 198 69 15 4 . . 5 2 0 . . .
0 0 4 0 25 10 6 158 60 70 74 8 5 12 1015 147 14 4 . . 4 1 0 . . .
0 0 6 0 16 12 3 118 63 41 59 8 5 17 152 94 18 4 . . 5 2 0 . . .
0 0 0 0 17 5 13 189 98 54 100 7 6 14 0.9 . . 4 . . . . 2 . . .
0 0 1 0 19 11 7 176 95 51 108 8 6 16 258 110 26 4 . . 4 2 0 . . .
1000 0.5 1 0 19 8 8 91 64 38 45 8 7 10 798 139 15 3 . . 4 2 0 . . .
1000 0.5 5 0 22 7 11 150 202 26 87 8 11 11 1058 113 21 4 . . 5 2 0 . . .
0 0 0 0 20 10 3 173 105 41 116 8 4 20 133 76 20 4 . . 4 3 0 . . .
0 0 1 3 24 7 6 183 216 42 97 9 4 22 280 52 16 2 . . 2 1 2 . . .
1000 0.5 0 0 20 10 13 152 160 41 82 8 7 19 390 53 32 4 . . 9 4 2 . . .
0 0 1 10 20 7 23 . . . . . . 7 0.9 234 . 4 . . . . 2 . . .
0 0 7 0 20 11 7 226 169 32 168 7 6 12 831 172 27 5 . . 6 4 0 . . .
0 0 4 0 26 11 3 185 90 34 129 8 3 23 168 90 16 4 . . 3 1 0 . . .
0 0 3 3 24 13 6 191 92 50 117 9 5 22 738 124 23 5 . . 5 1 0 . . .
0 0 0 0 17 6 5 177 385 40 89 5 4 27 619 173 20 4 . . . . 0 . . .
1000 1 20 20 24 8 3 139 140 32 72 9 5 21 72 169 10 3 . . 7 2 0 . . .
0 0 2 16 22 11 4 . . . . 8 5 23 382 110 16 4 . . 6 2 0 . . .
0 0 5 7 25 8 16 198 126 47 123 7 11 13 1303 119 28 4 0.723 ‐1.5 0 0 0 . . .
0 0 4 0 19 11 4 115 56 40 52 9 4 22 158 59 39 4 0.685 ‐1.8 . . 0 . . .
0 0 3 0 . 8 10 107 87 31 54 8 7 19 1507 101 34 4 0.773 ‐0.7 4 2 2 . . .
3000 0.3 3 0 . 8 15 205 206 31 132 7 9 17 548 . 23 3 0.841 ‐0.7 11 4 0 . . .
1000 1.5 0 0 26 5 20 88 177 18 38 8 7 14 443 67 20 4 0.816 ‐0.8 . . 0 . . .
0 0 15 15 25 3 3 146 171 28 79 9 3 25 60 77 26 4 0.703 ‐1.3 0 0 0 . . .
0 0 0 0 16 . 4 67 48 21 23 8 6 12 355 94 52 4 . . 0 0 0 . . .
0 0 2 0 24 7 11 175 93 68 79 8 7 14 536 131 24 3 0.496 ‐3.2 3 1 0 . . .
0 0 0 0 22 6 14 126 90 54 47 8 5 20 677 111 18 4 0.593 ‐2.5 5 3 0 . . .
0 0 0 1 25 12 4 151 93 32 85 8 3 26 69 84 36 5 0.731 ‐1.5 . . 0 . . .
0 0 1 0 19 8 7 196 71 52 110 7 6 15 377 129 30 4 0.638 ‐2.1 1 0 0 . . .
1000 2 0 0 17 8 9 111 85 41 48 9 8 14 100 67 38 4 1.01 0.6 0 0 0 . . .
0 0 1 18 21 12 8 186 139 41 116 8 6 19 389 59 19 4 0.535 ‐2.9 . . 0 . . .
1000 0.1 7 7 21 6 7 194 161 48 93 8 6 25 729 66 21 3 0.639 ‐2.1 3 1 1 3 3 4
0 0 15 15 23 8 6 308 355 70 157 9 6 19 464 138 12 3 0.55 ‐2.7 6 3 0 . . .
0 0 12 0 29 11 3 167 192 40 84 9 4 26 369 66 17 4 0.772 ‐1.2 4 2 0 . . .
0 0 3 0 18 8 13 109 41 36 57 7 8 14 428 67 35 4 0.707 ‐1.6 4 2 0 . . .
0 0 2 0 . 8 5 93 140 27 34 9 5 18 223 91 24 3 0.752 ‐1.3 2 1 0 . . .
0 0 2 10 23 8 5 194 82 58 107 9 5 23 342 61 26 4 0.658 ‐2 4 3 2 . . .
0 0 3 0 26 11 2 131 141 22 72 9 4 21 34 65 44 4 0.695 ‐1.4 5 3 0 . . .
1500 0.3 2 10 25 11 5 162 120 47 72 9 4 25 535 94 14 4 0.707 ‐1.6 1 1 0 . . .
0 0 0 3 29 10 2 124 95 40 45 9 4 20 60 60 29 5 0.744 ‐0.9 5 3 0 . . .
0 0 6 0 21 10 3 169 85 28 116 9 4 26 177 104 18 3 0.619 ‐2.1 5 3 1 2 3 4
0 0 0 0 18 6 28 231 481 20 109 4 13 7 1082 79 18 4 . . 6 4 0 . . .
0 0 6 0 21 8 11 271 282 26 156 5 7 17 301 109 20 4 0.693 ‐1.4 2 1 0 . . .
0 0 7 0 34 8 2 232 191 31 152 9 4 23 0.9 85 26 4 0.592 ‐2.3 7 4 0 . . .
0 0 0 0 19 5 17 130 104 29 69 8 12 22 1796 38 24 3 0.711 . 2 1 2 . . .
0 0 4 0 . 8 7 145 82 33 80 9 9 20 320 59 25 4 0.46 ‐3.5 4 3 0 . . .
0 0 0 0 19 6 7 110 52 39 57 8 4 20 718 66 31 5 0.855 ‐1.2 1 0 0 . . .
0 0 10 16 20 9 4 149 75 39 82 8 3 17 228 111 30 4 0.571 ‐2.6 5 3 0 . . .
0 0 2 2 20 6 6 204 179 41 118 9 6 22 557 118 17 4 0.569 ‐2.5 3 1 0 . . .
S.no H.No Age Res Sex Edu Occ Symp nkd dial gfr pain frac prur prox para smok alc sun amen milk diet vdur vdos bind bdur
690 767183d  62 3 1 3 1 12 1 3 18 0 0 1 1 0 0 0 8 . 100 2 0 0 1 1
691 766142d  29 2 2 5 1 3 1 1 13 0 0 0 1 0 0 0 0.5 0 200 1 1.5 10.3 4 0
692 769175d  59 2 1 5 4 3 1 3 6 0 0 1 0 0 0 0 2 . 0 2 1 7.5 4 0
693 752040d  62 2 1 5 5 1 1 3 17 0 0 0 0 0 0 0 0.5 . 0 2 0 0 4 0
694 741435d  55 3 1 1 3 6 1 3 19 1 0 0 0 0 0 0 6 . 0 1 0 0 4 0
695 735819d  51 2 2 2 1 36 2 3 26 1 0 0 0 0 0 0 0.5 0 0 2 0 0 4 0
696 678190d  32 8 1 3 6 1 1 3 5 1 0 1 1 0 0 0 0.5 . 200 2 1 3.65 4 0
697 671873d  50 13 2 2 1 6 2 3 10 1 0 0 1 0 0 0 1 60 0 1 0 0 4 0
698 695371d  25 1 2 5 1 1 1 3 5 0 0 0 0 0 0 0 0.5 0 100 2 1 7.5 4 0
699 678963d  59 5 1 1 3 1 1 3 27 0 0 0 0 0 1 0 4.5 . 200 2 0 0 4 0
700 688722d  32 1 2 2 2 2 1 3 3 1 0 1 1 0 0 0 0.5 0 250 2 2 30 4 0
701 689469d  45 3 1 5 2 0 1 3 27 0 0 0 0 0 0 0 4 . 0 2 0 0 4 0
702 687720d  40 8 1 5 1 0 1 1 5 0 0 0 0 0 1 0 6 . 0 2 1 7.5 4 0
703 688080d  35 1 1 2 2 2 1 2 2 0 0 0 1 0 0 0 8 . 100 2 0.3 5 4 0
704 623516d  22 3 1 4 1 0 1 1 4 0 0 0 0 0 0 0 1.5 . 0 2 0.5 3.65 4 0
705 635839d  48 1 2 3 1 0 8 3 23 1 0 0 1 0 0 0 3 144 200 2 0 0 4 0
706 757075d  33 2 1 3 3 0 1 3 29 0 0 0 0 0 0 0 3 . 200 2 0 0 4 0
707 627009d  79 5 1 1 3 0 1 3 29 0 0 0 0 0 0 0 1 . 0 2 0 0 4 0
708 629065d  49 4 1 3 5 0 2 3 14 0 0 0 0 0 1 0 0.5 . 500 2 0 0 4 0
709 635745d  60 3 2 3 1 3 2 3 23 0 0 1 1 0 0 0 2 120 250 2 0 0 4 0























cdos cdur ht dm bmi hb cr chol tg hdl ldl ca phosbic pth alp vitd alb bmd tscor echo1echo2 Xray ass apas apss
1000 1 1 3 18 9 4 155 62 43 97 8 3 15 103 208 . 4 1 0.5 6 2 0 . . .
500 1.5 0 0 24 9 4 . . . . 8 4 18 430 147 15 4 0.628 ‐2 4 1 0 . . .
500 1 18 0 24 8 7 . . . . 8 7 11 1574 106 41 4 . . 3 1 0 . . .
0 0 1 0 20 6 4 141 239 32 76 8 4 19 155 . 5 5 0.578 ‐2.6 3 2 0 . . .
0 0 0 0 17 10 2 . . . . 8 3 17 127 244 32 4 0.957 0.2 . . 0 . . .
0 0 13 20 24 8 2 118 202 25 68 8 2 22 118 . 12 4 0.706 ‐1.3 6 2 0 . . .
1500 1 5 0 21 9 12 137 47 30 100 8 6 22 0.9 . . 4 . . . . 2 . . .
0 0 1 2 30 9 6 345 229 44 264 9 5 18 0.9 . . 2 . . . . 2 . . .
1000 1 0 0 21 9 10 147 125 27 95 8 5 10 0.9 . . 5 . . . . 2 . . .
0 0 0 10 27 12 3 . . . . 8 3 20 42 79 34 5 . . 5 2 0 . . .
1000 2 1 0 20 8 16 183 168 27 124 8 9 11 222 78 17 4 . . 6 3 0 . . .
0 0 4 0 22 12 3 123 116 29 74 8 3 20 0.9 . . 5 . . . . 2 . . .
1500 1 1 0 19 10 12 137 135 35 74 8 8 17 0.9 . . 4 . . . . 2 . . .
1000 0.3 0 0 . 7 29 . . . . 7 6 12 0.9 . . 4 . . . . 2 . . .
1000 0.5 0 0 19 7 14 185 135 29 114 9 8 17 0.9 . . 4 . . . . 2 . . .
0 0 1 7 36 14 2 216 214 39 134 9 6 29 87 89 29 5 . . 1 0 0 . . .
0 0 2 0 20 10 3 . . . . 10 5 24 66 . 49 4 . . . . 2 . . .
0 0 0 0 20 9 2 168 114 39 110 8 5 22 0.9 . . 4 . . 6 3 0 . . .
0 0 10 12 26 10 5 . . . . 7 4 20 1169 182 40 4 . . 2 1 0 . . .
0 0 5 10 22 12 2 416 796 44 226 9 4 23 255 . 15 4 . . 2 1 0 . . .
0 0 0 0 . 11 6 110 67 40 67 8 6 15 1022 . . 5 . . 6 3 0 . . .
